# Peptide Database — Full Content Archive

> Peptide Database is a comprehensive, research-based reference for peptides used in scientific research. This file contains the complete text of all published guides and summaries of all peptide profiles. All information is sourced from published research.

- Website: https://peptide-db.com
- Calculator: https://peptide-db.com/calculator
- Guides: https://peptide-db.com/guides
- Lightweight index: https://peptide-db.com/llms.txt

Total guides: 9
Total peptides: 101
Total compounds: 66

---

## Guides

### Best Peptides for Mitochondrial Health: SS-31, MOTS-c, NAD+

URL: https://peptide-db.com/guides/mitochondrial-peptides

---
title: 'Best Peptides for Mitochondrial Health: SS-31, MOTS-c, NAD+'
description: 'How SS-31, MOTS-c, and NAD+ target mitochondrial energy production through different mechanisms. Dosing, evidence levels, and how they compare for cellular health.'
date: '2026-03-25'
lastUpdated: '2026-03-25'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'basics'
difficulty: 'intermediate'
readingTime: '16 min'

tags:
  - mitochondria
  - ss-31
  - mots-c
  - nad+
  - longevity
  - anti-aging
  - humanin
  - cellular energy

image: '/guides/mitochondrial-peptides.webp'
imageAlt: 'Mitochondria cross-section showing ATP energy production and peptide targeting'

published: true
keywords: 'best peptides for mitochondrial health, SS-31 vs MOTS-c, mitochondrial peptides, NAD+ therapy, elamipretide, MOTS-c benefits, ss-31 peptide, mitochondrial health supplements, cellular energy peptides'
canonical: 'https://peptide-db.com/guides/mitochondrial-peptides'
showToc: true

relatedPeptides:
  - ss-31
  - mots-c
  - nad-plus
  - humanin
  - epitalon

relatedGuides:
  - title: 'CJC-1295 and Ipamorelin: How the Stack Works'
    slug: 'cjc-1295-ipamorelin'
    image: '/guides/cjc-1295-ipamorelin-stack.webp'
    excerpt: 'Dual-pathway GH stimulation for recovery and anti-aging.'
  - title: 'KLOW Peptide Protocol: Ingredients, Dosing, and Research'
    slug: 'klow-peptide-protocol'
    image: '/guides/klow-peptide-protocol.webp'
    excerpt: 'A research-based breakdown of the four-peptide KLOW blend.'
---

<script>
  import { BarChart, ComparisonScale, SpectrumBar, Callout, MermaidDiagram } from '$lib/components/charts';
</script>

## Summary

Mitochondrial peptides are compounds that either target mitochondrial function directly or are encoded by mitochondrial DNA itself. Three have emerged as the most researched options for cellular energy, metabolic health, and longevity: [SS-31](/peptides/ss-31) (elamipretide), [MOTS-c](/peptides/mots-c), and [NAD+](/peptides/nad-plus).

### The Three Peptides

- **SS-31** is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, preventing lipid peroxidation and optimizing the electron transport chain. It has Phase II/III clinical trial data for heart failure and mitochondrial disease
- **MOTS-c** is a 16-amino-acid peptide encoded by mitochondrial DNA. It activates AMPK through the folate-AICAR pathway, improving insulin sensitivity by approximately 30% in animal models (Lee et al., Cell Metabolism, 2015)
- **NAD+** is a coenzyme (not technically a peptide) present in every cell. Levels decline roughly 50% between ages 40 and 60. Direct supplementation restores mitochondrial function, activates sirtuins, and supports DNA repair through PARP activation

### Why 2026

- The FDA reclassification of 14 peptides to Category 1 (February 2026) includes several compounds in this space
- SS-31 Phase III data from the Barth Syndrome trial (40mg daily, 48 weeks) showed trends toward cardiac improvement
- MOTS-c research has expanded from metabolic studies into neuroprotection and pancreatic islet cell senescence (Nature, 2025)
- A fourth peptide, [Humanin](/peptides/humanin), discovered in the brain of an Alzheimer's patient, is gaining attention for neuroprotection

[Browse all mitochondrial peptides](/peptides/best-for/mitochondria) | [Compare SS-31 vs MOTS-c](/compare/mots-c-vs-ss-31)

## Your Mitochondria Are Declining. That's the Problem.

Most conversations about aging focus on hormones, telomeres, or inflammation. They're downstream effects. The upstream driver is mitochondrial dysfunction.

A single cell contains hundreds to thousands of mitochondria. They produce roughly 90% of your body's ATP. When they stop working efficiently, energy production drops, reactive oxygen species accumulate, and cellular repair mechanisms falter. The result looks like aging: fatigue, cognitive decline, reduced exercise capacity, metabolic dysfunction.

Mitochondrial function declines measurably with age. NAD+ levels drop by roughly 50% between age 40 and 60. Cardiolipin oxidation increases. The electron transport chain becomes less efficient. This isn't speculation. It's measurable in blood work.

The three peptides in this guide target different parts of this decline. SS-31 stabilises the inner membrane. MOTS-c activates metabolic stress responses. NAD+ replenishes the coenzyme that every mitochondrial process depends on. Different entry points, same goal: keep the powerhouses running.

<MermaidDiagram
title="Mitochondrial Decline and Peptide Intervention Points"
chart={`     graph TD
      A[Aging] --> B[NAD+ Depletion]
      A --> C[Cardiolipin Oxidation]
      A --> D[AMPK Signaling Decline]
      B --> E[Reduced ATP Synthesis]
      C --> E
      D --> F[Impaired Metabolic Adaptation]
      E --> G[Cellular Dysfunction]
      F --> G
      H[NAD+ Therapy] -->|Restores| B
      I[SS-31] -->|Prevents| C
      J[MOTS-c] -->|Activates| D
  `}
/>

## SS-31: The Membrane Stabiliser

[SS-31](/peptides/ss-31) (also called elamipretide or Bendavia) is a synthetic aromatic-cationic tetrapeptide. It doesn't come from mitochondrial DNA. It was designed in a lab specifically to reach the inner mitochondrial membrane.

The mechanism is unusually precise. SS-31 binds to cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane. Cardiolipin is essential for the proper functioning of cytochrome c oxidase and other electron transport chain complexes. When cardiolipin oxidises (which happens increasingly with age), the electron transport chain loses efficiency, ATP production drops, and reactive oxygen species leak out.

SS-31 prevents that oxidation. It stabilises cardiolipin, restores electron transport chain efficiency, and reduces mitochondrial ROS. A 2020 study in aged mice showed 8 weeks of SS-31 reversed age-related muscle decline, increased ATP production, and reduced oxidative stress markers.

### Clinical Trials

SS-31 has the strongest clinical pipeline of any mitochondrial peptide. The key studies:

- **Primary Mitochondrial Myopathy Phase II** (2018): 36 patients, 40mg daily for 12 weeks. Improved 6-minute walk test and fatigue scores
- **Heart Failure** (2019): 0.25mg/kg/hr IV infusion reduced cardiac injury markers in heart failure patients
- **Barth Syndrome Phase III** (2021): 40mg daily for 48 weeks. Trends toward cardiac improvement, though primary endpoint was not met

<Callout type="research" title="Closest to FDA Approval">

SS-31 (elamipretide) is the only mitochondrial peptide with Phase III clinical trial data. The Barth Syndrome trial (TAZPOWER) showed trends but missed its primary endpoint. A related Phase II trial (PROGRESS-HF) for heart failure is ongoing. No mitochondrial peptide has received FDA approval.

</Callout>

### Dosing

| Protocol               | Dose    | Frequency   | Route      |
| ---------------------- | ------- | ----------- | ---------- |
| General support        | 5-10mg  | Once daily  | SubQ       |
| Athletic performance   | 10-20mg | Pre-workout | SubQ       |
| Clinical (trial doses) | 40mg    | Once daily  | SubQ or IV |

SS-31 is light-sensitive. Store in amber vials, refrigerated. Use within 30 days of reconstitution. [Calculate your dose](/calculator?peptide=ss-31)

## MOTS-c: The Metabolic Sensor

[MOTS-c](/peptides/mots-c) is fundamentally different from SS-31. It's not synthetic. It's encoded by your own mitochondrial DNA, specifically the 12S rRNA gene (MT-RNR1). Your body makes it. Levels decline with age.

The mechanism is indirect but powerful. MOTS-c inhibits the folate cycle, which leads to accumulation of AICAR, which activates AMPK. AMPK is sometimes called the "master metabolic switch." It triggers glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. A 2018 study (Kim et al., Cell Metabolism) showed MOTS-c translocates to the cell nucleus within 30 minutes of metabolic stress, where it binds stress-response transcription factors NRF2 and ATF1.

The 2015 landmark paper by Lee et al. in Cell Metabolism showed MOTS-c prevented obesity and improved insulin sensitivity by approximately 30% in high-fat diet mice. A 2021 Nature Communications study showed it enhanced physical performance across age groups, with exercise inducing an 11.9-fold increase in skeletal muscle MOTS-c. A 2022 study (Hyatt et al.) found a single dose improved running time by 12% and distance by 15%.

The latest research from 2025 (Nature) demonstrates MOTS-c prevents pancreatic islet cell senescence and delays diabetes onset. This is new territory for a peptide that was initially studied purely for metabolic effects.

<BarChart
title="MOTS-c Research: Key Effect Sizes"
data={[
{ label: 'Insulin sensitivity', value: 30, suffix: '% improvement', color: '#059669' },
{ label: 'Running distance', value: 15, suffix: '% increase', color: '#CC785C' },
{ label: 'Running time', value: 12, suffix: '% increase', color: '#CC785C' },
{ label: 'Muscle MOTS-c after exercise', value: 100, suffix: '% (11.9x)', color: '#6366f1' }
]}
maxValue={100}
barColor="#CC785C"
/>

### Dosing

| Protocol             | Dose    | Frequency   | Notes                             |
| -------------------- | ------- | ----------- | --------------------------------- |
| Conservative start   | 5mg     | Once daily  | Morning, before exercise          |
| Metabolic health     | 5-10mg  | Once daily  | SubQ                              |
| Anti-aging           | 15mg    | 3x weekly   | SubQ                              |
| Exercise performance | 10-15mg | Pre-workout | AMPK activation within 30 minutes |

Short half-life (approximately 30 minutes). Morning dosing before exercise is optimal for AMPK activation timing. Reconstituted MOTS-c degrades faster than most peptides. Use within 14 days.

<Callout type="warning" title="WADA Prohibited">

MOTS-c is a WADA prohibited substance under the S0 category (unapproved substances). Athletes subject to anti-doping testing cannot use it. SS-31 and NAD+ are not currently WADA prohibited.

</Callout>

[View MOTS-c profile](/peptides/mots-c) | [Calculate your dose](/calculator?peptide=mots-c) | [Model accumulation](/calculator/accumulation?peptide=mots-c)

## NAD+: The Universal Fuel

[NAD+](/peptides/nad-plus) isn't a peptide. It's a coenzyme. But it's included in every serious mitochondrial health discussion because it's the substrate that mitochondria run on. Without NAD+, the electron transport chain and citric acid cycle can't function. Without those, no ATP.

NAD+ participates in over 500 enzymatic reactions. It's required for sirtuin activation (the SIRT1-SIRT7 family linked to longevity), PARP-mediated DNA repair, and CD38-driven immune signalling. When NAD+ levels drop, all of these processes compete for a shrinking pool.

The decline is dramatic and measurable. Human studies show roughly 50% reduction in NAD+ levels between ages 40 and 60. This isn't gradual. It accelerates.

Direct NAD+ supplementation (IV, IM, or SubQ) bypasses the conversion steps needed for oral precursors like NMN and NR. A 2024 meta-analysis in Nature Metabolism confirmed the safety and efficacy of NAD+ precursors, while a 2023 study in Neuropharmacology Research demonstrated intranasal NAD+ delivery for direct brain access via olfactory and trigeminal pathways.

### Delivery Routes

| Route             | Dose       | Frequency   | Bioavailability    |
| ----------------- | ---------- | ----------- | ------------------ |
| IV infusion       | 250-1000mg | 1-2x weekly | 100%               |
| IM/SubQ injection | 100-500mg  | 2-3x weekly | High               |
| Intranasal        | 25-50mg    | 1-2x daily  | Direct CNS access  |
| Oral (NMN/NR)     | 100-500mg  | Daily       | Lower (first-pass) |

[View NAD+ profile](/peptides/nad-plus) | [Calculate your dose](/calculator?peptide=nad-plus)

## How They Work Together

These three peptides target mitochondrial function through completely independent pathways. That's what makes the combination interesting from a research perspective.

|                     | SS-31                       | MOTS-c                              | NAD+                               |
| ------------------- | --------------------------- | ----------------------------------- | ---------------------------------- |
| **Target**          | Inner membrane cardiolipin  | AMPK via folate-AICAR               | Electron transport chain substrate |
| **Mechanism**       | Prevents lipid peroxidation | Activates metabolic stress response | Restores coenzyme levels           |
| **Origin**          | Synthetic                   | Mitochondrial DNA-encoded           | Naturally occurring coenzyme       |
| **Half-life**       | ~2 hours                    | ~30 minutes                         | 1-4 hours (intracellular)          |
| **Clinical trials** | Phase II/III                | Preclinical + human PK              | Extensive (precursors)             |
| **WADA status**     | Not prohibited              | Prohibited (S0)                     | Not prohibited                     |

The interaction data from each peptide's profile confirms the synergies. SS-31 lists MOTS-c and NAD+ as synergistic. MOTS-c lists NAD+ precursors as synergistic. Humanin lists all three as synergistic.

<ComparisonScale
title="Human Clinical Evidence (1 = animal data only, 10 = FDA approved)"
items={[
{ label: 'SS-31', position: 7, color: '#059669' },
{ label: 'NAD+ (precursors)', position: 6, color: '#6366f1' },
{ label: 'MOTS-c', position: 3, color: '#CC785C' },
{ label: 'Humanin', position: 2, color: '#D4A27F' }
]}
min={1}
max={10}
leftLabel="Animal models only"
rightLabel="FDA approved"
/>

Check whether your stack has any conflicts: [Interaction checker](/tools/interactions)

## The Fourth Peptide: Humanin

[Humanin](/peptides/humanin) deserves a mention. It was the first mitochondria-derived peptide discovered, cloned in 2001 from the occipital lobe of an Alzheimer's patient (Hashimoto et al., PNAS). It's a 24-amino-acid peptide encoded from the 16S rRNA region of mitochondrial DNA.

Humanin's niche is cytoprotection. It blocks pro-apoptotic proteins like Bax, reduces beta-amyloid toxicity, and protects cells against oxidative stress. A 2020 study found centenarian offspring have significantly higher humanin levels than age-matched controls. Naked mole-rats, which live 30+ years (10x expected for their size), maintain stable humanin levels throughout life.

The analog HNG (Humanin G with a serine-to-glycine substitution at position 14) is roughly 1,000 times more potent than native humanin. Dosing for HNG is 0.5-2mg, 2x weekly, compared to 1-5mg for native humanin.

<Callout type="warning" title="Cancer Contraindication">

Humanin's anti-apoptotic mechanism means it could theoretically protect cancer cells from programmed death. Anyone with active malignancy or cancer history should avoid humanin and HNG. This concern also applies to Epitalon (telomerase activation).

</Callout>

## Safety Across the Category

All four mitochondrial peptides share an excellent safety profile relative to other peptide categories. No serious adverse events have been reported in clinical trials for SS-31 at doses up to 40mg daily for 48 weeks. MOTS-c and NAD+ are generally well-tolerated at standard doses.

The main concerns are specific to each:

- **SS-31**: Light-sensitive; degrades if exposed to light. Requires amber vials and dark storage
- **MOTS-c**: Monitor blood glucose if stacking with Metformin, Berberine, or other AMPK activators. Risk of additive hypoglycemia
- **NAD+**: IV infusion can cause flushing and temporary nausea. Avoid alcohol (significantly reduces NAD+ levels)
- **Humanin**: Active cancer contraindication due to anti-apoptotic effects

None of these peptides are FDA-approved for any indication. SS-31 is the closest, with Phase III data.

[View the full best-for mitochondrial health ranking](/peptides/best-for/mitochondria)

## Frequently Asked Questions

### What is the best mitochondrial peptide?

**SS-31 (elamipretide) has the strongest clinical data**, with Phase II and III trials in mitochondrial disease and heart failure. MOTS-c has the strongest metabolic data, including a 30% improvement in insulin sensitivity in animal models. NAD+ has the broadest evidence base through its precursors NMN and NR. The optimal choice depends on the specific goal.

### Can you stack mitochondrial peptides together?

SS-31, MOTS-c, NAD+, and Humanin all target different mechanisms and are listed as synergistic in their interaction profiles. SS-31 stabilises the membrane, MOTS-c activates AMPK, NAD+ replenishes the coenzyme pool. **No antagonistic interactions have been documented** between these four. Use the [interaction checker](/tools/interactions) to verify your specific combination.

### How long do mitochondrial peptides take to work?

SS-31 produces subtle energy improvements within 1-2 weeks, with significant exercise capacity changes at 4-8 weeks. MOTS-c activates AMPK within 30 minutes of administration, with metabolic benefits measurable at 2-4 weeks. **NAD+ IV produces acute improvements in energy and mental clarity within hours**, with sustained benefits building over 4-8 weeks.

### Is MOTS-c legal?

MOTS-c is **WADA prohibited under S0 (unapproved substances)**. It cannot be used by athletes subject to anti-doping testing. In the US, MOTS-c was on the FDA Category 2 list but is expected to move to Category 1 following the February 2026 reclassification announcement. SS-31 and NAD+ are not currently WADA prohibited.

### What is the difference between SS-31 and MOTS-c?

SS-31 is a synthetic peptide that physically binds to cardiolipin in the inner mitochondrial membrane, preventing oxidative damage. MOTS-c is encoded by mitochondrial DNA and works through AMPK signalling to improve metabolic adaptation. **SS-31 is structural protection; MOTS-c is metabolic programming.** They target different problems and are synergistic when combined.


---

### BPC-157 Human Clinical Trials (2025-2026): Complete Status & Results

URL: https://peptide-db.com/guides/bpc-157-human-trials

---
title: 'BPC-157 Human Clinical Trials (2025-2026): Complete Status & Results'
description: 'Complete status update on BPC-157 human clinical trials as of 2026. 3 published studies, 1 cancelled Phase I, FDA Category 2 status. What the evidence actually shows.'
date: '2025-12-28'
lastUpdated: '2026-03-29'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'research-methods'
difficulty: 'intermediate'
readingTime: '10 min'

tags:
  - bpc-157
  - clinical trials
  - human research
  - peptide research
  - safety data
  - 2026

image: '/BPC-157-CHAIN.webp'
imageAlt: 'BPC-157 peptide molecular chain structure'
invertImageInDark: true

published: true
keywords: 'bpc-157 human clinical trials 2025 2026, bpc-157 clinical trials status 2026, bpc-157 human studies, bpc-157 human clinical trials results, bpc-157 clinical trials evidence, is bpc-157 tested on humans'
canonical: 'https://peptide-db.com/guides/bpc-157-human-trials'
showToc: true

relatedPeptides:
  - bpc-157
  - tb-500
  - ghk-cu

relatedGuides:
  - title: 'BPC-157 Side Effects: Is It Safe?'
    slug: 'bpc-157-side-effects'
    excerpt: 'A comprehensive guide to BPC-157 safety, side effects, and long-term risks.'
---

## Summary

**Last updated: March 2026.** This guide covers every BPC-157 human clinical trial published to date, the current status of ongoing research, and what the evidence actually shows as of 2026.

[BPC-157](/peptides/bpc-157) has generated massive interest in the peptide community for its healing potential. But here's the uncomfortable truth: despite decades of promising animal research, human clinical data remains extremely limited.

### BPC-157 Human Clinical Trials Status (2025-2026)

- **Only 3 published human studies exist** as of March 2026—all pilot studies with small sample sizes
- **The largest trial was cancelled**: A 2015 Phase I study with 42 volunteers never published results
- **Total human subjects studied**: Fewer than 30 people across all published trials
- **No randomized controlled trials**: All existing studies lack placebo controls

### What the Human Studies Show

- **Interstitial cystitis (2024)**: 12 patients, 80-100% symptom resolution with bladder injections
- **Knee pain (2021)**: 16 patients, 87.5% reported significant relief at 6-12 months
- **IV safety (2025)**: 2 adults tolerated up to 20mg IV with no adverse effects

### Regulatory Reality

- **FDA Category 2** (2023): Cannot be legally compounded due to insufficient safety data
- **WADA prohibited** (2022): Banned under S0 Unapproved Substances for all athletes
- **Not approved anywhere**: No regulatory agency worldwide has approved BPC-157 for human use

[Browse all healing peptides →](/peptides?category=healing)

## The Gap Between Animal and Human Research

If you've read about BPC-157 online, you've likely encountered impressive claims: accelerated tendon healing, gut repair, nerve regeneration, and more. These claims come from a substantial body of animal research—over 100 studies spanning three decades.

The problem? Almost none of this has been validated in humans.

A 2025 systematic review in the _American Journal of Sports Medicine_ examined all BPC-157 research for orthopaedic applications. Of 544 articles screened, only 1 clinical study met inclusion criteria. The other 35 included studies were preclinical animal models.

> "Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available."
> — Vasireddi et al., American Journal of Sports Medicine, 2025

This gap matters. Animal studies don't always translate to humans. Mice and rats have different metabolisms, healing responses, and drug sensitivities. What works remarkably well in a rodent may not work—or may even be harmful—in people.

## The Cancelled Phase I Trial

The most significant missed opportunity in BPC-157 research occurred in 2015-2016.

### What Was Planned

PharmaCotherapia sponsored a Phase I clinical trial (NCT02637284) designed to be the first rigorous human safety study of BPC-157. The study enrolled 42 healthy volunteers aged 18-35 and aimed to establish:

- Safety profile in humans
- Pharmacokinetic data (how the body processes BPC-157)
- Optimal dosing parameters

### What Happened

In 2016, the researchers cancelled submission of results. No data was ever published. No explanation was provided publicly.

This leaves a critical gap: we still don't have the foundational pharmacokinetic data that would normally inform human dosing. The doses people use today are essentially extrapolated from animal studies—not based on actual human metabolism data.

## The Three Published Human Studies

As of March 2026, only three human studies on BPC-157 have been published. All were conducted by the same research group in Florida, and all are small pilot studies without placebo controls.

### 1. Intraarticular Knee Injection Study (2021)

**Study design**: Retrospective review
**Participants**: 16 patients with chronic knee pain
**Intervention**: Intraarticular injection of BPC-157 (2cc of 2000 mcg/mL solution)
**Follow-up**: 6-12 months

**Results**: 14 of 16 patients (87.5%) reported significant pain relief at follow-up.

**Limitations**:

- No control group
- Retrospective design
- Subjective outcome measures only
- Small sample size

### 2. Interstitial Cystitis Study (2024)

**Study design**: Pilot study
**Participants**: 12 women (ages 39-76) with moderate to severe interstitial cystitis who had failed pentosan polysulfate treatment
**Intervention**: Intravesical (bladder) injection of 10mg BPC-157
**Follow-up**: 6 weeks

**Results**: 10 of 12 patients reported complete resolution of symptoms. The remaining 2 experienced 80% symptom reduction. No adverse events reported.

> "This is the first report of intravesical BPC-157 injection to help patients with moderate to severe interstitial cystitis."
> — Lee et al., Alternative Therapies in Health and Medicine, 2024

**Limitations**:

- No control group
- Small sample size
- Short follow-up period
- Single-site study

### 3. Intravenous Safety Study (2025)

**Study design**: Pilot safety/pharmacokinetic study
**Participants**: 2 healthy adults (one 58-year-old male, one 68-year-old female)
**Intervention**: Day 1: 10mg IV infusion over 1 hour; Day 2: 20mg IV infusion over 1 hour
**Monitoring**: Vital signs, ECG, comprehensive metabolic panel, thyroid function

**Results**: No adverse events. No clinically meaningful changes in any monitored parameters. Plasma concentrations returned to baseline within 24 hours.

> "Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated."
> — Lee & Burgess, Alternative Therapies in Health and Medicine, 2025

**Limitations**:

- Only 2 participants
- Very short observation period
- No long-term follow-up
- No efficacy endpoints

## What These Studies Tell Us—And What They Don't

### What We Can Reasonably Conclude

1. **Short-term tolerance appears acceptable**: Across all three studies (roughly 30 participants total), no adverse events were reported. This is encouraging, though the sample size is too small for definitive safety conclusions.

2. **Various administration routes seem feasible**: Intraarticular, intravesical, and intravenous administration were all tolerated without apparent issues.

3. **Some therapeutic signals exist**: The interstitial cystitis results in particular suggest potential efficacy, though this needs placebo-controlled confirmation.

### What Remains Unknown

1. **Long-term safety**: The longest follow-up was 12 months for knee pain patients. We have no data on years of use.

2. **Optimal dosing**: Without proper pharmacokinetic studies, dosing recommendations remain theoretical.

3. **Drug interactions**: No human data exists on how BPC-157 interacts with medications.

4. **Cancer risk**: BPC-157 promotes angiogenesis (blood vessel formation). Whether this could theoretically support tumor growth in humans is unknown.

5. **Efficacy for most claimed uses**: Gut healing, tendon repair, nerve regeneration—none of these common use cases have human trial data.

## Regulatory Status: Why This Matters

### FDA Classification (2023)

In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance. This classification means:

- BPC-157 **cannot be legally compounded** by 503A or 503B pharmacies for human use
- The FDA identified concerns about **immunogenicity** (potential immune reactions)
- **Peptide-related impurities** in manufacturing pose risks
- **Insufficient safety data** exists to establish it's safe for humans

The practical impact: any BPC-157 available in the US today comes from either overseas suppliers or domestic gray-market sources operating outside FDA oversight.

### WADA Prohibition (2022)

The World Anti-Doping Agency added BPC-157 to the Prohibited List in 2022 under category S0: Non-Approved Substances. Key points:

- Banned **at all times**—in and out of competition
- **No Therapeutic Use Exemptions** are available
- Athletes risk disqualification for any detected presence
- Also appears on the **DoD Prohibited Dietary Supplement Ingredients List**

### What "Not Approved" Really Means

BPC-157 is not approved for human therapeutic use by any regulatory agency in the world—not the FDA, EMA, or any other authority. This isn't just a technicality. It means:

- No standardized manufacturing requirements exist
- No quality control oversight applies
- No batch-to-batch consistency is guaranteed
- Purity and actual content can vary wildly between sources

## The Quality Control Problem

Beyond the limited clinical data, anyone using BPC-157 faces a practical challenge: product quality.

### Manufacturing Concerns

Peptides are complex molecules. Proper synthesis requires:

- Precise amino acid sequencing
- Accurate folding
- Removal of synthesis byproducts
- Sterile handling and packaging

Without regulatory oversight, there's no guarantee any given BPC-157 product contains what the label claims.

### What Testing Has Found

Independent analyses of peptides sold as "research chemicals" or "supplements" have found:

- Products containing different peptides than labeled
- Purity levels far below claimed percentages
- Bacterial contamination
- Heavy metal contamination
- Incorrect concentrations

This isn't theoretical—it's documented. When you use unregulated peptides, you're trusting the manufacturer's quality control without any third-party verification requirement.

### Protecting Yourself

If you choose to use BPC-157 despite limited human data:

- Demand **Certificates of Analysis** (COAs) from third-party labs
- Verify the lab actually exists and conducted the testing
- Look for **HPLC purity testing** showing >98% purity
- Check for **endotoxin testing** (especially for injectables)
- Be skeptical of unusually low prices

Use our [dosing calculator](/calculator) to ensure accurate reconstitution and dosing.

## Comparing BPC-157 to Other Healing Peptides

BPC-157 isn't the only regenerative peptide with research interest. Here's how the human evidence compares:

| Peptide                        | Human Studies                  | FDA Status                   | Key Evidence Gap             |
| ------------------------------ | ------------------------------ | ---------------------------- | ---------------------------- |
| **BPC-157**                    | 3 pilot studies (~30 subjects) | Category 2 (cannot compound) | No RCTs, no pharmacokinetics |
| **[TB-500](/peptides/tb-500)** | Even fewer                     | Not evaluated                | Essentially no human data    |
| **[GHK-Cu](/peptides/ghk-cu)** | Limited cosmetic studies       | Allowed in topicals          | Systemic use data lacking    |

BPC-157 actually has more human data than most research peptides—which says more about the state of peptide research than about BPC-157's evidence base.

## What Would Proper Trials Look Like?

For BPC-157 to move from "experimental" to "evidence-based," the research community would need:

### Phase I (Safety)

- 50-100 healthy volunteers
- Multiple dose levels
- Comprehensive pharmacokinetic profiling
- Adverse event monitoring for 4-8 weeks minimum

### Phase II (Efficacy Signals)

- 100-300 patients with specific conditions
- Randomized, placebo-controlled design
- Validated outcome measures
- 3-6 month follow-up minimum

### Phase III (Confirmatory)

- 500-3000 patients
- Multi-site trials
- Long-term safety monitoring
- Comparison to existing treatments

Currently, we're stuck before Phase I even completes. The cancelled 2015 trial set this research back nearly a decade.

## The Anecdotal Evidence Question

Given limited clinical data, many BPC-157 users point to anecdotal reports as supporting evidence. Thousands of people claim benefits on forums, social media, and podcasts.

### Why Anecdotes Are Unreliable

1. **Placebo effect**: Expecting improvement creates real perceived improvement
2. **Selection bias**: People who feel better are more likely to report
3. **Regression to the mean**: Injuries often improve on their own
4. **Confounding variables**: Diet, rest, other treatments
5. **No verification**: Claims can't be independently confirmed

### Why Anecdotes Still Matter

Anecdotal reports aren't worthless—they generate hypotheses worth testing. The consistent themes in BPC-157 reports (gut healing, tendon recovery, reduced inflammation) align with animal research and suggest real effects may exist.

But anecdotes can't replace trials. They can tell us what to study, not what to conclude.

## Making Informed Decisions

Given everything above, how should you think about BPC-157?

### The Conservative Position

Wait for better evidence. The animal data is promising, but "promising animal data" describes countless compounds that failed in humans. The lack of safety pharmacokinetics is particularly concerning—we don't actually know how humans metabolize this peptide.

### The Risk-Tolerant Position

Some individuals accept the current evidence gaps given:

- Strong preclinical data
- Favorable (if limited) pilot study results
- Absence of reported serious adverse events
- Personal risk-benefit calculations

### Questions to Ask Yourself

1. **What am I trying to treat?** Is there an evidence-based alternative?
2. **What's my risk tolerance?** Are you comfortable with unknown unknowns?
3. **Can I source quality product?** Do you have access to verified, tested peptides?
4. **What's my exit strategy?** How will you monitor for problems?
5. **Have I consulted a healthcare provider?** Particularly important if you have existing conditions

## Frequently Asked Questions

### Are there any BPC-157 human trials currently recruiting?

As of March 2026, no registered clinical trials for BPC-157 are actively recruiting on ClinicalTrials.gov. The research appears to be at a standstill following the cancelled 2015 Phase I study.

### Why did the Phase I trial get cancelled?

No public explanation was provided. Possible reasons include funding issues, regulatory concerns, or preliminary data that didn't support continuation. Without official disclosure, we can only speculate.

### Is the lack of adverse events in human studies meaningful?

It's encouraging but not conclusive. With fewer than 30 total subjects studied, rare adverse events wouldn't be detected. Proper safety assessment requires larger sample sizes and longer observation periods.

### Could BPC-157 ever become FDA-approved?

In theory, yes. In practice, it would require a pharmaceutical company to invest tens of millions in clinical trials. The lack of patent protection (BPC-157 is a naturally-derived sequence) makes this investment unattractive commercially.

### Is it safe to use BPC-157 while taking other medications?

Unknown. No drug interaction studies have been conducted in humans. If you take medications—particularly those affecting blood pressure, clotting, or immune function—discuss with a healthcare provider.

## The Bottom Line

BPC-157 represents a frustrating gap between promise and proof. The animal research is extensive and consistent. The mechanistic rationale is sound. Early human signals are positive.

But we're still waiting for the kind of evidence that distinguishes proven therapies from experimental compounds.

**What we know**:

- BPC-157 shows remarkable effects in animal models
- Three small human studies report positive results and no adverse events
- Short-term tolerance appears acceptable based on limited data

**What we don't know**:

- Long-term safety in humans
- Optimal dosing for various conditions
- Drug interactions
- Efficacy for most claimed uses in humans
- Whether animal benefits translate to people

**The regulatory reality**:

- FDA has restricted compounding due to safety concerns
- WADA prohibits use by athletes
- No country has approved BPC-157 for therapeutic use

If you choose to use BPC-157, do so with clear eyes about the evidence gaps. Source carefully, dose conservatively, and monitor closely. And hope that someday, proper trials will finally answer the questions that decades of animal research have raised.

[Learn more about BPC-157 →](/peptides/bpc-157)

[Read about BPC-157 side effects →](/guides/bpc-157-side-effects)


---

### BPC-157 Side Effects: Is It Safe?

URL: https://peptide-db.com/guides/bpc-157-side-effects

---
title: 'BPC-157 Side Effects: Is It Safe?'
description: 'A comprehensive guide to BPC-157 safety, side effects, and long-term risks. Learn what the research says, commonly reported issues, and how to use this healing peptide responsibly.'
date: '2025-12-09'
lastUpdated: '2025-12-09'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'safety'
difficulty: 'intermediate'
readingTime: '12 min'

tags:
  - bpc-157
  - side effects
  - safety
  - healing
  - peptide research

image: '/BPC-157-CHAIN.webp'
imageAlt: 'BPC-157 peptide molecular chain structure'
invertImageInDark: true

published: true
keywords: 'bpc-157 side effects, is bpc-157 safe, bpc-157 safety, bpc-157 risks, bpc-157 long term, healing peptide safety'
canonical: 'https://peptide-db.com/guides/bpc-157-side-effects'
showToc: true

relatedPeptides:
  - bpc-157
  - tb-500
  - ghk-cu
---

## Summary

[BPC-157](/peptides/bpc-157) is one of the most talked-about healing peptides in recovery and regenerative health. Derived from a compound found in human gastric juice, it shows impressive potential for tissue repair, inflammation reduction, and gut protection—without altering hormone levels.

### What the Research Shows

- **Animal studies are promising**: BPC-157 demonstrates an extremely high safety margin in rodents, with no toxicity or organ damage even at doses much higher than typical human use
- **No lethal dose established**: Across multiple organ systems and injury models, BPC-157 shows cytoprotective effects with no measurable toxicity
- **Human data is limited**: Despite decades of animal research, controlled human trials are scarce—most human safety data comes from anecdotal reports

### Common Side Effects

- **Mild and temporary**: Headache, light-headedness, mild nausea, fatigue, appetite changes
- **Injection-related**: Site irritation, redness, swelling, or tenderness (usually resolves in 24–72 hours)
- **Rare reports**: Vivid dreaming, mood shifts, water retention (often related to stacking protocols)

### Key Safety Considerations

- **Source quality matters**: Unregulated peptide markets mean purity varies—always verify third-party testing
- **Dose conservatively**: 250–500mcg/day is effective for most goals; higher isn't always better
- **Cycle responsibly**: Limit use to 4–6 weeks per cycle with breaks between
- **Theoretical long-term concerns**: Chronic angiogenesis stimulation raises questions for cancer-prone individuals

[Browse all healing peptides →](/peptides?category=healing)

## What Is BPC-157 and How Does It Work?

[BPC-157](/peptides/bpc-157) is a synthetic peptide composed of 15 amino acids, derived from a protein found in gastric juice. It works by activating several key healing pathways:

**Angiogenesis**: BPC-157 stimulates the formation of new blood vessels, helping deliver nutrients and oxygen to damaged tissues.

**Fibroblast and collagen regulation**: It promotes tendon, ligament, and muscle remodeling by supporting structural repair.

**Cytoprotective effects**: BPC-157 protects cells in the gut and nervous system against inflammation, oxidative stress, and toxins.

**Neuroregulation**: It interacts with the nitric oxide (NO) and dopamine systems, potentially aiding in nerve repair and mood stabilization.

> "BPC-157 has demonstrated wound-healing, anti-inflammatory, and organ-protective properties across numerous preclinical studies."
> — Sikiric, P. et al. Current Pharmaceutical Design, 2020

Because of its wide-ranging regenerative potential, BPC-157 is now being used off-label for everything from joint recovery and tendon tears to leaky gut and post-concussion healing. But before diving into a protocol, it's crucial to evaluate the potential risks, side effects, and unknowns—especially for long-term use.

## Is BPC-157 Safe? What the Science Says

The short answer: BPC-157 appears to be safe in animal models and anecdotal human use, but definitive safety conclusions for long-term human use have not yet been established.

### What the Research Shows

BPC-157 has been studied for over two decades in animal models, with consistent findings:

> "BPC-157 has shown an extremely high safety margin in rodents, with no toxicity or organ damage reported even at doses much higher than those typically used in humans."
> — Sikiric, P. et al. Current Pharmaceutical Design, 2020

In various studies, BPC-157 was observed to:

- Accelerate healing of muscle, tendon, ligament, nerve, and gut tissue
- Reduce inflammation, fibrosis, and oxidative stress
- Protect organ systems (gut, liver, brain) under chemical or surgical stress
- Stabilize blood vessels and prevent internal bleeding in injury models

Importantly, these effects occurred without toxicity, even when administered in high or repeated doses.

> "No lethal dose has been established for BPC-157 in animal models, and it demonstrates consistent protection against drug-induced and surgical organ damage."
> — Perovic, D. et al. Molecules, 2020

### What About Human Data?

Here's the caveat: while the animal data is overwhelmingly positive, human studies are extremely limited. BPC-157 is not currently approved by the FDA, and its classification as a research chemical means it has not undergone rigorous human testing.

That said, BPC-157 has developed a strong reputation in performance and longevity communities. Thousands of anecdotal reports support its safety for:

- Subcutaneous and intramuscular injection
- Oral use for GI issues
- Short-term protocols (2–6 weeks)

Because of its unregulated status, quality and dosing inconsistencies in peptide sourcing pose additional risks. Users should proceed carefully—especially with high doses or long-term use.

## Commonly Reported Side Effects

While BPC-157 is generally well-tolerated and lacks hormonal side effects, it's not entirely side-effect-free. Most reported issues are mild and temporary.

### Mild Side Effects

These tend to resolve on their own within a few days:

- Headache or light-headedness
- Mild nausea or upset stomach (especially with oral use)
- Fatigue or lethargy in the first few days
- Appetite changes (increase or decrease)
- Injection site irritation—redness, swelling, or tenderness

> "Mild dizziness, nausea, and local irritation are among the most commonly reported side effects of subcutaneous BPC-157 injection, typically resolving within 24–72 hours."
> — Milekic, T. et al. Regenerative Medicine Reviews, 2021

### User-Reported Issues

In addition to clinical insights, user communities have reported rare but notable experiences:

- Increased vivid dreaming or sleep disruption
- Mood shifts (increased calmness or, less commonly, irritability)
- Water retention or bloating (often related to stacking with other peptides like [CJC-1295](/peptides/cjc-1295))

### Should You Be Concerned?

In most cases, these side effects are transient and dose-dependent. Starting with a conservative dose (250mcg daily) and adjusting slowly tends to eliminate most discomfort. Using pharmaceutical-grade peptides, rotating injection sites, and staying hydrated can also minimize unwanted effects.

## Serious Risks or Adverse Reactions

While BPC-157 has not been associated with serious complications in animal research, it's important to consider potential risks—especially given the lack of human trials.

### Injection Site Reactions

Improper technique or contaminated products can lead to:

- Localized infections
- Bruising, swelling, or tissue irritation
- Subcutaneous nodules from repeated injections in the same area

These issues are almost always linked to poor sterility practices or repeated use of the same injection site.

### Vascular Effects (Theoretical Risk)

Because BPC-157 stimulates angiogenesis and influences the nitric oxide system, some experts caution about excessive vascular growth in susceptible individuals.

> "Prolonged or high-dose use of BPC-157 may carry a theoretical risk of vascular proliferation in undesired tissues, particularly in individuals with cancer or pre-existing vascular disease."
> — Perovic, D. et al. Molecules, 2020

That said, no vascular tumors or blood pressure irregularities have been documented in animal models, even with prolonged use.

### Immune System Reactions

As a synthetic peptide, BPC-157 has the potential to provoke immune responses, especially if the product is low quality or used in high doses for long periods. However, no autoimmune or allergic complications have been confirmed in published studies.

### Organ Stress and Toxicity

One of BPC-157's strengths is its organ-protective effect. To date, there is no evidence of liver, kidney, or cardiac damage in any animal trials—even at extremely high doses.

> "Across multiple organ systems and injury models, BPC-157 showed cytoprotective effects and no measurable toxicity, even with high cumulative exposure."
> — Sikiric, P. et al. Current Pharmaceutical Design, 2020

## Long-Term Safety Concerns

The biggest gap in our understanding isn't short-term use—it's what happens with chronic exposure in humans. While BPC-157 has a strong safety record in animals, there are no long-duration human trials available.

### Lack of Human Clinical Trials

The majority of BPC-157 research has been conducted in rodents and other animal models. These studies consistently show:

- No toxicity, even at high doses
- Organ-protective and regenerative benefits
- Absence of tumor formation, cardiovascular damage, or metabolic disruption

> "Despite extensive animal research supporting BPC-157's safety, human safety and pharmacokinetics remain largely unstudied due to its classification as a research chemical."
> — Sikiric, P. et al. Journal of Clinical Medicine, 2021

Any long-term use beyond 6–8 weeks is based entirely on user experimentation, not medical data.

### Theoretical Risks with Chronic Use

Concerns raised by clinicians include:

- **Unregulated angiogenesis**: Overstimulation of blood vessel growth could hypothetically support tumor progression in cancer-prone individuals
- **Unknown signaling crosstalk**: While non-hormonal, BPC-157 interacts with systems that may influence downstream signaling
- **Immune tolerance**: Chronic exposure to any peptide could alter immune recognition over time

### Recommendations for Long-Term Users

If you plan to use BPC-157 beyond a standard 4–6 week cycle:

- Take extended breaks between cycles
- Use the lowest effective dose
- Rotate injection sites
- Monitor subjective markers (energy, GI symptoms, inflammation, blood pressure)

Until clinical data becomes available, the guiding principle should be minimal effective use for specific, time-bound recovery goals.

## Factors That Influence Side Effects

Not everyone experiences side effects—but when issues arise, they're often related to how the peptide is used, where it's sourced, or individual biological variability.

### 1. Dosage and Frequency

Higher doses don't always mean better results. Many side effects occur when users exceed recommended ranges.

- **Start low**: 250–500mcg per day is sufficient for most goals
- **Avoid front-loading** unless medically directed
- **Stick to 2–6 week cycles**

> "A bell-shaped dose-response has been observed with BPC-157, meaning excessive dosing may reduce or reverse therapeutic effects."
> — Sikiric, P. et al. Current Pharmaceutical Design, 2020

### 2. Injection Technique and Site

Improper injection technique is a major cause of local side effects.

- Use a new sterile needle for each injection
- Rotate sites to avoid tissue inflammation
- Inject subcutaneously for systemic use, intramuscularly near injury for targeted repair

### 3. Peptide Purity and Source

One of the most critical variables is where you get your peptide. Because BPC-157 is not FDA-approved, quality varies significantly.

- Look for third-party testing and Certificates of Analysis (COAs)
- Avoid vendors that don't list ingredients or batch info
- Be cautious with unusually cheap vials

Low-quality peptides may contain contaminants, incorrect sequences, or bacterial endotoxins.

### 4. Preexisting Health Conditions

Although generally well-tolerated, individuals with certain conditions may be more sensitive:

- **Cardiovascular disease**: Monitor blood pressure due to NO interaction
- **Autoimmune disorders**: Consider immune modulation risks
- **Cancer history**: Use with caution due to angiogenesis stimulation

Always consult a healthcare provider if you have preexisting conditions or take prescription medications.

## How to Use BPC-157 Responsibly

BPC-157's safety depends largely on how you use it. Responsible use means taking proactive steps to minimize risk.

### Source Pharmaceutical-Grade Peptides

Only purchase from vendors that provide third-party testing and Certificates of Analysis. Low-quality or mislabeled peptides are one of the most common sources of side effects.

### Start Low and Adjust

BPC-157 is effective even at low doses. Begin with 250mcg per day, observe your response over 3–7 days, and increase only if needed.

> "In peptide therapy, conservative titration with consistent monitoring tends to yield better outcomes and fewer side effects than aggressive front-loading."
> — Milekic, T. et al. Regenerative Medicine Reviews, 2021

### Follow Sterile Injection Protocols

- Use a new sterile needle each time
- Clean the vial top and injection site with alcohol
- Rotate injection sites
- Store reconstituted peptides in the fridge and dispose after 30 days

Use our [dosing calculator](/calculator) to determine correct injection volumes.

### Cycle Appropriately

Peptides aren't meant for indefinite use. Set a goal, follow a protocol, and cycle off.

- Limit use to 4–6 weeks per cycle
- Take breaks between cycles
- Avoid stacking multiple peptides unless experienced

### Consult a Medical Professional

Discussing peptide therapy with a knowledgeable healthcare provider can help you avoid contraindications, customize dosage, and monitor health responses.

## Frequently Asked Questions

### Is BPC-157 Safe for Women?

Yes. BPC-157 is non-hormonal—it doesn't interact with estrogen, testosterone, or other sex hormones. Women can use standard dosages, though those with lower body mass may start at the lower end (250mcg/day).

### Can You Use BPC-157 Long Term?

While many users have used BPC-157 for extended periods without immediate side effects, there is no long-term human safety data. Most experts recommend limiting use to 4–6 week cycles with 4–8 week breaks between.

### Can You Overdose on BPC-157?

No lethal dose has been established, and animal models show a very high safety threshold. However, unnecessarily high doses (>1000mcg/day) can increase headaches, fatigue, and diminishing returns.

### What Happens If You Stop Taking BPC-157 Suddenly?

Nothing dangerous. BPC-157 does not cause withdrawal symptoms or receptor dependence. Healing effects may gradually taper, but no rebound inflammation or hormonal disruption is expected.

### Is BPC-157 Safe to Combine With Other Peptides?

Yes, but stacking increases complexity. Many users successfully combine BPC-157 with:

- [TB-500](/peptides/tb-500) for enhanced tissue regeneration
- [CJC-1295](/peptides/cjc-1295) and [Ipamorelin](/peptides/ipamorelin) for GH-mediated recovery
- Antioxidants and collagen supplements for support

Introduce one compound at a time to track side effects properly.

## The Bottom Line

BPC-157 is one of the most promising healing peptides available today. From soft tissue repair and gut healing to neurological support, its benefits are backed by decades of preclinical research and growing anecdotal evidence.

But as with any compound not yet clinically approved for human use, its safety depends on:

- The quality of the peptide
- The accuracy of dose and administration
- The duration and purpose of use
- Your individual health profile and risk tolerance

> "While BPC-157 exhibits an extraordinary safety profile in animals, its long-term safety in humans remains to be fully established."
> — Sikiric, P. et al. Current Pharmaceutical Design, 2020

**If you're considering BPC-157:**

- Start with a low, effective dose and clear goal
- Limit cycles to 2–6 weeks
- Source only pharmaceutical-grade peptides
- Monitor your body's response closely
- Speak to a qualified healthcare provider if unsure

Used responsibly, BPC-157 may be one of the most valuable tools in your recovery toolkit. But informed use is the only safe use.

[Learn more about BPC-157 →](/peptides/bpc-157)

[Browse all peptides →](/peptides)


---

### BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

URL: https://peptide-db.com/guides/bpc-157-vs-tb-500

---
title: 'BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack'
description: 'How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.'
date: '2026-04-07'
lastUpdated: '2026-04-07'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'protocols'
difficulty: 'intermediate'
readingTime: '16 min'

tags:
  - bpc-157
  - tb-500
  - wolverine stack
  - peptide comparison
  - healing peptides
  - tissue repair
  - peptide stack
  - wolverine peptide

image: '/guides/bpc-157-vs-tb-500.webp'
imageAlt: 'BPC-157 localized tissue repair compared to TB-500 systemic cell migration healing peptides'

published: true
keywords: 'bpc 157 vs tb 500, bpc-157 vs tb-500, wolverine stack, wolverine peptide, bpc157 tb500, tb-500 peptide, bpc 157 and tb 500, peptide healing stack, wolverine stack peptide, tb 500 dosage, tb 500 benefits'
canonical: 'https://peptide-db.com/guides/bpc-157-vs-tb-500'
showToc: true

relatedPeptides:
  - bpc-157
  - tb-500
  - wolverine-stack
  - ghk-cu

relatedGuides:
  - title: 'BPC-157 Human Clinical Trials: Complete Status & Results'
    slug: 'bpc-157-human-trials'
    image: '/BPC-157-CHAIN.webp'
    excerpt: 'Every published BPC-157 human study through 2026, with detailed results and analysis.'
  - title: 'BPC-157 Side Effects: Is It Safe?'
    slug: 'bpc-157-side-effects'
    image: '/BPC-157-CHAIN.webp'
    excerpt: 'Research-based analysis of BPC-157 safety, side effects, and risk factors.'
  - title: 'KLOW Peptide Protocol: Ingredients, Dosing, and Research'
    slug: 'klow-peptide-protocol'
    image: '/guides/klow-peptide-protocol.webp'
    excerpt: 'Breakdown of the four-peptide KLOW blend including BPC-157 and TB-500.'
---

<script>
  import { BarChart, ComparisonScale, SpectrumBar, Callout, MermaidDiagram } from '$lib/components/charts';
</script>

## Summary

[BPC-157](/peptides/bpc-157) and [TB-500](/peptides/tb-500) are the two most commonly recommended healing peptides. They're often treated as interchangeable online. They shouldn't be.

### Key Differences

- **BPC-157** (1,419 Da, 15 amino acids) drives localized repair through VEGF upregulation and nitric oxide modulation. Dosed at 250-500mcg, once or twice daily. Half-life under 30 minutes
- **TB-500** (4,963 Da, 43 amino acids) works systemically by sequestering G-actin to enable cell migration toward injury sites. Dosed at 2-5mg, two or three times weekly. Half-life around 2 hours
- **The [Wolverine Stack](/peptides/wolverine-stack)** combines both: BPC-157 builds vascular infrastructure at the injury site while TB-500 mobilizes repair cells from across the body
- Neither is FDA-approved. BPC-157 has 3 small pilot studies with fewer than 30 total subjects. TB-500 (as thymosin beta-4) has Phase I, II, and III clinical trial data

### When to Pick Which

- **BPC-157 first**: gut healing, localized tendon/joint injuries, injuries you can inject near
- **TB-500 first**: systemic muscle damage, post-surgical recovery, multi-site inflammation
- **Both (Wolverine Stack)**: serious tissue damage, healing plateaus, comprehensive recovery

[Reconstitution calculator](/calculator) | [Accumulation plotter](/calculator/accumulation)

## Different Peptides, Different Jobs

BPC-157 clears your system in under 30 minutes. TB-500 sticks around for about 2 hours. One is dosed in micrograms. The other in milligrams. Molecular weight: 1,419 Daltons versus 4,963. Despite this, peptide forums treat them as interchangeable. They aren't.

Understanding how each peptide works at a cellular level determines whether you pick one, the other, or stack both. The mechanisms behind the shared "healing peptide" label have almost nothing in common.

## How BPC-157 Drives Localized Repair

[BPC-157](/peptides/bpc-157) (Body Protection Compound-157) is a synthetic pentadecapeptide originally isolated from a protective protein in human gastric juice. Sequence: Gly-Lys-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular weight: 1,419.53 Daltons. Half-life: under 30 minutes subcutaneously.

That short half-life isn't a weakness. It reflects the peptide's role as a localized signaling molecule rather than a systemic drug.

BPC-157's primary healing pathway runs through VEGFR2. Hsieh et al. (Journal of Molecular Medicine, 2017) demonstrated that BPC-157 activates VEGFR2, which triggers downstream Akt phosphorylation and eNOS expression. The result: new blood vessel formation at the injury site. This is why injecting near the injury matters. You're directing angiogenesis exactly where tissue needs it.

But blood vessels aren't the whole picture. A 2025 systematic review by Vasireddi et al. (HSS Journal, 36 studies from 1993-2024) confirmed BPC-157 also upregulates growth hormone receptor expression and reduces inflammatory cytokines in musculoskeletal injury models. Park et al. (Current Pharmaceutical Design, 2020) showed it stabilizes intestinal mucosal barriers and rescues NSAID-induced cytotoxicity. Staresinic et al. (Journal of Orthopaedic Research, 2003) documented accelerated Achilles tendon healing in rats with improved load-to-failure and Young's modulus values.

The common thread: BPC-157 builds infrastructure at the injury site. New blood vessels, collagen matrix, growth factor receptors. It prepares the ground so the body's own repair systems can work faster.

<MermaidDiagram
  title="BPC-157: Localized Repair Pathways"
  chart={`
    graph TD
      A[BPC-157 Administered Near Injury] --> B[VEGFR2 Activation]
      A --> C[Nitric Oxide Modulation]
      A --> D[GH Receptor Upregulation]
      B --> E[Akt → eNOS Signaling]
      E --> F[Angiogenesis at Injury Site]
      C --> G[Vasodilation & Blood Flow]
      D --> H[Enhanced Growth Factor Response]
      F --> I[Localized Tissue Repair]
      G --> I
      H --> I
  `}
/>

### BPC-157 human evidence

The human data is thin. Three pilot studies from a single research group in Florida, totaling fewer than 30 subjects.

Lee & Padgett (Alternative Therapies in Health and Medicine, 2021) injected BPC-157 into the knees of 16 patients with chronic pain. 87.5% reported significant relief at 6-12 months. No placebo control. A 2024 interstitial cystitis pilot by Lee et al. treated 12 women with bladder injections and saw 80-100% symptom resolution. A 2025 IV safety study confirmed no adverse effects at doses up to 20mg in two adults.

Small numbers. No randomization or blinding. But the results got attention. For the complete breakdown: [BPC-157 Human Clinical Trials](/guides/bpc-157-human-trials).

## How TB-500 Works Systemically

[TB-500](/peptides/tb-500) is a synthetic form of thymosin beta-4, the body's primary actin-sequestering protein. Molecular weight: 4,963.44 Daltons. Length: 43 amino acids. Half-life: approximately 2 hours. More than three times the size of BPC-157, with a pharmacokinetic window roughly four times longer.

Where BPC-157 builds infrastructure at one location, TB-500 controls traffic across the entire body.

The mechanism centers on G-actin. When tissue is damaged, repair cells need to physically travel to the injury site. That migration requires rapid cytoskeletal remodeling: cells extending pseudopods, reorganizing internal scaffolding, pulling themselves forward through tissue. All of that demands G-actin monomers. TB-500 regulates the supply by sequestering actin into a pool of ready-to-use building blocks.

Goldstein et al. (Expert Opinion on Biological Therapy, 2012) laid out five distinct effects from this one mechanism: cell migration, stem cell mobilization, new blood vessel formation, inflammation reduction, and decreased scar formation. One protein controlling actin availability produces all five downstream results.

<MermaidDiagram
  title="TB-500: Systemic Repair Through Actin Regulation"
  chart={`
    graph TD
      A[TB-500 Administered] --> B[G-Actin Sequestration]
      A --> C[Stem Cell Mobilization]
      A --> D[Anti-Inflammatory Signaling]
      B --> E[Cytoskeletal Remodeling]
      E --> F[Rapid Cell Migration to Injury]
      C --> G[Progenitor Cell Recruitment]
      F --> H[Tissue Repair & Regeneration]
      G --> H
      D --> I[Reduced Scar Formation]
      H --> J[Systemic Recovery]
      I --> J
  `}
/>

### TB-500 human evidence

The clinical picture is substantially stronger than BPC-157.

Wang et al. (Journal of Cellular and Molecular Medicine, 2021) published a Phase I dose-escalation study in 54 healthy subjects. Ascending IV doses from 0.05 to 25.0 mcg/kg produced only mild to moderate adverse events. Zero dose-limiting toxicities. Zero serious adverse events.

Treadwell et al. (Annals of the New York Academy of Sciences, 2012) reported two Phase II clinical trials where thymosin beta-4 accelerated healing of chronic pressure ulcers and venous stasis ulcers by approximately one month compared to placebo. Placebo-controlled data. Something BPC-157 doesn't have.

Sosne et al. (Cornea, 2015) ran a Phase II randomized trial in 9 severe dry eye patients. RGN-259 (0.1% thymosin beta-4 eye drops) achieved statistically significant improvements in both signs and symptoms, with effects persisting 28 days after treatment ended. That same group reached Phase III (International Journal of Molecular Sciences, 2022) with a randomized, double-masked trial demonstrating corneal healing in neurotrophic keratopathy patients.

Phase I, Phase II, Phase III. That's a clinical evidence trajectory BPC-157 hasn't approached.

## BPC-157 vs TB-500: Head to Head

| Property | BPC-157 | TB-500 |
|----------|---------|--------|
| **Molecular weight** | 1,419.53 Da | 4,963.44 Da |
| **Amino acids** | 15 | 43 |
| **Source protein** | Human gastric juice | Thymosin beta-4 |
| **Half-life** | Under 30 minutes | ~2 hours |
| **Typical dose** | 250-500mcg | 2-5mg |
| **Dosing frequency** | 1-2x daily | 2-3x weekly |
| **Primary mechanism** | VEGFR2/angiogenesis, NO modulation | Actin sequestration, cell migration |
| **Best application** | Localized injury, gut healing | Systemic repair, muscle regeneration |
| **Human trials** | 3 pilot studies (under 30 subjects) | Phase I, II, III (100+ subjects) |
| **FDA status** | Category 2 (restricted) | Not scheduled |
| **WADA status** | Prohibited (S0) | Prohibited |

<ComparisonScale
  title="Clinical Evidence Quality (1 = anecdotal only, 10 = Phase III RCT data)"
  items={[
    { label: 'BPC-157', position: 3, color: '#CC785C' },
    { label: 'TB-500 (Thymosin Beta-4)', position: 7, color: '#D4A27F' }
  ]}
  min={1}
  max={10}
  leftLabel="Anecdotal"
  rightLabel="Phase III RCT"
/>

The pharmacokinetic difference explains why these peptides are dosed so differently. BPC-157 peaks fast and clears fast. TB-500 peaks later and lingers.

<SpectrumBar
  title="BPC-157: Pharmacokinetic Window After Injection"
  segments={[
    { label: 'Peak', sublabel: '~5 min', width: 1, color: '#059669' },
    { label: 'Active', sublabel: '5-30 min', width: 2, color: '#CC785C' },
    { label: 'Cleared', sublabel: '>30 min', width: 4, color: '#91918D' }
  ]}
  leftLabel="Injection"
  rightLabel="Eliminated"
/>

<SpectrumBar
  title="TB-500: Pharmacokinetic Window After Injection"
  segments={[
    { label: 'Peak', sublabel: '~15 min', width: 1, color: '#059669' },
    { label: 'Active', sublabel: '15 min - 2 hrs', width: 4, color: '#D4A27F' },
    { label: 'Declining', sublabel: '2-4 hrs', width: 2, color: '#91918D' },
    { label: 'Cleared', sublabel: '>4 hrs', width: 1, color: '#666663' }
  ]}
  leftLabel="Injection"
  rightLabel="Eliminated"
/>

### When BPC-157 is the better choice

BPC-157 excels when the problem is in one place. A torn Achilles tendon, a rotator cuff you can inject near, gastric ulcers, NSAID-damaged gut lining, inflammatory bowel symptoms. Its angiogenic signaling concentrates at the injection site, building blood vessels and collagen matrix where you direct it.

Gastric stability is another advantage. BPC-157 remains active in stomach acid, making oral dosing viable for GI conditions. TB-500 doesn't survive oral administration reliably.

### When TB-500 is the better choice

TB-500 makes more sense for widespread damage. Multi-site injuries, full-body recovery after surgery, chronic inflammation across several joints, athletic recovery where the entire musculoskeletal system is under stress. Its longer half-life and systemic cell-mobilization mechanism cover territory that BPC-157's localized approach simply can't reach.

TB-500's wound healing data is also stronger in absolute terms. Placebo-controlled Phase II trials showing roughly one month of accelerated chronic ulcer healing. BPC-157 has nothing equivalent.

## The Wolverine Stack: Running Both Together

The name comes from the Marvel character's regenerative abilities. It stuck because the BPC-157 and TB-500 combination addresses tissue repair from two complementary angles that don't overlap.

The biological logic: BPC-157 upregulates VEGF and builds vascular infrastructure at injury sites. TB-500 sequesters G-actin to mobilize repair cells toward those sites. One peptide builds the roads. The other sends the repair crew down them.

### Standard protocol

**BPC-157**: 250mcg subcutaneous, twice daily (morning and evening). Inject near the injury site when accessible.

**TB-500**: 2-2.5mg subcutaneous, twice weekly (e.g., Monday and Thursday).

**Cycle length**: 6-8 weeks for active injury recovery.

**Optional loading phase**: TB-500 at 5mg twice weekly for the first 2 weeks, then reduce to 2-2.5mg for the remaining cycle.

Each peptide is reconstituted separately with bacteriostatic water. Don't mix them in the same syringe unless using a pre-made blend. Use separate injection sites when dosing on the same day. [Calculate your reconstitution volumes here](/calculator).

<BarChart
  title="Wolverine Stack: Expected Healing Progress Over 8 Weeks"
  data={[
    { label: 'Week 1-2: Inflammation reduction', value: 25, color: '#91918D' },
    { label: 'Week 2-4: Recovery improvements', value: 55, color: '#D4A27F' },
    { label: 'Week 4-6: Structural repair', value: 80, color: '#CC785C' },
    { label: 'Week 6-8: Peak tissue remodeling', value: 95, color: '#059669' }
  ]}
  maxValue={100}
  barColor="#CC785C"
/>

### Why the dosing looks so different

The asymmetry confuses people at first. BPC-157 in micrograms daily. TB-500 in milligrams weekly. The half-lives explain it.

BPC-157 clears in under 30 minutes. Frequent small doses maintain consistent signaling at the injury site throughout the day. Think of it as a daily signal flare telling the body where to send resources.

TB-500 lasts roughly 2 hours and distributes systemically. Less frequent, larger doses keep adequate tissue-level concentrations through the week. Two or three injections sustain the cell-migration effect without daily dosing.

### What about pre-mixed blends?

BPC-157/TB-500 blends exist, including the [KLOW protocol](/guides/klow-peptide-protocol) which adds [GHK-Cu](/peptides/ghk-cu) and [KPV](/peptides/kpv) to the stack. These trade dosing flexibility for convenience. If your injury responds better to higher TB-500, you can't adjust one peptide without changing the other in a blend.

For most use cases, separate vials provide more control over individual dosing. The [reconstitution calculator](/calculator) handles the math for both.

[View the full Wolverine Stack protocol data](/peptides/wolverine-stack)

## The Evidence Gap: What's Real and What's Extrapolated

<Callout type="research" title="Research Status as of April 2026">

BPC-157 has an extensive preclinical literature: over 100 animal studies across three decades. But only 3 small human pilot studies have been published, with fewer than 30 total subjects and no placebo controls. TB-500 (as thymosin beta-4) has Phase I safety data in 54 subjects, Phase II wound healing trials with placebo controls, and a completed Phase III corneal healing trial. The gap in clinical evidence quality between these two peptides is significant.

</Callout>

The most common mistake in peptide forums is treating preclinical evidence as equivalent to clinical evidence. BPC-157's 100+ animal studies demonstrate biological mechanism and therapeutic potential in rodent models. They don't demonstrate safety or efficacy in humans.

Mice heal differently than people. Dose extrapolations from 10 mcg/kg in a rat don't reliably predict human pharmacokinetics. The only published BPC-157 pharmacokinetic study (Xu et al., Frontiers in Pharmacology, 2022) showed 14-19% intramuscular bioavailability in rats and 45-51% in dogs. No human PK data has been published. The doses people use today are educated guesses based on animal extrapolation and community trial-and-error.

TB-500 sits on firmer ground clinically. But it's still not FDA-approved for healing or performance applications. The Phase III trial (Sosne et al., 2022) addressed corneal healing specifically, not the musculoskeletal uses most people want it for.

Both peptides need more human data. That's the honest answer. The question is how much uncertainty you're comfortable with, and whether the existing evidence justifies the risk for your specific situation.

## Safety: Shared Risks and Contraindications

Both BPC-157 and TB-500 promote angiogenesis. That's their healing mechanism. It's also the reason active cancer is a hard contraindication for both.

<Callout type="warning" title="Cancer and Angiogenesis Risk">

Both BPC-157 and TB-500 promote new blood vessel formation (angiogenesis). Tumor growth depends on blood supply. Anyone with active cancer, a history of cancer, or suspicious growths should avoid both peptides. This risk is theoretical but biologically plausible, and not one worth taking.

</Callout>

Other shared contraindications include pregnancy, breastfeeding, and concurrent anticoagulant therapy. Both peptides affect vascular growth in ways that may interact with blood thinners.

Reported side effects for both tend to be mild. BPC-157 users note headaches and light-headedness more frequently. TB-500 users report temporary fatigue and occasional lethargy in the first week. Injection site redness and swelling are the most common complaint for both. Neither peptide has produced serious adverse events in published human data.

For a deep dive into BPC-157's risk profile: [BPC-157 Side Effects: Is It Safe?](/guides/bpc-157-side-effects)

Both are prohibited by WADA. Competitive athletes should avoid use entirely. The legal status of BPC-157 is also in flux. It was placed on the FDA Category 2 list in 2023, but the [2026 reclassification process](/guides/fda-peptide-reclassification-2026) may restore compounding pharmacy access. TB-500 (thymosin beta-4) is not on the Category 2 list and has active Investigational New Drug applications.

## Frequently Asked Questions

### Can I take BPC-157 and TB-500 at the same time?

Yes. The [Wolverine Stack](/peptides/wolverine-stack) runs both concurrently: BPC-157 at 250mcg twice daily alongside TB-500 at 2-2.5mg twice weekly. They work through different receptors and pathways. No negative interactions have been documented. Use separate injection sites when dosing on the same day.

### Is TB-500 the same as thymosin beta-4?

Not exactly. Commercial TB-500 may contain the full 43-amino-acid thymosin beta-4 sequence or just the 7-amino-acid active fragment (Ac-LKKTETQ). Most clinical research used full-length thymosin beta-4. The fragment retains the actin-binding domain responsible for cell migration and wound healing but may differ in systemic distribution.

### Which one works better for tendon injuries?

BPC-157 has more direct tendon evidence. Staresinic et al. (Journal of Orthopaedic Research, 2003) showed accelerated Achilles tendon healing with improved biomechanical properties in rats. If you can inject near the injured tendon, BPC-157 likely has the advantage. For diffuse connective tissue issues affecting multiple sites, TB-500's systemic reach covers more ground.

### How long should a Wolverine Stack cycle last?

Standard cycles run 6-8 weeks. Inflammation reduction typically starts in week 1-2. Recovery improvements become noticeable around week 2-4. Structural tissue changes peak between week 4-8. Some protocols front-load TB-500 at 5mg twice weekly for the first two weeks before dropping to maintenance doses.

### Are BPC-157 and TB-500 legal?

Status varies by country and is changing. BPC-157 sits on the FDA Category 2 list (2023), restricting compounding pharmacy access, though the [2026 reclassification](/guides/fda-peptide-reclassification-2026) may change this. TB-500 is not on the Category 2 list and has active IND applications for ophthalmic uses. Both are sold as "research chemicals" in a legal grey area. Both are banned by WADA for competitive athletes.


---

### CJC-1295 and Ipamorelin: How the Stack Works

URL: https://peptide-db.com/guides/cjc-1295-ipamorelin

---
title: 'CJC-1295 and Ipamorelin: How the Stack Works'
description: 'How CJC-1295 and Ipamorelin work together to stimulate growth hormone through two separate pathways. Dosing protocols, DAC vs no-DAC, side effects, and alternatives compared.'
date: '2026-03-24'
lastUpdated: '2026-03-24'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'protocols'
difficulty: 'intermediate'
readingTime: '15 min'

tags:
  - cjc-1295
  - ipamorelin
  - growth hormone
  - peptide stack
  - ghrh
  - ghrp
  - cjc-1295 dac
  - sermorelin

image: '/guides/cjc-1295-ipamorelin-stack.webp'
imageAlt: 'CJC-1295 and Ipamorelin peptide stack pairing illustration'

published: true
keywords: 'cjc 1295 ipamorelin, cjc-1295 ipamorelin dosage, cjc-1295 ipamorelin stack, cjc 1295 ipamorelin benefits, cjc-1295 ipamorelin side effects, cjc-1295 vs cjc-1295 dac, ipamorelin dosage'
canonical: 'https://peptide-db.com/guides/cjc-1295-ipamorelin'
showToc: true

relatedPeptides:
  - cjc-1295
  - cjc-1295-dac
  - ipamorelin
  - cjc-ipa-protocol
  - sermorelin
  - ghrp-2

relatedGuides:
  - title: 'KLOW Peptide Protocol: Ingredients, Dosing, and Research'
    slug: 'klow-peptide-protocol'
    image: '/guides/klow-peptide-protocol.webp'
    excerpt: 'A research-based breakdown of the four-peptide KLOW blend.'
  - title: 'Peptides: What They Are, Side Effects, and Uses'
    slug: 'what-are-peptides'
    image: '/peptides.webp'
    excerpt: 'A comprehensive introduction to peptides and how they work.'
---

<script>
  import { BarChart, ComparisonScale, SpectrumBar, Callout, MermaidDiagram } from '$lib/components/charts';
</script>

## Summary

The [CJC-1295](/peptides/cjc-1295) and [Ipamorelin](/peptides/ipamorelin) stack is the most widely used growth hormone peptide combination. It works because the two peptides trigger GH release through completely different receptor systems, producing a combined effect greater than either one alone.

### How It Works

- **CJC-1295** is a GHRH analog that binds GHRH receptors on pituitary somatotroph cells, signalling the pituitary to produce and release growth hormone. It has **4x greater receptor affinity** than native GHRH (receptor binding study, 2010)
- **Ipamorelin** is a selective ghrelin receptor agonist (GHSR1a) that triggers GH release through an entirely separate pathway. A 1998 study (Raun et al.) showed it produces **no cortisol or prolactin elevation** even at 200x the effective dose
- **Combined**: CJC-1295 tells the pituitary to make GH. Ipamorelin tells it to release GH. Two signals, two pathways, one amplified pulse

### Key Numbers

- **Standard dose**: 100-300mcg of each peptide, 1-3x daily via subcutaneous injection
- **Cycle length**: 8-16 weeks on, 4-8 weeks off
- **Timeline**: improved sleep by week 1-2, body composition changes by week 4-8
- **DAC variant**: extends CJC-1295's half-life from 30 minutes to 6-8 days, but sacrifices pulsatile release pattern

[View the CJC/IPA protocol data](/peptides/cjc-ipa-protocol) | [Accumulation calculator](/calculator/accumulation)

## Two Pathways, One GH Pulse

Most peptide stacks combine compounds that work through similar mechanisms. The CJC-1295 and Ipamorelin combination doesn't. These two peptides hit entirely different receptor systems on the same target cells.

CJC-1295 (also called Mod GRF 1-29 or Modified GRF) is a synthetic analog of growth hormone-releasing hormone. Your hypothalamus naturally produces GHRH to tell the pituitary gland to secrete growth hormone. CJC-1295 mimics that signal with roughly four times the binding affinity of the natural hormone (in vitro receptor binding study, 2010). It's the accelerator.

Ipamorelin works through the ghrelin receptor, a completely separate signalling cascade. When ghrelin binds GHSR1a on pituitary somatotrophs, it triggers a calcium-dependent GH release that amplifies whatever GHRH is already doing. A 2002 cellular study (Cunha & Mayo) demonstrated that the presence of active GHS receptors potentiates GHRH signalling, meaning the two pathways don't just add up. They multiply.

That's the core argument for this stack. Not two peptides doing the same thing twice, but two peptides each removing a different bottleneck in GH secretion.

<MermaidDiagram
title="CJC-1295 + Ipamorelin: Dual-Pathway GH Stimulation"
chart={`     graph TD
      A[CJC-1295] -->|Binds GHRH Receptor| B[Pituitary Somatotrophs]
      C[Ipamorelin] -->|Binds Ghrelin Receptor GHSR1a| B
      B --> D[cAMP Production Increased]
      B --> E[Ca2+ Dependent Release]
      D --> F[GH Synthesis Upregulated]
      E --> G[GH Release Amplified]
      F --> H[Pulsatile GH Secretion]
      G --> H
      H --> I[IGF-1 Elevation]
      I --> J[Muscle Protein Synthesis]
      I --> K[Fat Metabolism]
      I --> L[Recovery & Repair]
  `}
/>

## CJC-1295: The Signal Sender

[CJC-1295 without DAC](/peptides/cjc-1295) is a 30-amino-acid GHRH analog weighing 3,367.97 Daltons. Its half-life sits between 30 minutes and 2 hours, which matters more than it sounds.

That short half-life is actually the point. Natural GH secretion is pulsatile. Your pituitary fires GH in bursts throughout the day, with the largest pulse occurring during deep sleep. CJC-1295 without DAC preserves that pattern. A 2008 human study (24 subjects, 100mcg three times daily for 30 days) confirmed preserved natural GH pulsatility with no pituitary desensitization.

A 2006 pharmacokinetic study in 12 subjects showed peak GH at 15-30 minutes post-injection with doses of 100-200mcg. The GH pulse rises, does its work, and clears. Just like the body intends.

**Molecular weight**: 3,367.97 Da | **Half-life**: 30 min - 2 hours | **30 amino acids**

## Ipamorelin: The Clean Releaser

[Ipamorelin](/peptides/ipamorelin) is a pentapeptide weighing 711.85 Da. Five amino acids. Small molecule, big selectivity advantage.

The selectivity is what separates Ipamorelin from older growth hormone secretagogues like [GHRP-2](/peptides/ghrp-2) and GHRP-6. All three bind the ghrelin receptor. But GHRP-2 and GHRP-6 also jack up cortisol, prolactin, and appetite. Ipamorelin doesn't. Raun et al. (1998) showed zero significant cortisol or ACTH elevation even at 200 times the effective GH-releasing dose. That study is why Ipamorelin became the default GHRP for clinical protocols.

A 2019 GH stimulation study found consistent elevation 30-60 minutes post-injection at 200mcg daily over 8 weeks. A 2020 body composition trial (250mcg daily, 12 weeks) documented lean mass gains and bone density improvements in adults over 45. A 2021 sleep study showed improved sleep latency and increased slow-wave sleep at 200mcg before bed.

**Molecular weight**: 711.85 Da | **Half-life**: ~2 hours | **5 amino acids**

<ComparisonScale
title="Side Effect Profile: Ipamorelin vs Other GH Secretagogues (1 = minimal, 10 = significant)"
items={[
{ label: 'Ipamorelin - Cortisol', position: 1, color: '#059669' },
{ label: 'Ipamorelin - Hunger', position: 2, color: '#059669' },
{ label: 'GHRP-2 - Cortisol', position: 5, color: '#CC785C' },
{ label: 'GHRP-2 - Hunger', position: 6, color: '#CC785C' },
{ label: 'GHRP-6 - Cortisol', position: 6, color: '#BF4D43' },
{ label: 'GHRP-6 - Hunger', position: 9, color: '#BF4D43' }
]}
min={1}
max={10}
leftLabel="Negligible impact"
rightLabel="Major impact"
/>

## DAC vs No-DAC: The Half-Life Trade-Off

This is the most common source of confusion. CJC-1295 comes in two variants, and they behave completely differently.

**DAC** stands for Drug Affinity Complex. It's a molecular modification that binds CJC-1295 to albumin in the blood, dragging its half-life from 30 minutes up to **6-8 days**. A 2006 study (Teichman et al.) in 12 subjects showed sustained GH and IGF-1 elevation lasting 6-10 days from a single injection, with peak levels at 2-4x baseline.

Sounds better, right? Longer duration, fewer injections. One shot a week instead of two or three daily.

The problem is physiology. Your body doesn't maintain GH at a constant elevated level. It pulses. The [CJC-1295 DAC](/peptides/cjc-1295-dac) variant provides continuous GHRH receptor stimulation, which is closer to exogenous HGH than to natural GH patterns. A 2012 animal study over 6 months found evidence of reduced GH pulse amplitude with prolonged DAC use, suggesting receptor desensitization. A 2015 pharmacokinetic comparison confirmed that the non-DAC variant preserves more physiological secretion patterns.

|                          | CJC-1295 (No DAC)                            | CJC-1295 with DAC                          |
| ------------------------ | -------------------------------------------- | ------------------------------------------ |
| **Half-life**            | 30 min - 2 hours                             | 6-8 days                                   |
| **Dosing**               | 100-300mcg, 2-3x daily                       | 1-2mg, once weekly                         |
| **GH pattern**           | Pulsatile (natural)                          | Sustained elevation                        |
| **Desensitization risk** | Low                                          | Higher with prolonged use                  |
| **Ipamorelin pairing**   | Strong (matched pulsatile timing)            | Reduced (continuous vs pulsatile conflict) |
| **Side effects**         | Fewer, milder                                | More water retention, joint issues         |
| **Convenience**          | Low (daily injections)                       | High (weekly)                              |
| **Best for**             | Long-term protocols, pairing with Ipamorelin | Short cycles prioritizing convenience      |

<Callout type="info" title="Which Pairs Better with Ipamorelin?">

CJC-1295 without DAC. The matched half-lives (30 min - 2 hours for CJC, ~2 hours for Ipamorelin) mean both peptides peak and clear together, creating a clean GH pulse. The DAC variant's continuous stimulation partially defeats the purpose of Ipamorelin's selective pulsatile release.

</Callout>

## Dosing Protocols

The [CJC/IPA protocol](/peptides/cjc-ipa-protocol) is typically dosed at a 1:1 ratio. Standard blended vials contain 2mg CJC-1295 + 2mg Ipamorelin (4mg total).

### Protocol Options

| Goal             | CJC-1295 Dose | Ipamorelin Dose | Frequency          | Notes                       |
| ---------------- | ------------- | --------------- | ------------------ | --------------------------- |
| General health   | 100mcg        | 100mcg          | 1x daily (bedtime) | Conservative starting point |
| Anti-aging/sleep | 150-200mcg    | 200mcg          | 1x daily (bedtime) | Most common protocol        |
| Body composition | 200-300mcg    | 250-300mcg      | 2x daily (AM + PM) | More aggressive             |
| Performance      | 200mcg        | 200-250mcg      | 2-3x daily         | Empty stomach required      |
| Conservative     | 150mcg        | 150mcg          | 5 days/week        | Weekend breaks              |

### Timing Rules

Timing matters more for this stack than for most peptides. GH release is blunted by insulin and elevated blood glucose.

- Inject on an **empty stomach**, at least 2-3 hours after your last meal
- Wait **20-30 minutes** after injection before eating
- **Before bed** is the single best timing, since it amplifies the natural nocturnal GH surge
- If dosing twice daily, morning (fasted) and bedtime are the standard windows
- Post-workout is an option for a third daily dose, but only if you haven't eaten recently

<SpectrumBar
title="Optimal Injection Timing Windows"
segments={[
{ label: 'Morning Fasted', sublabel: 'Strong', width: 2, color: '#059669' },
{ label: 'Mid-day', sublabel: 'Weak', width: 2, color: '#91918D' },
{ label: 'Post-Workout', sublabel: 'Moderate', width: 2, color: '#D4A27F' },
{ label: 'Pre-Bed', sublabel: 'Optimal', width: 3, color: '#059669' }
]}
leftLabel="Wake"
rightLabel="Sleep"
/>

### Cycle Structure

- **On cycle**: 8-16 weeks
- **Off cycle**: 4-8 weeks
- **Why cycle**: Ipamorelin's 2023 safety analysis noted potential receptor desensitization after 3-4 months of continuous use. Cycling resets sensitivity
- **Monitor**: IGF-1 bloodwork at baseline, mid-cycle, and post-cycle

[Calculate your reconstitution volumes](/calculator) | [Model accumulation over time](/calculator/accumulation)

## How It Compares to Alternatives

CJC-1295 + Ipamorelin isn't the only GH peptide option. Here's how it stacks up against the main alternatives.

### vs Sermorelin

[Sermorelin](/peptides/sermorelin) is the original GHRH analog. It was FDA-approved in 1997 for pediatric GH deficiency (discontinued in 2008 for manufacturing reasons, not safety). Its half-life is only 10-12 minutes with 6% subcutaneous bioavailability. CJC-1295's 30-minute to 2-hour half-life and higher receptor affinity make it the more practical choice for most protocols.

That said, Sermorelin has the strongest human evidence base of any GHRH analog. A 1992 study by Corpas et al. in 60-78 year old males doubled 12-hour GH release over 6 weeks. It's synergistic with Ipamorelin (3-5 fold GH increases documented). If you want the most clinically validated GHRH peptide, Sermorelin wins on evidence even though CJC-1295 wins on pharmacokinetics.

### vs GHRP-2

[GHRP-2](/peptides/ghrp-2) is more potent than Ipamorelin at raw GH stimulation. When combined with a GHRH peptide, GHRP-2 has produced up to 54-fold GH increases vs 20-fold with GHRH alone (Domestic Animal Endocrinology, 2000). But that potency comes with trade-offs: increased cortisol at higher doses, prolactin elevation, and a 35.9% increase in food intake (JCEM, 2010). Ipamorelin's selectivity makes it the better choice for people who don't want those side effects.

### vs MK-677 (Ibutamoren)

MK-677 is an oral ghrelin mimetic. Convenient (no injections), but it provides continuous GH elevation similar to CJC-1295 DAC, raising desensitization concerns. It also significantly increases appetite and can cause insulin resistance with extended use. CJC-1295 + Ipamorelin offers more precise control over GH timing and magnitude.

<BarChart
title="Relative GH Pulse Magnitude (approximate, based on published data)"
data={[
{ label: 'Ipamorelin alone', value: 3, suffix: 'x baseline' },
{ label: 'CJC-1295 alone', value: 4, suffix: 'x baseline' },
{ label: 'CJC-1295 + Ipamorelin', value: 8, suffix: 'x baseline', color: '#059669' },
{ label: 'GHRH + GHRP-2', value: 12, suffix: 'x baseline', color: '#CC785C' },
{ label: 'CJC-1295 DAC (sustained)', value: 3, suffix: 'x baseline' }
]}
maxValue={14}
barColor="#6366f1"
/>

## Side Effects and Safety

The CJC-1295 and Ipamorelin stack has a reputation as one of the milder peptide protocols. That reputation is mostly deserved, with a few caveats.

### Common Side Effects

- **Facial flushing and warmth**: 5-10 minutes post-injection. Resolves on its own. More common with CJC-1295 than Ipamorelin
- **Mild water retention**: Typical in the first 1-2 weeks, usually stabilises
- **Vivid dreams and improved sleep**: Technically a side effect, but most people consider this a benefit. Caused by GH's effect on slow-wave sleep
- **Mild hunger increase**: 20-30 minutes post-injection from Ipamorelin's ghrelin receptor activity. Much less pronounced than GHRP-6
- **Injection site reactions**: Minor redness or irritation. Standard for subcutaneous peptides

### Serious Concerns

- **The FDA has flagged immunogenicity risk** for both peptides, including rare anaphylactic reactions
- **Cardiovascular**: Transient flushing, warmth, and hypotension post-injection (FDA warning)
- **Carpal tunnel symptoms**: Numbness, tingling in hands. This signals excessive GH/IGF-1 and means the dose should come down
- **Blood glucose**: GH antagonises insulin. People with diabetes or insulin resistance need to monitor glucose closely
- **Joint pain**: Persistent joint discomfort beyond the first 2 weeks is a sign to reduce dose or pause

<Callout type="warning" title="Cancer Contraindication">

Growth hormone promotes cell proliferation. Anyone with active cancer, a history of cancer, or unscreened tumours should not use GH secretagogues. This applies to CJC-1295, Ipamorelin, GHRP-2, Sermorelin, MK-677, and exogenous HGH alike.

</Callout>

### Contraindications

- Active malignancy or cancer history
- Diabetic retinopathy
- Severe kidney disease
- Pregnancy or breastfeeding
- Existing carpal tunnel or nerve compression
- Pituitary tumours

### Monitoring

- **IGF-1 levels**: Baseline, mid-cycle (week 6-8), and 4 weeks post-cycle
- **Blood glucose**: Essential for anyone with metabolic concerns
- **Joint symptoms**: Persistent pain or carpal tunnel signs warrant dose reduction
- **Thyroid function**: Sermorelin studies found 6.5% of users developed hypothyroidism; similar monitoring is reasonable for any GH protocol

## The Practical Takeaway

The CJC-1295 + Ipamorelin stack works because it exploits a real biological principle: two independent signalling pathways converging on the same output. The human evidence for each individual peptide is solid. The stack logic is well-supported by receptor biology. And Ipamorelin's selectivity gives this combination a cleaner side effect profile than older GHRP-based stacks.

Use the non-DAC variant of CJC-1295 for the best pairing. Dose before bed on an empty stomach. Run 8-16 weeks, then cycle off. Get IGF-1 bloodwork. Don't skip that last part.

[CJC-1295 peptide profile](/peptides/cjc-1295) | [Ipamorelin peptide profile](/peptides/ipamorelin) | [CJC/IPA protocol data](/peptides/cjc-ipa-protocol) | [Reconstitution calculator](/calculator) | [Accumulation plotter](/calculator/accumulation)

## Frequently Asked Questions

### What does the CJC-1295 and Ipamorelin stack do?

CJC-1295 and Ipamorelin stimulate natural growth hormone release through two separate receptor pathways: **GHRH receptors (CJC-1295) and ghrelin receptors (Ipamorelin)**. The combination produces amplified GH pulses that support body composition, recovery, sleep quality, and anti-aging effects. Neither peptide is FDA-approved for these uses.

### What is the standard CJC-1295 Ipamorelin dosage?

The standard protocol is **100-300mcg of each peptide, injected subcutaneously 1-3 times daily** on an empty stomach. The most common single-dose protocol is 200mcg of each at bedtime. Pre-mixed blended vials typically contain a 1:1 ratio. Use the [reconstitution calculator](/calculator) for precise volumes.

### Should I use CJC-1295 with or without DAC?

**Without DAC for Ipamorelin pairing.** The non-DAC variant's 30 minute - 2 hour half-life matches Ipamorelin's timing, creating synchronized GH pulses. The DAC variant (6-8 day half-life) provides continuous stimulation that conflicts with Ipamorelin's pulsatile mechanism. DAC is better suited for standalone weekly protocols.

### What are the side effects of CJC-1295 and Ipamorelin?

Common side effects include **temporary facial flushing, mild water retention, vivid dreams, and slight hunger increase post-injection**. Serious concerns include carpal tunnel symptoms (sign of excessive GH), blood glucose changes, and FDA-flagged immunogenicity risk. Both peptides are contraindicated with active cancer due to GH's cell-proliferative effects.

### How long does a CJC-1295 Ipamorelin cycle last?

Standard cycles run **8-16 weeks on, followed by 4-8 weeks off**. Most users notice improved sleep within 1-2 weeks and body composition changes by week 4-8. The off-period prevents receptor desensitization, which Ipamorelin studies have flagged as a concern after 3-4 months of continuous use. Monitor IGF-1 bloodwork at baseline and mid-cycle.


---

### FDA Peptide Reclassification 2026: Which Peptides Are Coming Back

URL: https://peptide-db.com/guides/fda-peptide-reclassification-2026

---
title: 'FDA Peptide Reclassification 2026: Which Peptides Are Coming Back'
description: '14 of 19 restricted peptides are returning to legal compounding. Full list, timeline, which stay banned, and what it means for patients. Updated March 2026.'
date: '2026-03-30'
lastUpdated: '2026-03-30'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'safety'
difficulty: 'beginner'
readingTime: '8 min'

tags:
  - fda
  - peptide regulation
  - category 2
  - compounding pharmacy
  - bpc-157
  - legal status
  - 2026
  - rfk

image: '/guides/fda-peptide-reclassification-2026.webp'
imageAlt: 'FDA regulatory gavel over peptide molecular structures showing approved and restricted classifications'

published: true
keywords: 'FDA peptide reclassification 2026, are peptides legal again, which peptides are coming back, FDA category 2 peptides, peptide compounding pharmacy 2026, is BPC-157 legal, FDA peptide ban lifted 2026'
canonical: 'https://peptide-db.com/guides/fda-peptide-reclassification-2026'
showToc: true

relatedPeptides:
  - bpc-157
  - tb-500
  - thymosin-alpha-1
  - aod-9604
  - cjc-1295
  - ipamorelin
  - selank
  - semax
  - ghk-cu
  - kpv
  - mots-c
  - epitalon

relatedGuides:
  - title: 'BPC-157 Human Clinical Trials (2025-2026): Complete Status & Results'
    slug: 'bpc-157-human-trials'
    image: '/BPC-157-CHAIN.webp'
    excerpt: 'Every BPC-157 human study published to date and what the evidence actually shows.'
  - title: 'BPC-157 Side Effects: Is It Safe?'
    slug: 'bpc-157-side-effects'
    excerpt: 'Research-based safety profile and risk assessment for BPC-157.'
---

<script>
  import { BarChart, ComparisonScale, Callout } from '$lib/components/charts';
</script>

## Summary

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately **14 of 19 peptides** previously restricted under the FDA's Category 2 list would return to Category 1 status. This reverses a September 2023 decision that effectively banned compounding pharmacies from preparing widely used therapeutic peptides.

### What's Changing

- **14 peptides returning to legal compounding** including [BPC-157](/peptides/bpc-157), [TB-500](/peptides/tb-500), [Thymosin Alpha-1](/peptides/thymosin-alpha-1), [Ipamorelin](/peptides/ipamorelin), [Selank](/peptides/selank), [Semax](/peptides/semax), and [GHK-Cu](/peptides/ghk-cu)
- **5 peptides likely staying restricted** including [Melanotan II](/peptides/melanotan-ii), [GHRP-2](/peptides/ghrp-2), [GHRP-6](/peptides/ghrp-6), [LL-37](/peptides/ll-37), and [PEG-MGF](/peptides/peg-mgf)
- **Category 1 means** licensed compounding pharmacies can legally prepare these peptides under physician prescription
- **This is NOT FDA approval** — no peptide on this list has completed the clinical trial process required for drug approval

### Current Status (March 30, 2026)

The FDA has not yet published its formal updated list. Kennedy's announcement signals what is coming, but compounding pharmacies technically remain unauthorized to compound these substances until the official publication drops.

[Check interactions between any of these peptides →](/tools/interactions)

## The 19 Peptides: Where They Stand

In September 2023, the FDA moved 19 peptides from Category 1 to Category 2 on its Bulk Drug Substances Under Evaluation list. The stated rationale: "immunogenicity risk, peptide-related impurities, and limited human safety data."

The impact was immediate. Compounding pharmacies pulled these peptides from their shelves. Clinics that had built practices around peptide therapy lost access to their most prescribed compounds. Patients mid-protocol had their treatments interrupted. The gray market exploded.

Kennedy's position on the original decision was blunt: "The Category 2 designations effectively created and accelerated the very gray market they were designed to prevent."

### Returning to Category 1 (Legal Compounding)

These peptides are expected to regain compounding eligibility:

| Peptide | Category | Research Status | Primary Use |
|---------|----------|----------------|-------------|
| [BPC-157](/peptides/bpc-157) | Healing | Extensively studied (preclinical) | Tissue repair, gut healing, inflammation |
| [TB-500](/peptides/tb-500) | Healing | Well studied | Wound healing, muscle recovery |
| [Thymosin Alpha-1](/peptides/thymosin-alpha-1) | Immune | Well studied | Immune modulation, approved in 35+ countries |
| [AOD-9604](/peptides/aod-9604) | Metabolic | Well studied | Fat metabolism, formerly TGA-approved in Australia |
| [Ipamorelin](/peptides/ipamorelin) | Growth Hormone | Well studied | GH secretion, body composition, sleep |
| [CJC-1295](/peptides/cjc-1295) | Growth Hormone | Well studied | GH release (status contested — see below) |
| [Selank](/peptides/selank) | Cognitive | Well studied | Anxiety, cognitive function, approved in Russia |
| [Semax](/peptides/semax) | Cognitive | Well studied | Neuroprotection, approved in Russia/Ukraine |
| [GHK-Cu](/peptides/ghk-cu) | Skin/Healing | Well studied | Collagen synthesis, wound healing, hair growth |
| [KPV](/peptides/kpv) | Immune | Emerging | Anti-inflammatory, gut inflammation |
| [MOTS-c](/peptides/mots-c) | Longevity | Well studied | Mitochondrial function, insulin sensitivity |
| [Epitalon](/peptides/epitalon) | Longevity | Well studied | Telomerase activation, pineal regulation |
| [Kisspeptin-10](/peptides/kisspeptin) | Hormonal | Emerging | Reproductive hormone regulation |
| [DSIP](/peptides/dsip) | Sleep | Emerging | Sleep architecture, stress response |

<Callout type="warning" title="CJC-1295 Status Is Unclear">

Sources disagree on CJC-1295. Some list it as returning to Category 1 alongside Ipamorelin. Others flag it as staying restricted due to reported cardiac side effects. Until the FDA publishes the official list, its status remains uncertain. If you're planning a [CJC-1295/Ipamorelin protocol](/guides/cjc-1295-ipamorelin), monitor this closely.

</Callout>

### Likely Staying Restricted (Category 2)

Five peptides appear likely to remain on the restricted list due to safety concerns, misuse potential, or proximity to existing FDA-approved drug categories:

| Peptide | Concern | Details |
|---------|---------|---------|
| [Melanotan II](/peptides/melanotan-ii) | Cardiovascular + melanoma risk | Linked to nausea, blood pressure changes, and potential melanocyte stimulation raising skin cancer concerns |
| [GHRP-2](/peptides/ghrp-2) | Complex side effects | Elevates cortisol and prolactin — unlike [Ipamorelin](/peptides/ipamorelin) which is selective for GH only |
| [GHRP-6](/peptides/ghrp-6) | Complex side effects | Same cortisol/prolactin concerns as GHRP-2, plus significant appetite stimulation |
| [LL-37](/peptides/ll-37) | Limited safety data | Antimicrobial peptide with very limited human safety data for systemic compounding use |
| [PEG-MGF](/peptides/peg-mgf) | Limited clinical evidence | PEGylated growth factor with minimal published human data |

<ComparisonScale
  title="Research Evidence Level by Peptide (1 = limited data, 10 = Phase III / FDA-approved)"
  items={[
    { label: 'BPC-157', position: 4, color: '#CC785C' },
    { label: 'Thymosin Alpha-1', position: 8, color: '#059669' },
    { label: 'TB-500', position: 3.5, color: '#CC785C' },
    { label: 'Ipamorelin', position: 5, color: '#D4A27F' },
    { label: 'GHK-Cu', position: 5, color: '#D4A27F' },
    { label: 'Melanotan II', position: 4, color: '#BF4D43' },
    { label: 'Selank', position: 6, color: '#059669' },
    { label: 'GHRP-2', position: 4.5, color: '#BF4D43' }
  ]}
  min={1}
  max={10}
  leftLabel="Preclinical only"
  rightLabel="FDA-approved"
/>

Worth noting: Thymosin Alpha-1 has the strongest clinical backing of any peptide on this list. It's approved as a prescription drug in over 35 countries for hepatitis B and C treatment and as an immune adjuvant. Selank and Semax are both approved pharmaceuticals in Russia. The Category 2 restriction on these compounds was always harder to justify than for something like PEG-MGF, which has almost no published human data.

## What Category 1 Actually Means (and Doesn't Mean)

The Category 1 vs Category 2 distinction controls whether compounding pharmacies can legally prepare a substance. That's it. People are treating this announcement like the FDA just approved 14 new drugs. They didn't.

**Category 1 allows:**
- Licensed compounding pharmacies (503A and 503B) to legally prepare the peptide
- Physicians to prescribe it through a compounding pharmacy
- Quality-controlled, pharmaceutical-grade preparations with certificates of analysis
- Regulatory oversight of the compounding process

**Category 1 does NOT mean:**
- FDA drug approval (that requires Phase I-III clinical trials, NDA submission, and years of review)
- Over-the-counter availability
- Insurance coverage (these remain cash-pay, typically $300-700 per compound)
- That the peptide has been proven safe and effective in rigorous human trials
- That "research use only" gray-market products are suddenly legitimate

<Callout type="research" title="The Evidence Gap Remains">

Reclassification changes the legal pathway for access. It does not change the underlying evidence. [BPC-157 still has only 3 published human studies](/guides/bpc-157-human-trials) with fewer than 30 total subjects. TB-500 has zero completed human RCTs. The research gaps that existed before the ban still exist after the reclassification. What changes is that patients can now access pharmaceutical-grade preparations under medical supervision rather than unregulated gray-market products.

</Callout>

## The Gray Market Problem

Kennedy's argument for reclassification had a pragmatic core: the Category 2 restrictions didn't stop people from using these peptides. They just pushed demand underground.

When compounding pharmacies lost the ability to prepare BPC-157 and TB-500, patients didn't stop wanting them. They turned to "research chemical" suppliers, overseas pharmacies, and unregulated online vendors selling peptides labeled "for research purposes only." No physician oversight. No quality testing. No dosing guidance. No recourse if something went wrong.

The compounding pharmacy industry had quality controls: USP 797/795 compliance, PCAB accreditation, potency verification, sterility testing. The gray market has none of that. A 2024 analysis of gray-market peptide products found significant variability in actual peptide content versus label claims, contamination with bacterial endotoxins, and in some cases, entirely wrong compounds in the vial.

Reclassification to Category 1 doesn't validate these peptides as proven treatments. It does restore the regulated supply chain that provides basic quality assurance.

## The Supplement Angle

A separate but related push is happening simultaneously. On March 27, 2026, multiple outlets reported that dietary supplement manufacturers are lobbying the FDA to classify certain peptides as dietary supplement ingredients under the Dietary Supplement Health and Education Act (DSHEA).

This is a different regulatory pathway entirely. DSHEA allows supplement companies to sell products without pre-market approval as long as they don't make drug claims. If peptides like BPC-157 were classified as dietary supplements, they could be sold over the counter without a prescription.

The peptide therapy community is split on this. Proponents argue it would dramatically increase access. Critics argue it would remove the physician oversight that makes peptide therapy reasonably safe, and that supplement-grade manufacturing doesn't meet the purity standards needed for injectable compounds.

For now, the reclassification and the supplement push are separate tracks. Category 1 status restores the physician-prescription-plus-compounding-pharmacy model. The supplement pathway would bypass that model entirely.

## What This Means If You're Considering Peptide Therapy

If you've been using gray-market peptides, reclassification gives you a better option. Once the formal FDA publication drops:

1. **Find a physician** who prescribes peptide therapy. Telehealth peptide clinics exist in most states
2. **Get bloodwork first.** Baseline labs before starting any peptide protocol. The [interaction checker](/tools/interactions) can flag potential conflicts with other compounds you're using
3. **Use a licensed compounding pharmacy** — specifically one that's PCAB-accredited and FDA-registered. They'll provide certificates of analysis verifying potency and sterility
4. **Expect to pay out of pocket.** Insurance doesn't cover compounded peptides. Typical costs run $300-700 per compound depending on the peptide and pharmacy

If you've been waiting for legal access before trying peptides, this is the pathway. Not the gray market. Not "research chemical" vendors. A licensed physician and a regulated pharmacy.

## Timeline and What to Watch

| Date | Event |
|------|-------|
| September 29, 2023 | FDA moves 19 peptides to Category 2, restricting compounding |
| 2024 | Gray market explodes; compounding pharmacy industry pushes back |
| February 27, 2026 | HHS Secretary Kennedy announces reclassification on Joe Rogan Experience #2461 |
| March 2026 | Formal FDA publication expected but not yet released |
| TBD | Official Category 1 reinstatement takes effect |

The gap between announcement and implementation matters. Until the FDA actually publishes the updated list, compounding pharmacies cannot legally resume production. Kennedy said "within a couple of weeks" on February 27. It's now March 30. The publication is overdue but reportedly still in process.

When it drops, expect a rush. Compounding pharmacies will need time to source raw materials, validate batches, and restart production. Don't expect instant availability.

## Frequently Asked Questions

### Is BPC-157 legal again in 2026?

Not yet. HHS Secretary Kennedy announced that BPC-157 will return to Category 1 status, allowing licensed compounding pharmacies to legally prepare it under physician prescription. The formal FDA publication hasn't been released as of March 30, 2026. Once published, BPC-157 will be legally accessible through compounding pharmacies but will still require a prescription.

### Which peptides are staying banned?

Approximately 5 peptides are expected to remain on Category 2: [Melanotan II](/peptides/melanotan-ii) (melanoma and cardiovascular concerns), [GHRP-2](/peptides/ghrp-2) and [GHRP-6](/peptides/ghrp-6) (cortisol and prolactin elevation), [LL-37](/peptides/ll-37) (limited human safety data), and [PEG-MGF](/peptides/peg-mgf) (minimal clinical evidence). The CJC-1295 status is disputed between sources.

### Can I buy peptides over the counter after reclassification?

No. Category 1 status means compounding pharmacies can prepare these peptides with a valid physician prescription. It does not mean over-the-counter availability. A separate push by supplement manufacturers to classify peptides under DSHEA could eventually allow OTC sales, but that's a different regulatory track.

### Are compounded peptides as good as pharmaceutical-grade drugs?

Compounding pharmacies operating under USP 797/795 standards produce pharmaceutical-grade preparations with potency and sterility testing. They are subject to state pharmacy board oversight and, for 503B outsourcing facilities, FDA inspection. This is significantly better than gray-market "research chemical" products, but compounded drugs have not undergone the same clinical trial process as FDA-approved drugs.

### What should I do right now?

Wait for the formal FDA publication before seeking these peptides from compounding pharmacies. In the meantime, find a physician familiar with peptide therapy, get baseline bloodwork, and use the [interaction checker](/tools/interactions) to evaluate any stack you're considering. When access resumes, you'll have a provider relationship and lab baseline in place.


---

### KLOW Peptide Protocol: Ingredients, Dosing, and Research

URL: https://peptide-db.com/guides/klow-peptide-protocol

---
title: 'KLOW Peptide Protocol: Ingredients, Dosing, and Research'
description: 'What is the KLOW peptide blend? A research-based breakdown of its four components (GHK-Cu, KPV, BPC-157, TB-500), dosing protocols, how it compares to GLOW, and what the evidence actually supports.'
date: '2026-03-24'
lastUpdated: '2026-03-24'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'protocols'
difficulty: 'intermediate'
readingTime: '14 min'

tags:
  - klow
  - peptide blend
  - ghk-cu
  - kpv
  - bpc-157
  - tb-500
  - glow
  - peptide stacking

image: '/guides/klow-peptide-protocol.webp'
imageAlt: 'KLOW peptide protocol four-component molecular blend illustration'

published: true
keywords: 'klow peptide, klow peptide protocol, klow peptide blend, klow dosage, klow vs glow peptide, klow peptide dosing, klow 80mg vial, klow side effects'
canonical: 'https://peptide-db.com/guides/klow-peptide-protocol'
showToc: true

relatedPeptides:
  - klow-protocol
  - glow-protocol
  - ghk-cu
  - kpv
  - bpc-157
  - tb-500

relatedGuides:
  - title: 'BPC-157 Side Effects: Is It Safe?'
    slug: 'bpc-157-side-effects'
    image: '/BPC-157-CHAIN.webp'
    excerpt: 'A comprehensive guide to BPC-157 safety, side effects, and long-term risks.'
  - title: 'Every BPC-157 Human Trial Up to 2026'
    slug: 'bpc-157-human-trials'
    image: '/BPC-157-CHAIN.webp'
    excerpt: 'What we actually know about BPC-157 safety and efficacy in humans.'
---

<script>
  import { BarChart, ComparisonScale, SpectrumBar, Callout, MermaidDiagram } from '$lib/components/charts';
</script>

## Summary

The KLOW peptide protocol is a four-peptide blend combining [GHK-Cu](/peptides/ghk-cu) (50mg), [KPV](/peptides/kpv) (10mg), [BPC-157](/peptides/bpc-157) (10mg), and [TB-500](/peptides/tb-500) (10mg) into a single 80mg vial. It builds on the three-peptide [GLOW protocol](/peptides/glow-protocol) by adding KPV for enhanced anti-inflammatory action.

### What You Need to Know

- **Four distinct mechanisms in one injection**: collagen synthesis (GHK-Cu), NF-kB inhibition (KPV), growth factor modulation (BPC-157), and cell migration (TB-500)
- **No clinical trials exist on the KLOW combination itself**. All evidence comes from studies on individual components, none of which are FDA-approved
- **Standard dosing**: 200-500mcg total blend daily via subcutaneous injection, reconstituted with 3-4mL bacteriostatic water
- **Typical protocol length**: 4-6 weeks on, 2-4 weeks off. The GHK-Cu component carries a copper accumulation risk with prolonged use
- **KLOW vs GLOW**: the only difference is the addition of KPV. If chronic inflammation or gut issues aren't part of your picture, GLOW may be sufficient

[Use the blend calculator for KLOW dosing](/calculator/blend) | [View full KLOW profile](/peptides/klow-protocol)

## Four Peptides, Four Mechanisms: Why KLOW Exists

The peptide community didn't invent KLOW out of thin air. It emerged from the observation that the [GLOW protocol](/peptides/glow-protocol) (GHK-Cu + BPC-157 + TB-500) worked well for tissue repair and skin rejuvenation but left one gap: it didn't directly address systemic inflammation.

That's a problem when healing needs to happen alongside an active inflammatory response. Think autoimmune flare-ups, chronic gut inflammation, or recovery from illness where the immune system is still running hot. BPC-157 and TB-500 both have anti-inflammatory properties, sure, but their primary mechanisms target tissue repair pathways. They reduce inflammation as a secondary effect.

KPV is different. It walks straight into the cell nucleus and shuts down NF-kB, the master switch controlling inflammatory cytokine production (Kannengiesser et al., Anti-Inflammatory Mechanisms, 2020). No other peptide in the GLOW stack does that.

<MermaidDiagram
title="KLOW Protocol: Four Mechanisms of Action"
chart={`     graph TD
      A[KLOW Blend Injected] --> B[GHK-Cu 50mg]
      A --> C[KPV 10mg]
      A --> D[BPC-157 10mg]
      A --> E[TB-500 10mg]
      B --> F[Collagen & Elastin Synthesis]
      B --> G[Gene Expression Modulation]
      C --> H[NF-kB Pathway Inhibition]
      C --> I[TNF-alpha & IL-6 Reduction]
      D --> J[VEGF & Angiogenesis]
      D --> K[Growth Factor Expression]
      E --> L[Actin Regulation & Cell Migration]
      E --> M[Stem Cell Differentiation]
      F --> N[Tissue Regeneration]
      H --> N
      J --> N
      L --> N
  `}
/>

## What's Actually in a KLOW Vial

A standard KLOW vial contains 80mg total across four peptides in a fixed 5:1:1:1 ratio.

| Component                    | Amount | % of Blend | Role                                 | Research Status               |
| ---------------------------- | ------ | ---------- | ------------------------------------ | ----------------------------- |
| [GHK-Cu](/peptides/ghk-cu)   | 50mg   | 62.5%      | Collagen synthesis, gene modulation  | Well-studied individually     |
| [KPV](/peptides/kpv)         | 10mg   | 12.5%      | Anti-inflammatory (NF-kB inhibition) | Emerging research             |
| [BPC-157](/peptides/bpc-157) | 10mg   | 12.5%      | Tissue repair, angiogenesis          | Extensively studied (animals) |
| [TB-500](/peptides/tb-500)   | 10mg   | 12.5%      | Cell migration, wound healing        | Well-studied individually     |

GHK-Cu dominates the blend at 62.5%. That ratio reflects its naturally lower potency per milligram compared to the other three peptides and the fact that effective GHK-Cu doses (1-3mg daily) are significantly higher than effective BPC-157 doses (250-500mcg daily).

<Callout type="research" title="Evidence Reality Check">

Zero published studies have examined the KLOW four-peptide combination. All dosing protocols are extrapolated from individual component research and anecdotal community reports. The interaction effects between these four peptides administered simultaneously are unknown.

</Callout>

## Breaking Down Each Component

### GHK-Cu: The Collagen Engine

[GHK-Cu](/peptides/ghk-cu) (glycyl-L-histidyl-L-lysine copper complex) is a tripeptide naturally present in human plasma. Your body produces it. Levels decline with age: roughly 200 ng/mL at age 20, dropping to about 80 ng/mL by age 60.

What makes GHK-Cu unusual is scope. A 2018 analysis in the _International Journal of Molecular Sciences_ found it affects **31.2% of human genes**, modulating everything from collagen production to antioxidant enzyme expression. A separate 2015 study in _Biomedical Research International_ measured a **70% increase in type I and III collagen** and improved elastin production in skin tissue treated with GHK-Cu.

The copper ion isn't decorative. It's an essential cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin fibres. Without copper, those fibres form but don't properly connect.

**Molecular weight**: 404.96 Da | **Half-life**: 0.5-2 hours | **Sequence**: Gly-His-Lys-Cu2+

### KPV: The Inflammation Kill Switch

[KPV](/peptides/kpv) is a tripeptide derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It carries alpha-MSH's anti-inflammatory properties without causing skin darkening. Three amino acids. That's it.

The mechanism is direct. KPV enters cells and inhibits NF-kB signalling at the nuclear level, reducing production of TNF-alpha and IL-6 (Kannengiesser et al., 2020). A 2021 study on psoriasis models showed **60% reduction in psoriatic inflammatory markers**. In IBD models (2019), KPV reduced intestinal inflammation and supported barrier repair.

Critically, KPV doesn't cause immunosuppression the way corticosteroids do. It modulates inflammation rather than blanket-suppressing immune function. That distinction matters for long-term use.

**Half-life**: 1-2 hours | **Delivery**: Injectable, oral, topical, nasal

### BPC-157: The Healing Workhorse

[BPC-157](/peptides/bpc-157) has the deepest research base of the four. Over 100 animal studies spanning three decades. It's a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice, and it works primarily through VEGF-mediated angiogenesis and growth factor expression.

The strength of BPC-157 is breadth. Tendons, muscles, ligaments, gut lining, nerves, blood vessels. A 2017 study demonstrated enhanced VEGF expression and new blood vessel formation at injury sites. A 2020 safety evaluation found no serious adverse effects at 1000mcg/kg for 90 days in animal models.

The weakness is human evidence. Only [three published human studies exist as of early 2026](/guides/bpc-157-human-trials), all small pilot studies. A 2024 pilot on interstitial cystitis (12 patients) showed 80-100% symptom resolution. Promising, but far from definitive.

**Molecular weight**: 1,419.53 Da | **Half-life**: under 30 minutes | **15 amino acids**

### TB-500: The Migration Signal

[TB-500](/peptides/tb-500) is a synthetic fragment of thymosin beta-4, the principal actin-sequestering protein in mammalian cells. It regulates cell migration, which is the process of cells moving toward injury sites.

TB-500 has stronger human data than BPC-157. A 2012 Phase 2 trial in _Dermal Wound Healing_ studied chronic pressure ulcers. A 2016 cardiac trial demonstrated **over 50% improvement in left ventricular function** post-myocardial infarction. A 2014 Phase 2 trial showed benefit for dry eye (corneal healing).

The longer half-life (approximately 2 hours versus BPC-157's 30 minutes) means TB-500 distributes systemically. It doesn't need to be injected near the injury.

**Molecular weight**: 4,963.44 Da | **Half-life**: ~2 hours | **43 amino acids**

<ComparisonScale
title="Human Clinical Evidence by Component (1 = anecdotal only, 10 = Phase III trials)"
items={[
{ label: 'GHK-Cu (topical)', position: 6, color: '#059669' },
{ label: 'TB-500', position: 5, color: '#6366f1' },
{ label: 'BPC-157', position: 3, color: '#CC785C' },
{ label: 'KPV', position: 2, color: '#D4A27F' },
{ label: 'KLOW combo', position: 1, color: '#BF4D43' }
]}
min={1}
max={10}
leftLabel="Anecdotal reports"
rightLabel="Phase III randomised trials"
/>

## KLOW vs GLOW: Which One?

This is the question everyone asks. The answer depends on what problem you're trying to address.

|                              | GLOW                                          | KLOW                                           |
| ---------------------------- | --------------------------------------------- | ---------------------------------------------- |
| **Components**               | GHK-Cu + BPC-157 + TB-500                     | GHK-Cu + KPV + BPC-157 + TB-500                |
| **Total vial**               | 70mg                                          | 80mg                                           |
| **Primary focus**            | Skin rejuvenation, tissue repair              | Tissue repair + systemic inflammation          |
| **KPV included**             | No                                            | Yes (10mg)                                     |
| **Best for**                 | Aesthetic recovery, wound healing, anti-aging | Gut inflammation, autoimmune, complex recovery |
| **Injection site reactions** | More common (anecdotally)                     | Less common (KPV may reduce them)              |
| **Price**                    | Lower (3 peptides)                            | Higher (4 peptides)                            |

The practical decision point: **is active inflammation part of your picture?**

If you're dealing with a sports injury, post-surgical recovery, or skin rejuvenation without an underlying inflammatory condition, the [GLOW protocol](/peptides/glow-protocol) covers those bases. Adding KPV to that scenario provides marginal benefit.

If you're dealing with gut issues (IBD, leaky gut, chronic digestive inflammation), autoimmune flares, or any situation where the immune system is contributing to the problem, the KPV component makes KLOW the more targeted choice. KPV's ability to inhibit NF-kB at the nuclear level addresses root-cause inflammation in a way the GLOW stack can't.

<Callout type="info" title="Don't Stack KLOW with Individual Components">

Running KLOW alongside separate GHK-Cu, BPC-157, or TB-500 injections risks exceeding effective dose ranges. GHK-Cu in particular carries copper accumulation risk. Pick the blend OR individual peptides, not both.

</Callout>

## Dosing and Reconstitution

### Standard Protocol

The [KLOW blend calculator](/calculator/blend) handles the maths, but here's the reference protocol from the community:

**Reconstitution**: Add 3-4mL bacteriostatic water to the 80mg vial.

- With 4mL: concentration = 20mg/mL total blend
- With 3mL: concentration = 26.7mg/mL total blend

**Daily dose**: 200-500mcg total blend, subcutaneous injection, once daily.

At 20mg/mL concentration and a 500mcg daily dose, you're drawing 0.025mL (2.5 units on a standard insulin syringe). That's tiny. Use a [reconstitution calculator](/calculator) if you're unsure about the volume.

<SpectrumBar
title="KLOW Dosing Phases"
segments={[
{ label: 'Conservative', sublabel: '200mcg/day', width: 2, color: '#059669' },
{ label: 'Standard', sublabel: '200-500mcg/day', width: 3, color: '#CC785C' },
{ label: 'Aggressive', sublabel: '>500mcg/day', width: 2, color: '#BF4D43' }
]}
leftLabel="Lower risk, slower response"
rightLabel="Higher risk, no evidence of better outcomes"
/>

### Cycle Structure

- **On cycle**: 4-6 weeks daily injections
- **Off cycle**: 2-4 weeks break
- **Why cycle**: GHK-Cu carries copper accumulation risk with prolonged use. The break allows copper clearance. BPC-157 and TB-500 also lack long-term continuous-use safety data

### Reconstitution Steps

1. Remove vial cap, swab rubber stopper with alcohol
2. Draw 3-4mL bacteriostatic water with a sterile syringe
3. Inject slowly down the vial wall — not directly onto the powder
4. Gently swirl or roll until fully dissolved. **Never shake**. Shaking denatures the peptides
5. Solution should be clear. GHK-Cu may impart a light blue tint — that's normal. Green or dark discoloration means contamination
6. Label with date and concentration, store at 2-8C (standard refrigerator)
7. Use within 4-6 weeks

[Open the reconstitution calculator](/calculator)

### What the Component Doses Look Like

At 500mcg total KLOW blend daily, the individual component doses break down to:

<BarChart
title="Individual Peptide Dose per 500mcg KLOW Injection"
data={[
{ label: 'GHK-Cu', value: 312, suffix: 'mcg', color: '#059669' },
{ label: 'KPV', value: 62, suffix: 'mcg', color: '#6366f1' },
{ label: 'BPC-157', value: 62, suffix: 'mcg', color: '#CC785C' },
{ label: 'TB-500', value: 62, suffix: 'mcg', color: '#D4A27F' }
]}
maxValue={350}
barColor="#CC785C"
/>

Those individual doses are below the typical standalone ranges for each peptide (GHK-Cu 1-3mg, KPV 200-500mcg, BPC-157 250-500mcg, TB-500 2-5mg). The theory behind blends is that synergistic effects compensate for lower individual doses. That theory has not been tested in any published study.

## Side Effects and Safety Concerns

### Reported Side Effects

The KLOW combination hasn't been studied for safety. What we know comes from individual component research and user reports:

**Common (reported frequently in community forums):**

- Injection site redness, irritation, or mild swelling
- Light blue-green tint at injection site (from GHK-Cu copper complex — cosmetic only)
- Mild fatigue during the first week
- Temporary digestive changes

**Uncommon:**

- Headache or light-headedness
- Vivid dreams (commonly attributed to BPC-157)
- Appetite changes

**Rare but serious concerns:**

- **Copper toxicity** from prolonged GHK-Cu use — symptoms include metallic taste, fatigue, nausea, abdominal pain. This is why cycling is mandatory, not optional
- **Angiogenesis risk**: BPC-157 and TB-500 both promote new blood vessel formation. For most people, this is the desired healing mechanism. For anyone with active cancer or a history of cancer, new blood vessel growth could theoretically support tumour development. This is not theoretical for fun — it's a real pharmacological concern

<Callout type="warning" title="Cancer Contraindication">

Both BPC-157 and TB-500 stimulate angiogenesis (new blood vessel formation). Anyone with active malignancy or high cancer risk should avoid KLOW entirely. This applies to GLOW and the Wolverine Stack as well.

</Callout>

### Contraindications

- Active cancer or history of cancer (angiogenesis risk from BPC-157 and TB-500)
- Wilson's disease or copper metabolism disorders (GHK-Cu component)
- Pregnancy or breastfeeding (no safety data for any component)
- Active severe infections (theoretical concern with immune modulation from KPV)
- Current anticoagulant therapy (monitor closely — BPC-157 affects blood vessel dynamics)
- WADA-tested athletes: BPC-157 and TB-500 are both prohibited under S0 Unapproved Substances

## Expected Timeline

Individual responses vary, but the community-reported timeline looks roughly like this:

| Timeframe | What to Expect                                                             |
| --------- | -------------------------------------------------------------------------- |
| Days 1-7  | Subtle inflammation reduction (KPV effect). Some injection site adjustment |
| Week 2-3  | Noticeable decrease in inflammatory symptoms. Early skin texture changes   |
| Week 3-4  | Wound healing acceleration, improved gut function (if applicable)          |
| Week 4-6  | Full cycle assessment point. Collagen/elastin improvements visible         |
| Week 6+   | Diminishing returns begin. Cycle off to clear copper and reset             |

The KPV component tends to produce the fastest noticeable effect (days, not weeks) because NF-kB inhibition works quickly. GHK-Cu's collagen effects take the longest — visible skin improvements often require 6-8 weeks of consistent use.

## The Honest Assessment

KLOW is a well-designed blend on paper. Four peptides targeting four distinct mechanisms, combined in a single injection. The individual components all have legitimate research behind them, ranging from extensive (BPC-157's 100+ animal studies) to emerging (KPV's handful of preclinical models).

But "well-designed on paper" and "clinically validated" are different things. No one has studied whether these four peptides interact synergistically, antagonistically, or not at all when combined. No one has studied the pharmacokinetics of the blend versus individual administration. No one has established that the fixed 5:1:1:1 ratio is optimal for any specific condition.

That's not a reason to dismiss KLOW. It's a reason to be precise about what you know versus what you're assuming.

If you're going to run this protocol, use the [blend calculator](/calculator/blend) for accurate dosing, cycle properly (4-6 weeks maximum), monitor for copper toxicity signs, and don't combine KLOW with additional standalone doses of its components. Start conservative at 200mcg/day and titrate up only if needed.

[View full KLOW protocol data](/peptides/klow-protocol) | [Compare with GLOW protocol](/peptides/glow-protocol) | [Reconstitution calculator](/calculator)

## Frequently Asked Questions

### What is the KLOW peptide protocol?

KLOW is a four-peptide blend containing **GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg)** in a single 80mg vial. It targets tissue regeneration, collagen synthesis, and systemic inflammation through four distinct biological mechanisms. No clinical trials have studied this specific combination.

### What is the difference between KLOW and GLOW peptides?

GLOW contains three peptides (GHK-Cu, BPC-157, TB-500) totalling 70mg. **KLOW adds KPV as a fourth component**, bringing the total to 80mg. KPV inhibits NF-kB inflammatory signalling, making KLOW better suited for conditions involving chronic inflammation, gut issues, or autoimmune responses. GLOW is sufficient for skin rejuvenation and standard tissue repair.

### How do you dose the KLOW peptide blend?

Reconstitute the 80mg vial with 3-4mL bacteriostatic water. Inject **200-500mcg total blend subcutaneously once daily**. At 4mL reconstitution volume, a 500mcg dose equals 0.025mL (2.5 units on an insulin syringe). Use a [peptide reconstitution calculator](/calculator) for precise volumes.

### Is the KLOW peptide protocol safe?

No clinical safety studies exist for the four-peptide KLOW combination. Individual components have varying safety profiles: BPC-157 shows no toxicity in 90-day animal studies at high doses; GHK-Cu carries copper accumulation risk with prolonged use. **Both BPC-157 and TB-500 promote angiogenesis, which contraindicates use in anyone with active cancer.** Cycle 4-6 weeks on, 2-4 weeks off.

### How long should you run a KLOW cycle?

Most protocols recommend **4-6 weeks on, followed by 2-4 weeks off**. The mandatory break is primarily driven by the GHK-Cu component — copper accumulates with continuous use and needs clearance time. Some users report noticeable anti-inflammatory effects (from KPV) within the first week, while collagen-related benefits (from GHK-Cu) typically require 6-8 weeks.


---

### Mitochondrial Supplements: What Actually Works (2026)

URL: https://peptide-db.com/guides/mitochondrial-supplements

---
title: 'Mitochondrial Supplements: What Actually Works (2026)'
description: 'An evidence-based ranking of mitochondrial supplements from CoQ10 to peptides. What has clinical trial data, what is marketing, and where peptides like SS-31 and MOTS-c fit.'
date: '2026-03-25'
lastUpdated: '2026-03-25'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'basics'
difficulty: 'beginner'
readingTime: '12 min'

tags:
  - mitochondria
  - supplements
  - CoQ10
  - NAD+
  - NMN
  - SS-31
  - MOTS-c
  - PQQ

image: '/guides/mitochondrial-supplements.webp'
imageAlt: 'Mitochondrial supplements and peptide therapies arranged from basic to advanced'

published: true
keywords: 'mitochondrial supplements, mitochondria supplements, best mitochondrial supplement, CoQ10 mitochondria, NAD supplement, NMN supplement, SS-31, MOTS-c, mitochondrial health supplements'
canonical: 'https://peptide-db.com/guides/mitochondrial-supplements'
showToc: true

relatedPeptides:
  - ss-31
  - mots-c
  - nad-plus
  - humanin

relatedGuides:
  - title: 'Best Peptides for Mitochondrial Health: SS-31, MOTS-c, NAD+'
    slug: 'mitochondrial-peptides'
    image: '/guides/mitochondrial-peptides.webp'
    excerpt: 'Deep dive into how the three main mitochondrial peptides work through different mechanisms.'
---

<script>
  import { BarChart, ComparisonScale, Callout, MermaidDiagram } from '$lib/components/charts';
</script>

## Summary

Most mitochondrial supplement guides are written by companies selling the supplements. This one isn't. Here's the honest breakdown of what has clinical evidence, what's speculative, and where research peptides fit in.

### The Short Version

- **CoQ10** is the most established mitochondrial supplement. It's a direct component of the electron transport chain. Statin users and people over 50 benefit the most. Evidence is solid for heart failure (Mortensen et al., 2014, n=420). Dose: 100-300mg daily
- **NAD+ precursors (NMN, NR)** restore a coenzyme that declines roughly 50% between ages 40-60. Clinical trials confirm they raise NAD+ levels. Whether that translates to meaningful health outcomes in healthy people is still being established
- **Urolithin A** has the best recent clinical trial data. A 2022 RCT (n=66, 4 months, 1000mg daily) showed improved muscle endurance in adults over 65
- **PQQ** triggers mitochondrial biogenesis through PGC-1alpha. Limited human data. 10-40mg daily
- **Peptides (SS-31, MOTS-c)** are the research frontier. SS-31 has Phase II/III trials. MOTS-c improved insulin sensitivity 30% in animal models. Neither is FDA-approved. Both represent a different category from oral supplements

[View our mitochondrial peptide rankings](/peptides/best-for/mitochondria)

## The Supplement Tier List

Not all mitochondrial supplements have the same quality of evidence behind them. A 2021 NIH review of dietary supplements for mitochondrial disorders found that "few clinical trials have been completed assessing the efficacy" of commonly used compounds. That's a polite way of saying most of what's sold has weak backing.

Here's how they actually stack up.

<ComparisonScale
title="Clinical Evidence Strength (1 = theoretical, 10 = large RCTs)"
items={[
{ label: 'CoQ10', position: 7, color: '#059669' },
{ label: 'NAD+ precursors (NMN/NR)', position: 6, color: '#059669' },
{ label: 'Urolithin A', position: 6, color: '#6366f1' },
{ label: 'Creatine', position: 5, color: '#CC785C' },
{ label: 'Alpha-lipoic acid', position: 4, color: '#D4A27F' },
{ label: 'PQQ', position: 3, color: '#D4A27F' },
{ label: 'L-Carnitine', position: 4, color: '#D4A27F' },
{ label: 'SS-31 (peptide)', position: 7, color: '#059669' },
{ label: 'MOTS-c (peptide)', position: 3, color: '#CC785C' }
]}
min={1}
max={10}
leftLabel="Theoretical / in vitro"
rightLabel="Phase III / large RCTs"
/>

## Tier 1: Strong Clinical Evidence

### CoQ10 (Ubiquinone/Ubiquinol)

CoQ10 sits inside the electron transport chain. It's not a supplement that "supports" mitochondria from the outside. It IS part of the machinery. Complex I passes electrons to CoQ10, which shuttles them to Complex III. Without adequate CoQ10, ATP production drops at the source.

The strongest evidence comes from heart failure. The Q-SYMBIO trial (Mortensen et al., JACC Heart Failure, 2014) randomised 420 patients to 300mg CoQ10 or placebo for 2 years. The CoQ10 group had a **43% reduction in cardiovascular mortality**. That's not a marginal effect.

Statin users are a clear population who benefit. Statins block HMG-CoA reductase, which is also involved in CoQ10 synthesis. Blood levels of CoQ10 drop 40% on statins. Supplementation at 100-200mg daily restores levels.

**Dose**: 100-300mg daily. Ubiquinol (reduced form) is better absorbed than ubiquinone, but both work. Take with fat.

### NAD+ Precursors (NMN, NR)

NAD+ itself can't be taken orally. It gets broken down in the gut. Instead, precursors like NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are converted to NAD+ after absorption.

A 2024 meta-analysis in Nature Metabolism confirmed that NR supplementation reliably raises blood NAD+ levels in humans. A separate trial found improvements in long-COVID cognitive symptoms with NR. The University of Washington published a 2022 study showing NMN at 250mg daily improved muscle insulin sensitivity in prediabetic women.

The question isn't whether NMN/NR raise NAD+ levels. They do. The question is whether raising NAD+ in otherwise healthy people produces meaningful functional improvements. The jury is still out on that for non-clinical populations.

For direct NAD+ (IV or injection), [see our NAD+ peptide profile](/peptides/nad-plus).

**Dose**: NMN 250-500mg daily; NR 300-1000mg daily. Morning dosing preferred.

### Urolithin A

This one surprised the research community. Urolithin A is a gut metabolite of ellagitannins (found in pomegranates and berries). Most people don't produce enough of it naturally because it requires specific gut bacteria.

A 2022 randomised controlled trial (Singh et al., JAMA Network Open, n=66, adults over 65, 1000mg daily for 4 months) showed improved muscle endurance compared to placebo. A 2019 study (Andreux et al., Nature Metabolism, n=60) showed improved mitochondrial biomarkers at 500-1000mg daily.

The mechanism is mitophagy. Urolithin A activates the recycling of damaged mitochondria, clearing out dysfunctional ones so healthy ones can replace them. It doesn't boost existing mitochondria. It replaces the broken ones.

**Dose**: 500-1000mg daily.

## Tier 2: Moderate Evidence

### Creatine

Most people associate creatine with muscle. But creatine is a phosphate donor for ATP regeneration. It works in every cell, not just muscle. A randomised crossover study in 7 patients with mitochondrial myopathy found creatine supplementation increased grip strength and dorsiflexion torque by 11%.

For brain health, creatine is increasingly studied. It's cheap, safe at 3-5g daily, and has decades of safety data. Not mitochondria-specific, but it supports the energy system that mitochondria feed into.

**Dose**: 3-5g daily. No loading phase needed.

### Alpha-Lipoic Acid

Works as both a fat- and water-soluble antioxidant inside mitochondria. The best evidence is for diabetic neuropathy (600mg IV, multiple RCTs). For general mitochondrial support, the data is thinner. Commonly stacked with acetyl-L-carnitine.

**Dose**: 300-600mg daily (R-lipoic acid preferred).

### L-Carnitine / Acetyl-L-Carnitine (ALCAR)

Carnitine transports fatty acids into mitochondria for oxidation. Deficiency impairs fat metabolism at the mitochondrial level. ALCAR adds an acetyl group that crosses the blood-brain barrier.

Evidence exists for fatigue in elderly populations and as an adjunct in mitochondrial disease. A PMC review (Nicolson, 2014) noted benefits for chronic fatigue. But healthy people with normal carnitine levels may not see much effect.

**Dose**: L-carnitine 500-2000mg daily; ALCAR 500-1500mg daily.

## Tier 3: Emerging / Limited Evidence

### PQQ (Pyrroloquinoline Quinone)

PQQ activates PGC-1alpha, the master regulator of mitochondrial biogenesis. In theory, more PGC-1alpha means more mitochondria. Animal data supports this. Human data is limited to small studies showing improvements in sleep quality and C-reactive protein at 20mg daily.

A 2024 review suggested 40mg daily for 8-12 weeks for measurable effects. But there are no large RCTs.

**Dose**: 10-40mg daily.

<Callout type="info" title="The Marketing Problem">

Most "mitochondrial support" supplements combine small doses of CoQ10, PQQ, B vitamins, and various plant extracts into a single capsule. The doses are typically below what clinical trials used. A capsule with 50mg CoQ10 and 5mg PQQ is not the same as the 300mg CoQ10 used in Q-SYMBIO or the 40mg PQQ studied for mitochondrial biogenesis. Check the label.

</Callout>

## The Peptide Tier: Research Frontier

Standard supplements work through the gut. They're absorbed, metabolised, and whatever reaches your mitochondria has been diluted along the way. Peptides bypass that. They're injected directly into the bloodstream and reach mitochondria at therapeutic concentrations.

Two peptides are specifically designed for mitochondrial function. Neither is FDA-approved. Both have stronger mechanistic data than most oral supplements.

### SS-31 (Elamipretide)

[SS-31](/peptides/ss-31) binds directly to cardiolipin in the inner mitochondrial membrane. Cardiolipin is essential for electron transport chain function. When it oxidises with age, ATP production drops. SS-31 prevents that oxidation.

Phase II trial data (2018, 36 patients with primary mitochondrial myopathy, 40mg daily for 12 weeks) showed improved 6-minute walk test and fatigue scores. A Phase III trial for Barth Syndrome (48 weeks) showed trends toward cardiac improvement.

This is the closest any mitochondrial peptide has come to FDA approval.

**Dose**: 5-10mg daily SubQ for general support; 40mg daily in clinical trials. [Calculate your dose](/calculator?peptide=ss-31)

### MOTS-c

[MOTS-c](/peptides/mots-c) is encoded by your own mitochondrial DNA. Your body produces it naturally. Levels decline with age. It activates AMPK (the same pathway that Metformin and exercise activate) and improved insulin sensitivity by roughly 30% in animal studies (Lee et al., Cell Metabolism, 2015). A single dose improved running time by 12% and distance by 15% (Hyatt et al., 2022).

MOTS-c is WADA prohibited. It's not available through pharmacies. It exists in the research peptide space.

**Dose**: 5-10mg daily SubQ. [View MOTS-c profile](/peptides/mots-c)

For a detailed comparison of these peptides, read our [complete mitochondrial peptide guide](/guides/mitochondrial-peptides).

<BarChart
title="Approximate Cost per Month (USD, typical sourcing)"
data={[
{ label: 'CoQ10 (300mg)', value: 30 },
{ label: 'NMN (500mg)', value: 50 },
{ label: 'Urolithin A', value: 60 },
{ label: 'Creatine (5g)', value: 10, color: '#059669' },
{ label: 'NAD+ IV (weekly)', value: 400, color: '#BF4D43' },
{ label: 'SS-31', value: 150, color: '#CC785C' },
{ label: 'MOTS-c', value: 120, color: '#CC785C' }
]}
maxValue={450}
barColor="#6366f1"
/>

## How to Stack Them

A practical approach based on evidence tiers:

**Foundation (everyone)**:

- CoQ10 100-300mg daily (especially if on statins or over 50)
- Creatine 3-5g daily

**Second layer (longevity-focused)**:

- NMN 250-500mg or NR 300mg daily
- Urolithin A 500-1000mg daily

**Research tier (advanced, with medical oversight)**:

- NAD+ IV 250-500mg weekly or SubQ 100-500mg 2-3x weekly
- SS-31 5-10mg daily SubQ
- MOTS-c 5-10mg daily SubQ (WADA prohibited)

Check interactions between any peptides in your stack: [Interaction checker](/tools/interactions)

Use our [cost calculator](/tools/cost) to work out per-dose pricing.

## Frequently Asked Questions

### What is the best supplement for mitochondrial health?

**CoQ10 at 100-300mg daily has the strongest clinical evidence for mitochondrial support**, including a major RCT showing 43% reduced cardiovascular mortality in heart failure patients. For people focused on longevity, NAD+ precursors (NMN or NR) address the age-related decline in a coenzyme that mitochondria depend on.

### Do mitochondrial supplements actually work?

Some do, some don't. CoQ10, NAD+ precursors, and Urolithin A have randomised controlled trial data in humans. **PQQ and many "mitochondrial blend" supplements have mostly animal data or very small human studies.** The dose on the label matters. Most combo supplements underdose every ingredient.

### What is the difference between supplements and peptides for mitochondria?

Oral supplements are absorbed through the gut, metabolised by the liver, and reach mitochondria in reduced concentrations. **Peptides like SS-31 are injected and reach mitochondria directly at therapeutic levels.** SS-31 physically binds to cardiolipin in the inner membrane. No oral supplement does this. Peptides are not FDA-approved and require medical oversight.

### How much CoQ10 should I take for mitochondria?

The Q-SYMBIO heart failure trial used **300mg daily of CoQ10 for 2 years** and showed significant mortality reduction. For general mitochondrial support, 100-200mg daily is standard. Take with a meal containing fat for better absorption. Ubiquinol is better absorbed than ubiquinone in older adults.

### Can you take NAD+ orally?

NAD+ itself breaks down in the gut. **Oral precursors NMN (250-500mg) and NR (300-1000mg) are converted to NAD+ after absorption.** They reliably raise blood NAD+ levels (confirmed by 2024 meta-analysis in Nature Metabolism). For direct NAD+, IV infusion (250-1000mg) or SubQ injection (100-500mg) bypasses conversion entirely. See our [NAD+ profile](/peptides/nad-plus) for dosing protocols.


---

### Peptides: What They Are, Side Effects, and Uses

URL: https://peptide-db.com/guides/what-are-peptides

---
title: 'Peptides: What They Are, Side Effects, and Uses'
description: 'A comprehensive guide to peptides, their health benefits, potential side effects, and how to use them safely. Learn about collagen peptides, muscle-building peptides, and more.'
date: '2025-12-09'
lastUpdated: '2025-12-09'
author: 'Peptide Database'
authorBio: 'Peptide Database provides research-based information on peptides, dosing protocols, and scientific references for educational purposes.'
authorImage: '/pep-logo.webp'
authorUrl: 'https://peptide-db.com'

category: 'basics'
difficulty: 'beginner'
readingTime: '10 min'

tags:
  - peptides
  - health
  - collagen
  - muscle building
  - anti-aging
  - beginner guide

image: '/peptides.webp'
imageAlt: 'Peptide molecules and health illustration'

published: true
keywords: 'what are peptides, peptides for health, collagen peptides, peptide benefits, peptide side effects, how to use peptides, bioactive peptides, peptide supplements'
canonical: 'https://peptide-db.com/guides/what-are-peptides'
showToc: true

relatedPeptides:
  - bpc-157
  - tb-500
  - ghk-cu
---

## Summary

Peptides are short chains of amino acids — the fundamental building blocks of proteins — that act as signaling molecules telling your body's cells what to do. They influence processes like skin repair (collagen and elastin production) and [metabolic regulation](/peptides?category=weight-loss). Found naturally in foods and our bodies, peptides are used in skincare to firm skin and reduce wrinkles, and in medicine for conditions like diabetes, infection, and pain management. However, misuse (particularly with [growth hormone peptides](/peptides?category=growth-hormone)) carries health risks.

### What They Are & How They Work

- **Building Blocks**: Amino acids link together to form peptides; many peptides form a polypeptide, which then folds into a protein — think of it like Lego bricks assembling into a structure
- **Messengers**: Applied topically or ingested, peptides signal cells to perform specific functions, such as boosting collagen and elastin production in skin
- **Variety**: Different sequences of amino acids create different peptides with unique jobs, from [immune support](/peptides?category=immune) to [hormone regulation](/peptides?category=growth-hormone)

### Uses & Applications

- **Skincare**: Peptides like [GHK-Cu](/peptides/ghk-cu) improve skin barrier function, reduce wrinkles, enhance firmness, and fight acne by promoting collagen production and providing antimicrobial effects
- **Medicine**: Pharmaceutical peptides like [Semaglutide](/peptides/semaglutide) and [Tirzepatide](/peptides/tirzepatide) treat diabetes, while others address HIV, cancer, and chronic pain
- **Athletic & Body Composition**: Synthetic peptides like [CJC-1295](/peptides/cjc-1295) and [Ipamorelin](/peptides/ipamorelin) mimic growth hormones for muscle building, though this carries risks including metabolic and cardiovascular issues

[Browse all peptides →](/peptides)

## What Are Peptides?

Peptides are short strings of amino acids, typically containing between 2 and 50 amino acids linked together. If you're familiar with proteins, think of peptides as their smaller cousins — they share the same building blocks but in shorter chains.

This smaller size actually works in your favor. Peptides are easier for your body to absorb because they're already partially broken down. They can penetrate your skin and intestinal lining more readily, allowing them to enter your bloodstream faster than larger protein molecules.

### Where Do Peptides Come From?

The peptides found in supplements are typically derived from plant or animal protein sources:

- Eggs
- Milk and dairy
- Meat
- Fish and shellfish
- Beans and lentils
- Soy
- Oats
- Flaxseed and hemp seeds
- Wheat

### Bioactive Peptides

Scientists are particularly interested in what they call "bioactive peptides" — those that have a measurable beneficial effect on the body. The specific effects depend on the sequence of amino acids in each peptide. Different sequences do different things.

The most popular peptide supplements you'll encounter are collagen peptides for skin health and creatine peptides for athletic performance. Beyond supplements, peptides like [BPC-157](/peptides/bpc-157) and [TB-500](/peptides/tb-500) have gained attention in research circles for their regenerative properties.

## Uses and Benefits

Research indicates that bioactive peptides may:

- Lower high blood pressure
- Kill harmful microbes
- Reduce inflammation
- Prevent blood clot formation
- Improve immune function
- Act as antioxidants

Let's break down the most common reasons people turn to peptides.

### Slowing Down the Aging Process

Collagen is the protein responsible for keeping your skin, hair, and nails healthy. As we age, collagen production naturally declines — that's where collagen peptides come in.

A 2022 review found that collagen supplements can help reduce or delay skin aging. A follow-up systematic review in 2023 confirmed these findings, showing positive effects on skin health. The research also suggests that peptide complexes can provide anti-wrinkle benefits.

For those interested in skin health, [GHK-Cu](/peptides/ghk-cu) is another peptide worth exploring — it's been studied for its role in skin remodeling and wound repair.

### Improving Wound Healing

Since collagen is essential for healthy skin, it makes sense that collagen peptides could speed up wound healing. A 2021 review highlighted collagen's potential in this area.

There's also exciting research into antimicrobial peptides — a class of peptides that may fight bacteria, fungi, parasites, and viruses. With antibiotic resistance becoming a growing concern, these peptides could offer promising alternatives.

Peptides like [BPC-157](/peptides/bpc-157) have been studied specifically for their healing properties, showing potential in accelerating tissue repair.

### Preventing Age-Related Bone Loss

Bone health is another area where peptides show promise. Research suggests that moderate collagen peptide intake can help increase bone mass — potentially beneficial for those dealing with conditions like osteoporosis.

A 2018 study found that collagen peptide supplementation increased bone mineral density in postmenopausal women. A 2021 follow-up confirmed that long-term use can significantly improve bone markers.

### Building Strength and Muscle Mass

For those focused on fitness, peptide supplements may help increase muscle mass and strength. A 2019 study showed that combining peptide supplements with resistance training was more effective than exercise alone. Similar results appeared in a 2022 study.

Growth hormone secretagogues (GHS) are a specific group of peptides that stimulate the body's natural production of human growth hormone. These are being explored for treating conditions involving muscle wasting.

If you're interested in muscle-building peptides, check out our pages on [CJC-1295](/peptides/cjc-1295) and [Ipamorelin](/peptides/ipamorelin), which are commonly used together.

> **Note:** The World Anti-Doping Agency has banned many performance-enhancing peptides, including follistatin. Athletes subject to drug testing should be aware of prohibited substances.

## Side Effects

For healthy individuals, peptide supplements are unlikely to cause serious side effects. After all, they're similar to the peptides naturally present in the foods you eat every day.

That said, a few important caveats:

1. **Research is ongoing** — we don't have complete long-term data on all peptides
2. **Supplements aren't tightly regulated** — the FDA doesn't oversee supplements the same way they do medications
3. **Quality varies** — not all peptide products are created equal

### Who Should Be Cautious

Consult a healthcare provider before using peptides if you:

- Are pregnant or breastfeeding
- Take medications (especially blood thinners or hormone-related drugs)
- Have an existing medical condition
- Have a history of allergic reactions

## How to Use Peptides

The timing and dosage of peptide supplements varies significantly depending on the type and brand. Here are some general guidelines:

### For Oral Supplements (Collagen, etc.)

- Follow package instructions exactly
- Most collagen supplements are taken daily
- Can typically be mixed into beverages or food
- Consistency matters more than timing

### For Injectable Peptides

If you're working with peptides that require reconstitution, proper technique is essential for maintaining peptide stability. Always use bacteriostatic water and follow sterile procedures.

You can use our [dosing calculator](/calculator) to determine the correct injection volume based on your peptide concentration.

### General Best Practices

1. **Never exceed the recommended serving size**
2. **Store properly** — most peptides need refrigeration after reconstitution
3. **Track your response** — note any changes, positive or negative
4. **Discontinue use if adverse reactions occur** and consult a doctor

## The Bottom Line

Peptides represent a fascinating area of health research with genuine potential. From skin health and wound healing to bone density and muscle building, the applications are wide-ranging.

But let's be real — peptides aren't magic. They work best as part of a broader approach to health that includes proper nutrition, exercise, and medical guidance when needed.

If you're considering peptides, do your homework. Start with well-researched options like collagen peptides, consult with a healthcare provider, and source your products from reputable suppliers.

For more detailed information on specific peptides, browse our [peptide database](/peptides) or explore peptides by [category](/categories).


---

## Peptide Profiles

### 5-Amino-1MQ

URL: https://peptide-db.com/peptides/5-amino-1mq

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function. Not a true peptide, but a small molecule compound used in longevity and metabolic optimization protocols.

**Mechanism:** Inhibits NNMT enzyme systemically, preventing NAD+ degradation and maintaining elevated cellular NAD+ levels to support mitochondrial function and metabolic processes.

**Key Benefits:**
- Enhanced NAD+ levels
- Improved mitochondrial function
- Better energy metabolism
- Enhanced cellular repair
- Improved insulin sensitivity
- Longevity support
- Convenient daily oral dosing


---

### Abaloparatide

URL: https://peptide-db.com/peptides/abaloparatide

Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk.

**Mechanism:** Abaloparatide works through selective activation of the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts and osteocytes. It preferentially binds to the RG (relaxed, G-protein-coupled) conformational state of PTH1R, which elicits a transient downstream cyclic AMP signaling response favoring anabolic bone formation over resorption. This selective binding pattern produces more bone-building activity with less hypercalcemic effect compared to native PTH. The result is increased cortical and trabecular bone volume, density, and improved microarchitecture.

**Key Benefits:**
- FDA-approved for osteoporosis treatment
- Actively builds new bone (anabolic mechanism)
- Superior hip BMD gains vs teriparatide in trials
- Reduces vertebral fracture risk significantly
- Reduces nonvertebral fracture risk
- Lower hypercalcemia risk than teriparatide
- Works through selective PTH1R activation
- Benefits seen within 6 months


---

### ACE-031

URL: https://peptide-db.com/peptides/ace-031

ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain. It functions as a decoy receptor, binding and neutralizing myostatin and other TGF-beta superfamily members that normally limit muscle growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy (DMD), ACE-031 reached Phase 2 clinical trials before development was halted due to vascular side effects including nosebleeds and telangiectasia. In healthy volunteers, a single dose produced significant increases in lean mass and reductions in fat mass within 29 days.

**Mechanism:** ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling. Blocking this pathway removes the natural brake on muscle protein synthesis and satellite cell proliferation, resulting in rapid skeletal muscle hypertrophy. The Fc fusion domain extends circulating half-life through FcRn-mediated recycling and provides bivalent ligand binding.

**Key Benefits:**
- Significant lean mass increases (up to 1.7% in 29 days) observed in Phase 1 trials
- Simultaneous reduction in fat mass alongside muscle gains
- Long half-life (12-15 days) allows infrequent dosing
- Broad TGF-beta ligand neutralization for robust anti-catabolic effects
- Dose-dependent increases in thigh muscle volume confirmed by MRI


---

### Adalank

URL: https://peptide-db.com/peptides/adalank

Enhanced derivative of Selank with improved stability, blood-brain barrier penetration, and extended half-life compared to parent compound. Parent compound Selank approved in Russia since early 2000s.

**Mechanism:** Modulates GABAergic neurotransmission, upregulates hippocampal BDNF, influences serotonin metabolism, and provides immunomodulatory effects without benzodiazepine-like dependency.

**Key Benefits:**
- Potent anxiolytic effects without sedation
- Enhanced cognitive function
- Stress resilience
- Improved mood and emotional stability
- Neuroprotection via BDNF upregulation
- No tolerance, dependency, or withdrawal


---

### Adamax

URL: https://peptide-db.com/peptides/adamax

Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement, neuroprotection, and neuroplasticity.

**Mechanism:** Crosses BBB via enhanced lipophilicity from adamantane; upregulates BDNF and TrkB receptor sensitivity; modulates dopamine, norepinephrine, and serotonin; stabilizes microtubules via ADNP-derived mechanisms; provides antioxidant and anti-inflammatory neuroprotection.

**Key Benefits:**
- Enhanced cognitive function and mental clarity
- Improved focus and complex task handling
- Neuroprotection against oxidative stress
- Neuroplasticity support through BDNF upregulation
- Potential mood enhancement
- Stress resilience through HPA axis modulation


---

### Adipotide

URL: https://peptide-db.com/peptides/adipotide

Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.

**Mechanism:** CKGGRAKDC ligand homes to prohibitin/annexin A2 on white-fat endothelium; linked D-(KLAKLAK)2 disrupts mitochondrial membranes post-internalization, triggering localized endothelial apoptosis and adipocyte loss.

**Key Benefits:**
- Rapid fat-mass reduction via selective white adipose tissue vascular targeting
- Improved insulin sensitivity following adipose reduction
- Non-CNS peripheral mechanism distinct from appetite suppressants


---

### AHK-Cu

URL: https://peptide-db.com/peptides/ahk-cu

Synthetic copper-binding tripeptide targeting dermal papilla cells and hair follicles. Stimulates hair follicle elongation, promotes cell proliferation, increases VEGF production, and inhibits TGF-β1. Supports skin regeneration through fibroblast activation and collagen synthesis.

**Mechanism:** AHK-Cu penetrates scalp delivering copper directly to dermal papilla cells. Activates proliferation pathways, elevates Bcl-2/Bax ratio (anti-apoptotic), increases VEGF for blood flow, reduces TGF-β1, and promotes SOD production for oxidative stress reduction.

**Key Benefits:**
- Hair follicle elongation stimulation
- Dermal papilla cell proliferation
- VEGF upregulation for improved scalp circulation
- TGF-β1 reduction (counters DHT effects)
- Anti-apoptotic protection for follicles
- Collagen synthesis support
- Convenient topical application
- Fibroblast activation for skin regeneration


---

### AICAR

URL: https://peptide-db.com/peptides/aicar

AICAR is a cell-permeable nucleoside analog that activates AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis. Originally studied for cardiac ischemia protection, it gained attention as an 'exercise mimetic' due to its metabolic effects.

**Mechanism:** Once inside cells, AICAR is phosphorylated to ZMP, which mimics AMP and activates AMPK. This triggers metabolic pathways typically activated during exercise: increased glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.

**Key Benefits:**
- AMPK pathway activation
- Enhanced fatty acid oxidation
- Improved glucose uptake
- Potential endurance enhancement
- Mitochondrial biogenesis stimulation


---

### AOD-9604

URL: https://peptide-db.com/peptides/aod-9604

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.

**Mechanism:** Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.

**Key Benefits:**
- Targets fat loss through selective lipolysis
- Avoids growth hormone side effects
- No effect on blood glucose or insulin
- Does not increase IGF-1 levels
- Metabolically safer than full hGH
- Emerging cartilage repair potential


---

### Ara 290

URL: https://peptide-db.com/peptides/ara-290

Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.

**Mechanism:** Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.

**Key Benefits:**
- Proven tissue protection
- Nerve regeneration
- Anti-inflammatory effects
- Excellent safety profile in clinical trials


---

### B7-33

URL: https://peptide-db.com/peptides/b7-33

B7-33 is a single-chain peptide analog of human relaxin-2 that selectively activates the relaxin family peptide receptor 1 (RXFP1). Unlike native relaxin-2, which requires a complex two-chain A/B structure connected by disulfide bonds, B7-33 achieves RXFP1 activation with a much simpler single-chain design. This makes it significantly easier and more cost-effective to synthesize. Preclinical research demonstrates potent anti-fibrotic, vasodilatory, and cardioprotective properties, positioning B7-33 as a promising therapeutic candidate for fibrotic diseases, heart failure, and vascular dysfunction.

**Mechanism:** Selectively activates RXFP1, the primary receptor for relaxin-2, triggering downstream signaling cascades that inhibit fibroblast activation and collagen deposition, promote extracellular matrix remodeling via increased matrix metalloproteinase (MMP) activity, enhance nitric oxide-mediated vasodilation, and reduce inflammatory cytokine expression. B7-33 appears to preferentially engage pERK1/2 signaling pathways while showing reduced cAMP activation compared to native relaxin-2, suggesting biased agonism at RXFP1.

**Key Benefits:**
- Potent anti-fibrotic activity across multiple organ systems
- Improved vasodilation and vascular compliance
- Cardioprotective effects and potential to attenuate cardiac remodeling
- Much simpler to synthesize than native two-chain relaxin-2
- Selective RXFP1 agonism with biased signaling profile
- Preclinical efficacy in models of heart failure and fibrosis


---

### BAM-15

URL: https://peptide-db.com/peptides/bam-15

BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.

**Mechanism:** BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.

**Key Benefits:**
- Increases fat oxidation without affecting food intake
- Reduces body fat mass in research models
- 7-fold more potent than DNP with better safety
- Does not cause dangerous hyperthermia
- No effect on lean body mass
- Improves insulin sensitivity
- Orally bioavailable
- Activates AMPK and PGC-1α pathways
- Synergistic with GLP-1 agonists (semaglutide)


---

### BPC-157

URL: https://peptide-db.com/peptides/bpc-157

Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood vessel formation, enhances collagen synthesis, modulates growth factor expression, and protects against tissue damage through localized or systemic delivery.

**Mechanism:** Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways.

**Key Benefits:**
- Accelerated tendon, ligament, muscle, and bone healing
- Localized tissue repair with direct targeting
- Superior bioavailability
- Anti-inflammatory effects
- Angiogenesis promotion
- Gastric and intestinal protection


---

### Bronchogen

URL: https://peptide-db.com/peptides/bronchogen

Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair.

**Mechanism:** Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.

**Key Benefits:**
- Supports bronchial tissue function
- Regulates protein synthesis in lungs
- Targets bronchopulmonary system
- Maintains respiratory epithelium
- Part of Khavinson bioregulator family
- Epigenetic mechanism of action
- Tissue-specific targeting
- Well-tolerated in research


---

### Cagrilintide

URL: https://peptide-db.com/peptides/cagrilintide

Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.

**Mechanism:** Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.

**Key Benefits:**
- FDA development candidate with extensive Phase 3 data
- Superior weight loss in combination with semaglutide (22.7%)
- Once-weekly convenience
- 2.2% HbA1c reduction with CagriSema


---

### Cardiogen

URL: https://peptide-db.com/peptides/cardiogen

Cardiogen is a Khavinson bioregulator peptide consisting of four amino acids, derived from heart tissue research. Unlike larger peptides that work on cell surfaces, Cardiogen penetrates directly to the cell nucleus where it binds to specific DNA regions to regulate gene expression. This epigenetic mechanism supports tissue repair and improves cardiovascular function, particularly benefiting the heart and blood vessels.

**Mechanism:** Cardiogen works through epigenetic regulation by penetrating cell nuclei and interacting with specific DNA regions, histones, and nucleosomes. It regulates which genes are activated or suppressed without changing DNA sequence. This mechanism supports cardiac tissue repair, enhances myocardial function, and improves cardiovascular tissue regeneration by influencing gene expression in heart cells.

**Key Benefits:**
- Supports cardiac tissue repair and regeneration
- Regulates cardiovascular gene expression
- Improves myocardial function
- May support post-cardiac event recovery
- Epigenetic mechanism for targeted action
- Works at DNA/nuclear level
- Part of comprehensive anti-aging protocols
- Well-researched Khavinson peptide


---

### Cartalax

URL: https://peptide-db.com/peptides/cartalax

Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.

**Mechanism:** Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.

**Key Benefits:**
- Joint and connective tissue support
- Potential anti-aging effects on fibroblasts
- Cartilage regeneration support
- Established safety profile in Russian clinical practice


---

### Cerebrolysin

URL: https://peptide-db.com/peptides/cerebrolysin

Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.

**Mechanism:** IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.

**Key Benefits:**
- Direct brain delivery
- Standardized dosing
- Extensive clinical evidence
- Ready-to-use formulation
- Used clinically in 50+ countries


---

### Chonluten

URL: https://peptide-db.com/peptides/chonluten

Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.

**Mechanism:** Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.

**Key Benefits:**
- Normalizes respiratory system function
- Regulates protein synthesis in lung tissue
- Inhibits inflammatory TNF production
- Restores lung alveolar tissues
- Maintains bronchial mucous membranes
- Supports antioxidant gene expression
- May slow cell aging (geroprotective)
- Modulates mucosal function


---

### CJC-1295 (without DAC)

URL: https://peptide-db.com/peptides/cjc-1295

Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this version preserves natural GH pulsatility without continuous elevation.

**Mechanism:** Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

**Key Benefits:**
- Preserves natural GH pulsatility
- Minimal side effects
- No receptor desensitization
- Precise GH release control
- 4x greater receptor affinity than native GHRH


---

### CJC-1295 with DAC

URL: https://peptide-db.com/peptides/cjc-1295-dac

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.

**Mechanism:** DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.

**Key Benefits:**
- Convenient weekly dosing
- Sustained GH/IGF-1 elevation
- 6-8 day half-life
- Significant body composition changes


---

### CJC/IPA Protocol

URL: https://peptide-db.com/peptides/cjc-ipa-protocol

A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.

**Mechanism:** CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.

**Key Benefits:**
- Sustained GH elevation (6-8 days from CJC-1295)
- Selective pulsatile release without cortisol suppression
- Complementary dual-pathway optimization
- Preservation of natural GH rhythm
- Enhanced muscle protein synthesis and recovery


---

### Cortagen

URL: https://peptide-db.com/peptides/cortagen

Cortagen is a Khavinson bioregulator tetrapeptide (AEDP) with primary effects on the brain and central nervous system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it regulates inflammatory responses in the nervous system, restores balance between pro- and anti-oxidative processes, and stimulates interleukin-2 expression. Research shows potential benefits for ischemic brain injury recovery, nerve regeneration, and reducing autoimmune reactions affecting the CNS.

**Mechanism:** Cortagen works through epigenetic regulation by penetrating cell nuclei and interacting with DNA to modulate gene expression. In the heart, it affects genes including Pass1, Hsc70, Bmp2, Wnt4, Eps15, and Eps15-rs. It powerfully regulates inflammatory responses in the nervous system, helping restore proper balance between oxidative and anti-oxidative processes. Cortagen stimulates IL-2 expression and helps regulate immune function, particularly by reducing autoimmune reactions.

**Key Benefits:**
- Regulates central nervous system function
- Powerful anti-inflammatory effects in brain
- Supports nerve regeneration
- Restores oxidative balance
- Stimulates interleukin-2 expression
- Reduces autoimmune reactions
- Beneficial after ischemic brain injury
- Modulates gene expression in neural tissue


---

### Crystagen

URL: https://peptide-db.com/peptides/crystagen

Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression.

**Mechanism:** Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).

**Key Benefits:**
- Normalizes immune function in 82% of patients
- Stimulates normal lymphocyte proliferation
- Inhibits tumor cell growth (antitumor activity)
- Doubles HSP gene expression (stress resistance)
- Reduces respiratory viral infections
- Activates B-cell immune system
- Normalizes IL-6 expression
- Effective after radiation/chemotherapy


---

### Cyclic Glycine-Proline

URL: https://peptide-db.com/peptides/cyclic-glycine-proline

Endogenous cyclic dipeptide found in plasma, breast milk, and cerebrospinal fluid. Functions as metabolite of IGF-1, regulating its bioavailability through competitive binding to IGFBP-3. Demonstrates neuroprotective, cognitive-enhancing, and cardioprotective properties supported by clinical trials.

**Mechanism:** Competes with IGF-1 for IGFBP-3 binding, normalizing bioavailable IGF-1 levels. Acts as positive allosteric modulator of AMPA and GABA-A receptors. Increases BDNF levels via Akt/MDM2-p53 pathway activation.

**Key Benefits:**
- Neuroprotection and cognitive enhancement
- IGF-1 optimization
- Cardiovascular support
- Metabolic health improvement
- Blood-brain barrier penetration
- Convenient oral administration


---

### Dihexa

URL: https://peptide-db.com/peptides/dihexa

Dihexa is a synthetic oligopeptide derived from angiotensin IV that potently enhances cognitive function by promoting synaptogenesis. It is 10 million times more potent than BDNF at promoting synapse formation through HGF/c-Met receptor activation.

**Mechanism:** Binds to hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and potentiates its activity at c-Met receptor, activating PI3K/AKT pathways and promoting new synaptic connections with extraordinary potency.

**Key Benefits:**
- Dramatic synaptogenesis promotion
- 10 million times more potent than BDNF
- Cognitive enhancement and memory improvement
- Neuroprotection and potential neuroregeneration
- Applications for Alzheimer's, TBI, age-related cognitive decline
- Oral bioavailability


---

### DNSP-11

URL: https://peptide-db.com/peptides/dnsp-11

DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health.

**Mechanism:** DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.

**Key Benefits:**
- Protects dopaminergic neurons from neurotoxic insults
- Stimulates dopamine production via tyrosine hydroxylase upregulation
- Smaller molecule with improved bioavailability compared to full GDNF
- Does not require GFRalpha1/RET receptor complex for activity
- Preclinical evidence for neuroprotection in Parkinson's disease models
- Compatible with intranasal and subcutaneous administration


---

### DSIP

URL: https://peptide-db.com/peptides/dsip

DSIP is a naturally occurring nonapeptide discovered in 1974 in rabbit brain. Originally isolated for sleep-promoting properties, it has diverse neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation without traditional sedative effects.

**Mechanism:** Modulates multiple neurotransmitter systems including GABA enhancement, NMDA receptor interaction, and endogenous opioid system modulation. Also regulates hypothalamic-pituitary-adrenal axis for stress response.

**Key Benefits:**
- Enhanced sleep quality through slow-wave sleep promotion
- Stress reduction via cortisol modulation
- Potential pain relief
- Mood stabilization without traditional sedative effects
- No tolerance or dependence reported
- Short cycle duration (5-10 days)


---

### Epitalon

URL: https://peptide-db.com/peptides/epitalon

Epitalon is a synthetic tetrapeptide developed by Russian scientist Vladimir Khavinson with 35+ years of research. It activates telomerase at extremely low concentrations to maintain telomere length, stimulates melatonin production, and modulates gene expression through epigenetic mechanisms.

**Mechanism:** Activates telomerase at extremely low concentrations (10⁻¹⁷ to 10⁻¹⁵ M) to maintain telomere length, stimulates melatonin production from the pineal gland, and modulates gene expression through epigenetic mechanisms.

**Key Benefits:**
- Telomere extension and cellular replicative lifespan extension
- Enhanced melatonin production
- Improved immune function
- Potential lifespan extension (25-33% in animal studies)
- Systemic anti-aging through cellular rejuvenation
- Short cycle duration with long-lasting effects


---

### Erythropoietin (EPO)

URL: https://peptide-db.com/peptides/epo

Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow cells promotes survival and maturation of red blood cell precursors, increasing oxygen-carrying capacity. Due to performance-enhancing effects, it is banned in competitive sports.

**Mechanism:** EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production. Under hypoxic stress, endogenous EPO production can increase up to 1000-fold, demonstrating the body's powerful oxygen-sensing regulatory system.

**Key Benefits:**
- Stimulates red blood cell production
- Increases oxygen-carrying capacity
- FDA-approved for anemia treatment
- Improves endurance capacity
- Supports patients with chronic kidney disease
- Helps chemotherapy-induced anemia
- Well-characterized mechanism of action
- Extensively studied safety profile


---

### FGL

URL: https://peptide-db.com/peptides/fgl

FGL is a synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). It mimics the interaction between NCAM and fibroblast growth factor receptor 1 (FGFR1), activating downstream signaling cascades that promote synaptic plasticity, neurogenesis, and neuroprotection. Research has primarily been conducted in animal models, where FGL has shown promise for cognitive enhancement, stroke recovery, and neurodegenerative disease models.

**Mechanism:** FGL binds to and activates FGFR1, triggering receptor autophosphorylation and downstream signaling through the MAPK/ERK and PI3K/Akt pathways. This activation promotes long-term potentiation (LTP), enhances synaptic plasticity, stimulates neurogenesis in the hippocampus, and provides neuroprotective effects against excitotoxicity and oxidative stress.

**Key Benefits:**
- Activates FGFR1 to promote synaptic plasticity
- Stimulates hippocampal neurogenesis
- Provides neuroprotection against excitotoxic and ischemic injury
- Enhances long-term potentiation (LTP) in preclinical models
- Potential cognitive enhancement via NCAM-mimetic signaling


---

### FOXO4-DRI

URL: https://peptide-db.com/peptides/foxo4-dri

FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The 'DRI' modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.

**Mechanism:** FOXO4-DRI competes with FOXO4 for binding to p53, disrupting their protective interaction in senescent cells. This causes p53 to be excluded from the nucleus and triggers cell-intrinsic apoptosis (programmed cell death). Critically, this mechanism is highly selective: the FOXO4-p53 interaction is a specific vulnerability of senescent cells, while FOXO4 is minimally expressed in healthy tissues, leaving functional cells largely unharmed.

**Key Benefits:**
- Selective elimination of senescent cells
- Restoration of tissue homeostasis
- Improved fitness and physical function in aged models
- Restored fur density in aged mice
- Improved kidney function
- Alleviates chemotherapy-induced senescence
- Restores testosterone in aged males
- Reduces senescent chondrocytes in cartilage
- High selectivity spares healthy cells


---

### GHK-Cu

URL: https://peptide-db.com/peptides/ghk-cu

Naturally occurring copper tripeptide found in human plasma, saliva, and urine. GHK-Cu affects 31.2% of human genes and declines significantly with age—from ~200 ng/ml at age 20 to ~80 ng/ml at age 60. Known for exceptional skin regeneration, wound healing, and anti-aging properties.

**Mechanism:** Penetrates skin layers, activates fibroblasts, stimulates collagen and elastin synthesis, promotes angiogenesis, and modulates inflammatory responses. The copper ion is essential for enzyme cofactor activity in tissue repair processes.

**Key Benefits:**
- Enhanced collagen production (70% increase in type I and III)
- Improved skin elasticity
- Reduced fine lines and wrinkles
- Accelerated wound healing
- Hair growth stimulation
- Antioxidant protection


---

### GHRP-2

URL: https://peptide-db.com/peptides/ghrp-2

GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor.

**Mechanism:** GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.

**Key Benefits:**
- Potent stimulation of natural growth hormone release
- Enhanced muscle growth and recovery
- Improved body composition and fat metabolism
- Better sleep quality and recovery
- Increased appetite (can be beneficial for bulking)
- Maintains natural GH pulsatile release patterns
- Synergistic effects when combined with GHRH peptides


---

### GHRP-6

URL: https://peptide-db.com/peptides/ghrp-6

GHRP-6 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It was one of the first GHRPs developed and works by binding to the ghrelin receptor (GHS-R1a). Unlike direct HGH injections, GHRP-6 enhances the body's natural GH production while keeping negative feedback mechanisms balanced. It is known for its potent appetite-stimulating effects.

**Mechanism:** GHRP-6 binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by ghrelin. This initiates a signaling cascade in the hypothalamus and pituitary gland, triggering a rapid pulse of natural GH secretion. The released GH then signals the liver to secrete IGF-1, which promotes muscle growth and fat metabolism. GHRP-6 also stimulates ghrelin release, causing significant appetite increase.

**Key Benefits:**
- Potent stimulation of natural growth hormone release
- Significant increase in appetite (beneficial for bulking/weight gain)
- Enhanced muscle growth through elevated GH and IGF-1
- Improved fat metabolism and body composition
- Cardioprotective effects observed in research
- Enhanced recovery from exercise and injury
- Cytoprotective and anti-inflammatory properties
- Maintains natural GH pulsatile release


---

### Glow Protocol

URL: https://peptide-db.com/peptides/glow-protocol

Combination featuring BPC-157, TB-500, and GHK-Cu marketed for skin rejuvenation and anti-aging. Individual components have research support, but combination protocols require careful dosing to avoid exceeding therapeutic ranges.

**Mechanism:** BPC-157 provides anti-inflammatory effects; TB-500 supports angiogenesis; GHK-Cu stimulates collagen production. Fixed-ratio combinations may deliver individual peptides outside optimal therapeutic ranges.

**Key Benefits:**
- Single injection delivers multiple regenerative peptides
- Theoretical additive effects from combined components
- Convenience factor versus individual peptide administration


---

### Glutathione

URL: https://peptide-db.com/peptides/glutathione

Glutathione is the body's master antioxidant, a tripeptide produced naturally by the liver. It protects cells against free radicals, peroxides, and heavy metals while eliminating toxins including drugs and pollutants. Injectable glutathione bypasses gastrointestinal breakdown for superior bioavailability compared to oral supplements. Research supports benefits for neurological health, immune function, skin health, and anti-aging.

**Mechanism:** Glutathione acts as the primary intracellular antioxidant, directly neutralizing reactive oxygen species and regenerating other antioxidants like vitamins C and E. It plays crucial roles in detoxification by conjugating with toxins for elimination, supports immune function through T-cell regulation, protects mitochondria, and maintains cellular redox balance. The thiol group of cysteine provides its antioxidant activity.

**Key Benefits:**
- Master antioxidant - protects against oxidative stress
- Detoxification of heavy metals and toxins
- Immune system support and T-cell function
- Neuroprotective effects
- Skin health and potential brightening effects
- Liver protection and function
- Mitochondrial support
- Anti-aging properties


---

### Gonadorelin

URL: https://peptide-db.com/peptides/gonadorelin

Gonadorelin is a synthetic form of the naturally occurring gonadotropin-releasing hormone (GnRH). It stimulates the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which in turn regulate testosterone production in men and ovulation in women. It is FDA-approved for diagnostic testing and fertility treatment. The pulsatile nature of GnRH secretion is critical for proper reproductive function.

**Mechanism:** Gonadorelin acts as an agonist of the GnRH receptor in the anterior pituitary. When administered in pulses (mimicking natural secretion patterns every 60-120 minutes), it stimulates release of FSH and LH. LH then stimulates Leydig cells in the testes to produce testosterone, or triggers ovulation in women. Continuous exposure paradoxically causes receptor downregulation and suppressed hormone production.

**Key Benefits:**
- Stimulates natural testosterone production
- Maintains testicular function during hormone therapy
- Supports fertility in hypogonadal conditions
- FDA-approved for diagnostic and therapeutic use
- Can restore LH and FSH pulsatility
- Alternative to hCG for testicular stimulation
- Preserves endogenous hormone production


---

### HCG

URL: https://peptide-db.com/peptides/hcg

HCG is a glycoprotein hormone naturally produced by the placenta during pregnancy that binds LH receptors to stimulate testosterone and estrogen biosynthesis. FDA-approved for cryptorchidism, hypogonadotropic hypogonadism, and ovulation induction.

**Mechanism:** Binds to LH receptors on Leydig cells in testes, stimulating testosterone production with a half-life of 24-36 hours, peak levels 6-12 hours post-injection, and 40-50% bioavailability via SubQ or IM routes.

**Key Benefits:**
- Maintains testicular function during TRT
- Preserves fertility and prevents testicular atrophy
- Stimulates endogenous testosterone production
- Induces ovulation in women
- FDA-approved for multiple indications
- Well-established safety profile


---

### Hexarelin

URL: https://peptide-db.com/peptides/hexarelin

Hexarelin is one of the most potent synthetic growth hormone secretagogues available. It stimulates GH release by binding to the GHS-R1a receptor in the pituitary and hypothalamus, mimicking the action of ghrelin. Notably, Hexarelin demonstrates synergistic effects when combined with GHRH, producing GH responses greater than the arithmetic sum of either peptide alone. It also shows unique cardioprotective properties mediated through the CD36 receptor.

**Mechanism:** Hexarelin binds to the growth hormone secretagogue receptor 1a (GHS-R1a) in the brain and pituitary gland. This binding initiates a signaling cascade that stimulates somatotroph cells in the anterior pituitary to produce and release growth hormone. Hexarelin also has slight, dose-dependent effects on prolactin, ACTH, and cortisol release. Its cardioprotective effects are mediated through CD36 receptor activation and modulation of calcium channels in cardiomyocytes.

**Key Benefits:**
- Most potent GHRP for GH stimulation
- Powerful synergy with GHRH peptides
- Cardioprotective effects via CD36 receptor
- Enhanced muscle growth and strength
- Improved fat metabolism
- Better recovery and tissue repair
- Maintains natural GH pulsatility
- Stable against proteolytic enzymes


---

### HGH

URL: https://peptide-db.com/peptides/hgh

Human Growth Hormone (HGH/Somatropin) is a 191-amino acid polypeptide hormone FDA-approved for pediatric and adult growth hormone deficiency, HIV-associated wasting, and other conditions. It provides both direct and indirect (IGF-1 mediated) anabolic effects.

**Mechanism:** Binds to GH receptors on target tissues, triggering JAK2-STAT5 signaling pathway. Direct effects include lipolysis, protein synthesis, and metabolic regulation. Indirect effects via IGF-1 promote growth and anabolism. Half-life ~3 hours subcutaneously.

**Key Benefits:**
- Improved body composition (increased lean mass, decreased fat)
- Enhanced bone mineral density
- Improved lipid profile
- Increased exercise capacity
- Better quality of life and mood
- Skin, hair, and nail improvements
- Enhanced recovery and healing


---

### HGH Fragment 176-191

URL: https://peptide-db.com/peptides/hgh-frag-176-191

HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.

**Mechanism:** Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism. The fragment selectively targets adipose tissue to promote fat oxidation.

**Key Benefits:**
- Stimulates lipolysis without growth hormone side effects
- Does not affect blood glucose or insulin sensitivity
- Does not increase IGF-1 levels
- Selectively targets fat metabolism
- No impact on bone or organ growth


---

### HMG

URL: https://peptide-db.com/peptides/hmg

Human Menopausal Gonadotropin (HMG) is a hormonally active medication containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in a 1:1 ratio, extracted from the urine of postmenopausal women. FDA-approved for fertility treatment, HMG stimulates ovarian follicle development in women and spermatogenesis in men. While largely replaced by recombinant gonadotropins in some settings, HMG remains an effective and cost-efficient option for ovulation induction and assisted reproduction.

**Mechanism:** HMG acts on gonadal tissue through two mechanisms: FSH stimulates growth and maturation of ovarian follicles containing eggs in women, and promotes spermatogenesis in men. LH stimulates ovulation and corpus luteum formation in women, and Leydig cells in men to produce testosterone. Highly purified HMG (HP-hMG) has enhanced FSH receptor activity with reduced inactive proteins. The LH component modifies follicular development and decreases intermediate-sized follicles, potentially resulting in safer, more controlled stimulation.

**Key Benefits:**
- FDA-approved for fertility treatment
- Stimulates ovarian follicle development
- Contains both FSH and LH naturally
- Promotes spermatogenesis in men
- Cost-effective alternative to recombinant FSH
- LH activity may improve fertilization rates
- Long clinical track record
- Lower OHSS incidence with HP-hMG


---

### Humanin

URL: https://peptide-db.com/peptides/humanin

Humanin was the first mitochondria-derived peptide (MDP) discovered, originally cloned from the occipital lobe of an Alzheimer's patient. It is a 24-amino acid peptide encoded from the 16S rRNA region of mitochondrial DNA with potent neuroprotective, cytoprotective, and anti-apoptotic properties. Research shows humanin levels decline with age but remain stable in long-lived species like naked mole-rats, and offspring of centenarians have significantly higher humanin levels.

**Mechanism:** Humanin exerts its effects through multiple mechanisms. It interacts with cell surface receptors including FPRL1 and CNTFR, activating PI3K/AKT signaling pathways that promote cell survival. It blocks pro-apoptotic proteins like Bax, reduces beta-amyloid toxicity in neurons, protects against oxidative stress, and promotes mitochondrial biogenesis. These actions support healthy cellular aging at a fundamental level.

**Key Benefits:**
- Potent neuroprotection against Alzheimer's and Parkinson's pathology
- Extended lifespan in animal models (C. elegans)
- Improved metabolic healthspan parameters
- Reduced inflammatory markers
- Cytoprotective effects across multiple cell types
- Anti-apoptotic activity
- Mitochondrial optimization and biogenesis
- Protection against oxidative stress


---

### IGF-1 DES

URL: https://peptide-db.com/peptides/igf-1-des

IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.

**Mechanism:** IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.

**Key Benefits:**
- Approximately 10x more potent than native IGF-1
- 100% bioactive -- does not bind to IGF binding proteins
- Extremely short half-life enables localized, site-specific action
- Promotes satellite cell activation for muscle hyperplasia
- Minimal systemic exposure compared to IGF-1 LR3


---

### IGF-1 LR3

URL: https://peptide-db.com/peptides/igf-1-lr3

IGF-1 LR3 is a synthetic 83-amino acid analog of insulin-like growth factor-1 that has never been approved for human use. The N-terminal extension and R3 substitution reduce binding protein interaction, maintaining elevated free circulating levels with ~3x greater potency than native IGF-1.

**Mechanism:** Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels for extended anabolic effects.

**Key Benefits:**
- Approximately 3x more potent than native IGF-1
- Promotes muscle hypertrophy and hyperplasia in animal models
- 15-20% lean mass gains observed in 4-week rat studies
- Anti-catabolic effects preserve muscle during cachexia
- 20-30 hour half-life for sustained effects


---

### IllumiNeuro Protocol

URL: https://peptide-db.com/peptides/illumineuro-protocol

IllumiNeuro is a cognitive enhancement peptide blend combining four nootropic peptides: PE-22-28 (neuritogenic), Pinealon (pineal bioregulator), NA-Semax Amidate (neuroprotective/cognitive), and NA-Selank Amidate (anxiolytic/cognitive). The standard formulation contains 48mg total (PE-22-28 10mg + Pinealon 10mg + NA-Semax 20mg + NA-Selank 8mg). This blend targets multiple neurological pathways for comprehensive cognitive support, though no clinical studies exist on this specific four-peptide combination.

**Mechanism:** Each peptide contributes distinct neurological mechanisms: PE-22-28 promotes neurite outgrowth and neural connectivity through sphingosine-1-phosphate receptor modulation; Pinealon is a bioregulator that supports pineal gland function and circadian regulation; NA-Semax Amidate provides BDNF upregulation and neuroprotection; NA-Selank Amidate offers anxiolytic effects through GABA modulation and immune-neuroendocrine regulation. Together, they theoretically address cognitive enhancement, neuroprotection, mood support, and neural regeneration.

**Key Benefits:**
- Multi-pathway cognitive enhancement
- Neuroprotective and neuritogenic effects
- Anxiolytic properties from NA-Selank
- BDNF upregulation from NA-Semax
- Circadian/sleep support from Pinealon
- Convenience of single injection
- Extended-action amidate forms included


---

### Ipamorelin

URL: https://peptide-db.com/peptides/ipamorelin

Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produce consistent GH pulses without significant side effects common to other growth hormone releasing peptides.

**Mechanism:** Binds selectively to ghrelin receptors in pituitary gland, stimulating natural GH release with direct systemic delivery via injection, consistent GH pulse stimulation, no significant cortisol or prolactin elevation, and minimal hunger response.

**Key Benefits:**
- Optimal GH stimulation with superior bioavailability
- Body composition improvements (lean mass, fat loss)
- Enhanced recovery and anti-aging effects
- Minimal side effects compared to other GHRPs
- No significant cortisol or prolactin elevation
- Improved sleep quality


---

### Kisspeptin

URL: https://peptide-db.com/peptides/kisspeptin

Kisspeptin acts as a master regulator of the reproductive system, stimulating GnRH neurons essential for puberty, fertility, and reproductive function.

**Mechanism:** Binds to GPR54/KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release, which stimulates pituitary LH/FSH secretion and gonadal steroid production.

**Key Benefits:**
- Potent reproductive hormone stimulation (LH/FSH)
- Restoration of natural testosterone production
- Fertility enhancement
- Sexual function support
- Hypogonadism treatment potential


---

### KLOW Protocol

URL: https://peptide-db.com/peptides/klow-protocol

KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).

**Mechanism:** Each peptide contributes distinct biological pathways: GHK-Cu modulates gene expression for tissue repair, TB-500 enhances cellular migration and wound healing, BPC-157 upregulates growth factors for tissue regeneration, and KPV inhibits NF-κB inflammatory pathway.

**Key Benefits:**
- Theoretical synergistic multi-pathway tissue repair
- Anti-inflammatory effects across multiple mechanisms
- Cellular regeneration support
- Convenience of single injection dosing
- KPV may reduce injection site reactions versus GLOW


---

### KPV

URL: https://peptide-db.com/peptides/kpv

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.

**Mechanism:** Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.

**Key Benefits:**
- Systemic anti-inflammatory effects
- No pigmentation/tanning effects
- Immune modulation without immunosuppression
- Potential for autoimmune conditions
- Gut health support
- Multiple delivery routes available


---

### L-Carnitine

URL: https://peptide-db.com/peptides/l-carnitine

L-Carnitine is an amino acid derivative naturally produced in the body and essential for transporting long-chain fatty acids into mitochondria for energy production. Injectable forms bypass digestive absorption limitations of oral supplements.

**Mechanism:** Acts as a carrier molecule, shuttling long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system. This is the rate-limiting step in fatty acid oxidation for energy production.

**Key Benefits:**
- Enhanced fatty acid transport to mitochondria
- Improved energy production from fats
- Better bioavailability than oral forms
- Support for exercise recovery
- Potential cognitive benefits


---

### Livagen

URL: https://peptide-db.com/peptides/livagen

Livagen is a Khavinson bioregulator tetrapeptide (KEDA) with significant hepatoprotective and immunomodulatory properties. Structurally similar to Epitalon, it normalizes immune and antioxidant status while restoring liver function in hepatitis conditions. Livagen is best known for its ability to decondense chromatin, activating silent genes including ribosomal genes to boost protein synthesis and cellular activity. Maximum protective effects occur during aging.

**Mechanism:** Livagen works through direct effects on DNA structure and function. It decondenses chromatin (tightly packed DNA), increasing expression of certain genes and improving the 'youthful' profile of cells. The peptide activates multiple genes in lymphocytes, including previously silent ribosomal genes, boosting protein synthesis and cell activity. It exhibits hepatoprotective effects through normalizing immune and antioxidant status in liver tissue.

**Key Benefits:**
- Significant hepatoprotective properties
- Decondenses chromatin to activate genes
- Restores liver function in hepatitis
- Normalizes immune status
- Improves antioxidant status
- Activates ribosomal gene expression
- Maximum effects occur during aging
- Boosts protein synthesis and cell activity


---

### LL-37

URL: https://peptide-db.com/peptides/ll-37

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from hCAP18 that exhibits broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while modulating immune responses.

**Mechanism:** Provides direct antimicrobial activity through membrane disruption, promotes wound healing by enhancing keratinocyte migration and angiogenesis, and modulates immune responses without systemic exposure when used topically.

**Key Benefits:**
- Direct wound healing acceleration
- Broad-spectrum antimicrobial activity
- Activity against resistant bacteria (MRSA, MDRPA)
- Enhanced tissue regeneration
- Immune modulation
- Local antimicrobial protection


---

### Mazdutide

URL: https://peptide-db.com/peptides/mazdutide

First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.

**Mechanism:** Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.

**Key Benefits:**
- Up to 20% body weight loss
- Superior glycemic control versus semaglutide
- Increased energy expenditure via glucagon receptor activation
- Improved cardiometabolic markers (BP, lipids, liver fat)
- Once-weekly injection convenience


---

### Melanotan I

URL: https://peptide-db.com/peptides/melanotan-i

Synthetic analog of α-MSH that selectively targets MC1 receptors for melanin stimulation. FDA-approved as SCENESSE implant for erythropoietic protoporphyria (EPP). Research-grade injectable form enables flexible dosing versus the implant version.

**Mechanism:** Subcutaneous injection delivers peptide directly into systemic circulation. Selectively activates MC1R receptors to stimulate melanin production. Short half-life of approximately 30 minutes necessitates multiple daily dosing for sustained effect.

**Key Benefits:**
- Precise dosing control with rapid tanning onset
- Flexible home administration unlike implant version
- Visible tanning within 1-2 weeks with UV exposure
- Enhanced photoprotection through increased melanin
- More selective for MC1R than Melanotan II


---

### Melanotan II

URL: https://peptide-db.com/peptides/melanotan-ii

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors throughout the body. MC1R activation triggers melanin production for tanning, while MC4R affects sexual arousal and appetite control.

**Mechanism:** Binds to melanocortin receptors (MC1R for tanning, MC4R for sexual function and appetite) to stimulate melanin production, enhance libido, and suppress appetite through hypothalamic pathways.

**Key Benefits:**
- Rapid tanning without UV exposure
- Enhanced sexual function and libido
- Appetite suppression
- Improved mood via melanocortin activation
- Photoprotection through increased melanin


---

### MGF

URL: https://peptide-db.com/peptides/mgf

Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.

**Mechanism:** Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain exhibits distinct activity from mature IGF-1.

**Key Benefits:**
- Satellite cell activation for muscle repair
- Recovery support following mechanical stress
- Localized tissue regeneration
- Natural upregulation after exercise


---

### MK-677

URL: https://peptide-db.com/peptides/mk-677

Oral compound activating ghrelin receptors to trigger growth hormone release while preserving natural production. Achieves superior oral bioavailability exceeding 60% with a 24-hour half-life, making it unique among GH secretagogues for its convenient once-daily oral dosing.

**Mechanism:** Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns.

**Key Benefits:**
- 97% increase in 24-hour growth hormone secretion
- 40-72% elevation in IGF-1 levels
- Enhanced sleep quality with improved REM patterns
- Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
- 15% basal metabolic rate increase within 2 weeks
- Oral administration (no injections required)


---

### MOTS-c

URL: https://peptide-db.com/peptides/mots-c

MOTS-c is a mitochondrial-derived peptide that operates as a mitohormone through the Folate-AICAR-AMPK pathway. Under metabolic stress, it translocates to the nucleus to bind stress-response transcription factors (NRF2, ATF1/ATF7), regulating genes involved in metabolism and cellular adaptation.

**Mechanism:** Inhibits the folate cycle leading to AMPK activation. Under metabolic stress, translocates to nucleus to bind stress-response transcription factors, regulating genes involved in metabolism, insulin sensitivity, and cellular adaptation.

**Key Benefits:**
- Enhanced insulin sensitivity (~30% improvement)
- Improved glucose metabolism and tolerance
- AMPK pathway activation
- Mitochondrial function optimization
- Exercise performance enhancement (12-15% improvement)
- Potential lifespan extension (6.4% median increase in mice)


---

### NA Semax Amidate

URL: https://peptide-db.com/peptides/na-semax-amidate

Enhanced and stabilized version of Russian nootropic Semax with superior stability, extended half-life, and enhanced bioavailability through acetylation and amidation modifications.

**Mechanism:** Bypasses blood-brain barrier via olfactory nerves with direct brain access; enhances BDNF upregulation and hippocampal plasticity.

**Key Benefits:**
- Direct brain access via olfactory nerves
- Rapid onset (15-30 minutes)
- Proven cognitive efficacy
- Extended half-life vs standard Semax
- Enhanced BDNF upregulation


---

### NA-Selank Amidate

URL: https://peptide-db.com/peptides/na-selank-amidate

NA-Selank Amidate is an enhanced version of Selank, the anxiolytic nootropic peptide developed at Russia's Institute of Molecular Genetics. The N-acetyl group improves blood-brain barrier penetration and creates more stable metabolites, while the C-terminal amidation further enhances metabolic stability and receptor binding. Unlike benzodiazepines, it provides anxiety relief without sedation, dependency, or cognitive impairment.

**Mechanism:** NA-Selank Amidate modulates multiple neurotransmitter systems including GABA, dopamine, and serotonin, while regulating brain-derived neurotrophic factor (BDNF). It allosterically modulates GABAA receptors without causing the sedation or dependency of benzodiazepines. The peptide activates serotonin metabolism in the hypothalamus and brainstem, and increases BDNF levels to promote neuronal growth and differentiation.

**Key Benefits:**
- Pronounced anxiolytic effects without sedation
- Enhanced blood-brain barrier penetration (vs standard Selank)
- Improved metabolic stability and longer half-life
- Nootropic effects with enhanced memory and learning
- Increased BDNF levels for neuroplasticity
- No dependency or withdrawal effects
- Immune-modulating properties
- Effects persist after treatment cessation


---

### NAD+

URL: https://peptide-db.com/peptides/nad-plus

NAD+ is a crucial coenzyme found in every cell, involved in energy generation and cellular maintenance that naturally declines with age. Supplementation may support cellular health, boost energy, enhance cognitive function, and promote longevity through multiple delivery methods.

**Mechanism:** Direct delivery to bloodstream ensures maximum cellular availability for energy production via ATP synthesis, DNA repair through PARP activation, and sirtuin-mediated longevity pathways. Supports mitochondrial function and metabolic homeostasis.

**Key Benefits:**
- Restores mitochondrial function and ATP synthesis
- Enhances glucose and fat metabolism
- Improves oxygen utilization and endurance
- Activates DNA repair mechanisms
- Supports longevity pathways via sirtuins
- Improves mental clarity and focus


---

### Orforglipron

URL: https://peptide-db.com/peptides/orforglipron

First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.

**Mechanism:** Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.

**Key Benefits:**
- Significant weight loss (up to 12.4% at 72 weeks)
- Robust diabetes control (HbA1c reduction 1.3-1.6%)
- Once-daily oral tablet format
- No refrigeration or food restrictions required
- Reduced cardiovascular risk markers


---

### Ovagen

URL: https://peptide-db.com/peptides/ovagen

Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.

**Mechanism:** Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.

**Key Benefits:**
- Reduces long-term liver fibrosis
- Protects GI mucosal layer
- Defense against antibiotic damage
- Protection from environmental toxins
- May protect against chemotherapy GI effects
- Tissue-specific targeting via PEPT transporters
- Direct DNA regulation
- Part of comprehensive anti-aging protocols


---

### Oxytocin

URL: https://peptide-db.com/peptides/oxytocin

Nine-amino-acid peptide hormone produced in hypothalamus, released by posterior pituitary. Functions in social bonding, trust, empathy, reproduction, childbirth, lactation. FDA-approved synthetically for labor induction and postpartum hemorrhage.

**Mechanism:** Binds oxytocin receptors on uterine smooth muscle, triggering calcium influx and myometrial contractions. Stimulates prostaglandin release. In CNS, modulates GABAergic, serotonergic, dopaminergic neurotransmission; reduces cortisol and HPA axis activity.

**Key Benefits:**
- FDA-approved for labor induction with precise dosing via IV
- Immediate onset in obstetric settings
- Established safety profile in clinical use
- Researched for anxiety, PTSD, autism, sexual dysfunction


---

### P21

URL: https://peptide-db.com/peptides/p21

P21 is a nootropic peptide derived from ciliary neurotrophic factor (CNTF) that enhances neurogenesis and cognitive function. It contains an adamantane moiety that enables blood-brain barrier penetration. Research shows it increases BDNF expression, inhibits LIF signaling to promote neurogenesis, and reduces tau and amyloid pathology in Alzheimer's disease models. Remarkably, P21 can boost neurogenesis in diseased brains above levels seen in healthy untreated brains.

**Mechanism:** P21 operates through multiple pathways: it inhibits leukemia inhibitory factor (LIF) signaling, removing a key roadblock to neurogenesis and shifting the brain toward a more embryologic state favoring neuron growth. It increases brain-derived neurotrophic factor (BDNF) expression and activates the BDNF/TrkB/PI3-K/AKT/GSK3β pathway. This pathway modulation improves cognitive function and reduces tau and amyloid pathologies.

**Key Benefits:**
- Potent promotion of neurogenesis in the dentate gyrus
- Increased BDNF expression
- Reduced tau protein pathology
- Reduced amyloid-beta plaque formation
- Improved cognitive function and memory
- Restored synaptic deficits in cortex and hippocampus
- Reduced mortality rate in AD models
- Crosses blood-brain barrier effectively


---

### Pancragen

URL: https://peptide-db.com/peptides/pancragen

Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.

**Mechanism:** Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures to modulate pancreatic gene expression. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Its small size (4 amino acids, ~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA.

**Key Benefits:**
- Corrects impaired glucose tolerance
- Normalizes insulin levels
- Normalizes C-peptide levels
- Improves endocrine pancreatic function
- Supports pancreatic cell differentiation
- Regulates melatonin expression
- Reduces metabolic syndrome incidence
- Upregulates key pancreatic transcription factors


---

### PE-22-28

URL: https://peptide-db.com/peptides/pe-22-28

Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects.

**Mechanism:** Selectively blocks TREK-1 potassium channels (IC50: 0.12 nM). Enhances serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis.

**Key Benefits:**
- Rapid antidepressant effects within 4 days (preclinical)
- Hippocampal neurogenesis and synaptogenesis
- Enhanced serotonergic neurotransmission
- Extended ~23 hour duration of action
- 300-500x greater potency than full-length Spadin


---

### PEG-MGF

URL: https://peptide-db.com/peptides/peg-mgf

Modified IGF-1 variant with PEG attachment extending half-life from minutes to hours. Activates muscle satellite cells following mechanical stress or injury.

**Mechanism:** Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. E-peptide domain exhibits distinct activity from mature IGF-1.

**Key Benefits:**
- Extended half-life through PEGylation
- Satellite cell activation for muscle repair
- Recovery support following mechanical stress
- Potential neuroprotection against oxidative stress


---

### Pinealon

URL: https://peptide-db.com/peptides/pinealon

Developed in Russia, Pinealon demonstrates unique DNA-interaction for neuroprotection and cognitive enhancement. Benefits traumatic brain injury recovery and age-related cognitive decline with excellent safety profile.

**Mechanism:** Penetrates nuclear membranes to directly interact with DNA, modulates gene expression via histone H1.3 binding and MAPK/ERK pathway activation.

**Key Benefits:**
- Direct DNA interaction
- Neuroprotection
- Cognitive enhancement
- Excellent safety profile
- 40+ years of clinical use in Russia


---

### PNC-27

URL: https://peptide-db.com/peptides/pnc-27

PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. It contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. The peptide selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes, forming pores that cause cell necrosis. Critically, PNC-27 has no effect on normal cells because healthy cells don't express HDM-2 on their membranes. Research shows effectiveness against pancreatic cancer, breast cancer, leukemia, and melanoma.

**Mechanism:** PNC-27 exploits a unique vulnerability of cancer cells: the presence of HDM-2 (human double minute 2, also called MDM2) on their cell surface. The peptide's p53 residues adopt a conformation that binds directly to membrane-bound HDM-2, inducing transmembrane pore formation. This causes rapid tumor cell necrosis (not apoptosis). Additionally, PNC-27 enters cancer cells and disrupts mitochondrial membranes. Normal cells lack surface HDM-2 expression and are completely spared.

**Key Benefits:**
- Selectively kills cancer cells only
- No effect on normal healthy cells
- Induces rapid cancer cell necrosis
- Works on multiple cancer types
- Unique membrane pore mechanism
- Does not require p53 function in target cells
- Eradicates tumors in mouse models
- Spares human stem cells


---

### Prostamax

URL: https://peptide-db.com/peptides/prostamax

Prostamax is a Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis.

**Mechanism:** Prostamax works through epigenetic regulation by altering chromatin structure. It increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide influences heterochromatin arrangements in human lymphocytes and normalizes age-related changes in cellular function.

**Key Benefits:**
- Reduces prostate inflammation
- Decreases prostatic swelling
- Reduces vascular congestion (hyperemia)
- Decreases immune cell infiltration
- Reduces scarring in prostate tissue
- Promotes chromatin decondensation
- Reactivates age-repressed genes
- Improves lymphocyte function


---

### PT-141

URL: https://peptide-db.com/peptides/pt-141

FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Works centrally in the nervous system to trigger sexual arousal pathways independent of vascular mechanisms, unlike traditional ED medications.

**Mechanism:** Selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of peripheral vascular mechanisms. Works within 45 minutes with effects lasting 6-12 hours.

**Key Benefits:**
- FDA-approved pharmaceutical route
- Predictable absorption profile
- Effective for both male and female sexual dysfunction
- Works within 45 minutes
- Effective in PDE5 inhibitor-resistant cases
- Central mechanism (not dependent on blood flow)


---

### Retatrutide

URL: https://peptide-db.com/peptides/retatrutide

Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medications.

**Mechanism:** Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation.

**Key Benefits:**
- Superior weight loss (24.2% at 48 weeks)
- Improved glycemic control (HbA1c reduction up to 2.16%)
- Enhanced cardiovascular benefits
- Hepatic fat reduction (up to 82%)
- Triple mechanism addresses obesity through multiple pathways


---

### Selank

URL: https://peptide-db.com/peptides/selank

Selank is a synthetic heptapeptide analog of the naturally occurring immune peptide tuftsin, developed by the Russian Academy of Sciences. It provides anxiolytic effects comparable to benzodiazepines but without sedation, amnesia, tolerance, or withdrawal.

**Mechanism:** Works through allosteric modulation of GABA-A receptors, serotonin and dopamine system optimization, enkephalin degradation inhibition, IL-6 and cytokine balance regulation, and BDNF upregulation in the hippocampus.

**Key Benefits:**
- Rapid onset anxiolytic effects
- Enhanced BDNF expression (30% increase)
- Improved stress resilience
- Cognitive enhancement
- Immune modulation
- No tolerance or withdrawal
- Neuroprotective effects


---

### Semaglutide

URL: https://peptide-db.com/peptides/semaglutide

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetite suppression and glycemic control. The 7-day half-life enables convenient weekly dosing.

**Mechanism:** Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways.

**Key Benefits:**
- 15-20% average body weight reduction
- Established cardiovascular protection
- Convenient once-weekly dosing options
- Comprehensive safety data from extensive trials
- Flexible injectable and oral formulations


---

### Semax

URL: https://peptide-db.com/peptides/semax

Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) fragment 4-10, originally developed in Russia for stroke recovery. It achieves enhanced CNS penetration through direct transport via olfactory epithelium and trigeminal nerves, bypassing the blood-brain barrier.

**Mechanism:** Rapidly increases BDNF levels, modulates dopaminergic and serotonergic systems, and achieves direct brain delivery through olfactory transport with 0.093% blood-brain barrier penetration (vs 0.01% IV).

**Key Benefits:**
- Rapid brain delivery via intranasal route
- Rapidly increases BDNF levels
- Extensive clinical research in Russia
- Easy self-administration
- Modulates dopamine and serotonin systems
- Neuroprotective effects


---

### Sermorelin

URL: https://peptide-db.com/peptides/sermorelin

Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while preserving physiological pulsatile patterns. Originally FDA-approved in 1997 for pediatric GH deficiency, it was discontinued in 2008 for manufacturing reasons, not safety concerns.

**Mechanism:** Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary axis integrity and allowing natural somatostatin negative feedback.

**Key Benefits:**
- FDA-proven efficacy
- Maintains natural GH pulsatile patterns
- Preserves pituitary function
- 1.26kg lean mass increase documented in elderly
- IGF-1 mediated anabolic effects
- Allows natural feedback regulation


---

### SLU-PP-332

URL: https://peptide-db.com/peptides/slu-pp-332

Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.

**Mechanism:** Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.

**Key Benefits:**
- Exercise mimetic effects without physical activity
- 12% weight loss in 28 days
- 70% increased endurance
- 25% enhanced fatty acid oxidation
- Improved insulin sensitivity
- Reduced hepatic steatosis
- Cardiac protection
- Reversal of age-related mitochondrial dysfunction


---

### SNAP-8

URL: https://peptide-db.com/peptides/snap-8

Synthetic octapeptide functioning as topical Botox alternative, targeting dynamic facial wrinkles through SNARE complex modulation. Up to 63% wrinkle depth reduction demonstrated clinically.

**Mechanism:** Mimics SNAP-25 protein N-terminal, competitively inhibits SNARE complex formation, reduces acetylcholine release at neuromuscular junctions.

**Key Benefits:**
- Non-invasive alternative to botulinum toxin
- Up to 63% wrinkle depth reduction demonstrated clinically
- Safe for sensitive periorbital areas
- No recovery time required
- Gradual, natural-appearing results


---

### SS-31

URL: https://peptide-db.com/peptides/ss-31

SS-31 (Elamipretide) is an aromatic-cationic tetrapeptide that selectively binds to cardiolipin in the inner mitochondrial membrane, preventing lipid peroxidation and optimizing electron transport chain function for enhanced cellular energy production.

**Mechanism:** Selectively binds to cardiolipin in inner mitochondrial membrane, preventing lipid peroxidation and optimizing electron transport chain function. This improves ATP production and reduces oxidative damage at the mitochondrial level.

**Key Benefits:**
- Directly protects mitochondria
- Improves cellular energy production (ATP)
- Reduces oxidative damage
- Enhances exercise capacity
- Excellent safety profile in clinical trials
- Cardioprotective effects


---

### Survodutide

URL: https://peptide-db.com/peptides/survodutide

Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.

**Mechanism:** Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.

**Key Benefits:**
- Superior weight loss vs monotherapy (14.9% at 46 weeks)
- Once-weekly convenient dosing
- Proven efficacy in obesity, MASH, and Type 2 diabetes
- 62% MASH improvement in clinical trials


---

### TB-500

URL: https://peptide-db.com/peptides/tb-500

A synthetic 7-amino acid fragment corresponding to the actin-binding region of thymosin beta-4, originally developed for equine use with retained tissue repair properties. TB-500 acts as principal actin-sequestering protein, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation.

**Mechanism:** Acts as principal actin-sequestering protein, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation for comprehensive regenerative effects.

**Key Benefits:**
- Superior systemic tissue repair
- Accelerated muscle, tendon, and ligament healing
- Enhanced cell migration and angiogenesis
- Comprehensive regenerative effects
- Neuroprotective properties


---

### TB-500 (Ac-LKKTETQ)

URL: https://peptide-db.com/peptides/tb-500-fragment

TB-500 (Ac-LKKTETQ) is a synthetic derivative of thymosin beta-4 consisting of the N-terminal acetylated 17-23 amino acid fragment. This sequence represents the active site within thymosin beta-4 responsible for actin binding, cell migration, and wound healing. Research shows it promotes endothelial cell differentiation, angiogenesis, keratinocyte migration, collagen deposition, and decreases inflammation. The acetylation protects against N-terminal degradation while maintaining biological activity.

**Mechanism:** TB-500 contains the LKKTETQ sequence which is the actin-binding motif of full-length thymosin beta-4. This fragment shares many properties of the parent protein regarding cell proliferation, differentiation, and migration. It promotes angiogenesis by upregulating VEGF expression and enhancing endothelial cell sprouting. The peptide undergoes serial cleavage at the C-terminus during metabolism, while the N-terminal acetylation provides protection from degradation.

**Key Benefits:**
- Promotes wound healing
- Enhances cell migration
- Supports angiogenesis (new blood vessel formation)
- Reduces inflammation
- Promotes keratinocyte migration
- Supports collagen deposition
- Enhances tissue repair
- Active region of thymosin beta-4


---

### Teriparatide

URL: https://peptide-db.com/peptides/teriparatide

Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.

**Mechanism:** Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.

**Key Benefits:**
- FDA-approved for osteoporosis treatment
- Actively builds new bone (anabolic)
- Increases spine bone density by 5-9%
- Reduces vertebral fracture risk by 65%
- Reduces nonvertebral fractures by 35%
- Works differently than antiresorptive drugs
- Benefits seen within 3 months
- Creates 'anabolic window' for bone growth


---

### Tesa/IPA Protocol

URL: https://peptide-db.com/peptides/tesa-ipa-protocol

The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.

**Mechanism:** The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.

**Key Benefits:**
- Synergistic GH release from dual pathways
- More physiological pulsatile GH secretion
- Tesamorelin's proven lipodystrophy benefits
- Ipamorelin's clean side effect profile
- Does not significantly affect cortisol or prolactin
- Single injection convenience
- May improve body composition, sleep, and recovery


---

### Tesamorelin

URL: https://peptide-db.com/peptides/tesamorelin

Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-20% visceral fat reduction in clinical trials while preserving subcutaneous fat.

**Mechanism:** Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat.

**Key Benefits:**
- FDA-approved formulation
- Selective visceral fat targeting (15-20% reduction)
- Proven clinical efficacy
- Standardized dosing
- 37% liver fat reduction in NAFLD
- Preserved subcutaneous fat


---

### Testagen

URL: https://peptide-db.com/peptides/testagen

Testagen is a Khavinson bioregulator tetrapeptide (KEDG) originally isolated from testicular tissue extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it promotes testosterone biosynthesis by stimulating Leydig cell activity and improving cellular metabolism in testicular tissue. Research shows it helps restore normal communication within the hypothalamic-pituitary-gonadal (HPG) axis, governing testosterone production and spermatogenesis.

**Mechanism:** Testagen works through epigenetic regulation, crossing both cell and nuclear membranes to interact directly with DNA of target tissues. It penetrates into cytoplasm, nucleus, and nucleolus of cells, interacting with various cellular components including DNA and RNA. The peptide can discriminate between different nucleotide sequences and recognize cytosine methylation status. It interacts with the anterior pituitary gland and endocrine pathways involved in testosterone and TSH synthesis, restoring HPG axis communication.

**Key Benefits:**
- Promotes testosterone biosynthesis
- Stimulates Leydig cell activity
- Improves testicular cellular metabolism
- Restores HPG axis communication
- Supports spermatogenesis
- Reduces prostatic inflammation
- Enhances male reproductive balance
- May normalize testosterone at any age


---

### Thymalin

URL: https://peptide-db.com/peptides/thymalin

Thymalin is a natural peptide bioregulator derived from calf thymus gland, developed in the Soviet Union in the 1970s. It contains a mixture of thymic peptides that support immune restoration, anti-aging, and tissue regeneration. Research spanning decades has shown significant geroprotective effects, with studies demonstrating up to 2-fold reduction in mortality rates and 4-fold reduction when combined with Epithalamin.

**Mechanism:** Thymalin's immunoprotective action stems from short peptides (KE, EW, EDP) that specifically bind to double-stranded DNA and histone proteins to regulate gene expression. It stimulates differentiation and activity of T-lymphocytes, especially CD4+ and CD8+ cells, promotes cytokine regulation, enhances antigen response, and stimulates stem cell differentiation. It also affects gerontogene activity and immune system protein synthesis.

**Key Benefits:**
- Potent immune system restoration and modulation
- Significant geroprotective (anti-aging) effects
- Reduced mortality rate in clinical studies (2.0-2.1 fold)
- Normalized cardiovascular, endocrine, and nervous system function
- Reduced acute respiratory disease incidence (2.0-2.4 fold)
- Enhanced T-lymphocyte differentiation (CD4+, CD8+)
- Antitumor effects in animal studies
- Safe for elderly populations with no side effects


---

### Thymogen

URL: https://peptide-db.com/peptides/thymogen

Thymogen (EW dipeptide) is a Khavinson bioregulator consisting of glutamic acid and tryptophan, originally isolated from calf thymus extracts (Thymalin) in the late 1980s. Developed by Professor Vladimir Khavinson, it has been registered in Russia since 1990 in multiple forms including injectable solution, nasal spray, and topical cream. Thymogen modulates both humoral and cellular immunity, activates T-cell differentiation, and has demonstrated geroprotective (anti-aging) and antitumor activities in research studies.

**Mechanism:** Thymogen works through multiple immunomodulatory mechanisms: (1) activates T-cell differentiation and T-cell recognition of peptide-MHC complexes, (2) induces changes in intracellular cyclic nucleotide composition, (3) activates neutrophilic chemotaxis and phagocytosis, (4) normalizes T-lymphocyte concentrations and ratios (CD3+, CD4+, CD8+), (5) stimulates production of immunoglobulins (IgA, IgG, IgE, IgM), and (6) enhances lymphocyte differentiation receptor expression. Research suggests Thymogen may interact specifically with the AACG DNA sequence, affecting gene expression. The peptide is rapidly distributed to thymus, lymph nodes, liver, adrenals, and kidneys.

**Key Benefits:**
- Modulates humoral and cellular immunity
- Activates T-cell differentiation
- Normalizes T-lymphocyte populations (CD3+, CD4+, CD8+)
- Stimulates immunoglobulin production
- Enhances regeneration and cellular metabolism
- Demonstrated geroprotective (anti-aging) activity
- Antitumor activity in research models
- Registered pharmaceutical in Russia
- Multiple delivery forms available


---

### Thymosin Alpha 1

URL: https://peptide-db.com/peptides/thymosin-alpha-1

Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.

**Mechanism:** Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

**Key Benefits:**
- Primary FDA-studied route with extensive clinical validation
- Maximum immune modulation through systemic circulation
- Established dosing from 35+ countries of clinical use
- Exceptional safety profile (<1% serious adverse events)
- Reduces pro-inflammatory cytokines 40-60%
- Approved in 35+ countries


---

### Thymosin Beta-4

URL: https://peptide-db.com/peptides/thymosin-beta-4

Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.

**Mechanism:** Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.

**Key Benefits:**
- Systemic regenerative effects
- Proven clinical efficacy
- Optimal bioavailability for tissue repair
- Promotes angiogenesis
- Reduces inflammation


---

### Thymulin

URL: https://peptide-db.com/peptides/thymulin

Thymulin is a nonapeptide hormone exclusively secreted by thymic epithelial cells, discovered by Jean-François Bach in the 1970s. Unlike thymalin (a peptide extract mixture), thymulin is a single, defined 9-amino-acid peptide that requires zinc binding for biological activity. It plays a crucial role in T-cell differentiation and maturation within the thymus. Serum thymulin levels decline significantly with age and zinc deficiency, contributing to age-related immune decline (immunosenescence). Research has explored thymulin's potential in restoring immune function, managing autoimmune conditions, and as an anti-inflammatory agent.

**Mechanism:** Thymulin exerts its effects through binding to high-affinity receptors on T-lymphocytes and other immune cells. The zinc-thymulin complex is the biologically active form - without zinc, the peptide has no immunological activity. Thymulin promotes: (1) differentiation of immature T-cells into mature T-cell subsets, (2) modulation of cytokine release including IL-2 and interferon-gamma, (3) regulation of T-helper and T-suppressor cell balance, (4) enhancement of NK cell activity, and (5) anti-inflammatory effects through suppression of pro-inflammatory mediators. It also has neuroendocrine effects, influencing the hypothalamic-pituitary-adrenal axis.

**Key Benefits:**
- Essential for T-cell maturation and differentiation
- Modulates immune responses (immunomodulatory)
- Anti-inflammatory properties
- Declines with age - restoration may combat immunosenescence
- Well-defined single peptide (unlike extracts)
- Studied in autoimmune disease research
- Neuroendocrine regulatory effects
- Zinc-dependent activity allows for regulation


---

### Tirzepatide

URL: https://peptide-db.com/peptides/tirzepatide

Revolutionary dual receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Demonstrates efficacy superior to single-mechanism alternatives with 15-22% body weight reduction in clinical trials. The first-in-class dual GIP/GLP-1 agonist provides enhanced metabolic benefits compared to GLP-1-only medications.

**Mechanism:** Dual agonist targeting both GIP and GLP-1 receptors, producing glucose-dependent insulin stimulation, delayed gastric emptying, glucagon suppression, and central satiety signaling via hypothalamic pathways.

**Key Benefits:**
- Dramatic weight loss (15-22% body weight)
- Superior diabetes control
- Reduced cardiovascular risk (26% reduction in MACE)
- Improved insulin sensitivity
- Appetite suppression
- Preserved muscle mass with exercise


---

### Tri-Heal Max Protocol

URL: https://peptide-db.com/peptides/tri-heal-max-protocol

Tri-Heal Max is an enhanced healing peptide blend featuring a higher dose of TB-500 (25mg) combined with BPC-157 (10mg) and KPV (10mg) for a total of 45mg per vial. This formulation emphasizes TB-500's tissue repair and cellular migration properties, complemented by BPC-157's growth factor upregulation and KPV's anti-inflammatory effects. The higher TB-500 ratio (2.5:1:1) compared to standard healing stacks targets more significant tissue damage or accelerated recovery needs.

**Mechanism:** Each peptide contributes distinct healing pathways: TB-500 (Thymosin Beta-4) enhances cellular migration, promotes actin polymerization, and supports blood vessel formation for tissue repair; BPC-157 upregulates growth factors (VEGF, EGF), accelerates wound healing, and provides gastrointestinal protection; KPV (alpha-MSH fragment) inhibits the NF-κB inflammatory pathway, reduces pro-inflammatory cytokines, and may improve injection site tolerability. Together, they address inflammation, tissue regeneration, and cellular repair.

**Key Benefits:**
- Enhanced TB-500 dosing for significant injuries
- Multi-pathway tissue regeneration
- Anti-inflammatory effects from KPV
- Complementary healing mechanisms
- Single injection convenience
- May accelerate recovery from surgery or injury
- Targets both acute and chronic tissue damage


---

### Vesilute

URL: https://peptide-db.com/peptides/vesilute

Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.

**Mechanism:** Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.

**Key Benefits:**
- Supports bladder and urinary tract function
- May improve prostate health in men
- Regulates smooth muscle function
- Enhances pelvic tissue blood flow
- Supports cellular regeneration
- Part of comprehensive Khavinson bioregulator protocols
- Well-tolerated in research
- Oral bioavailability as small dipeptide


---

### Vesugen

URL: https://peptide-db.com/peptides/vesugen

Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression.

**Mechanism:** Vesugen works through epigenetic regulation by interacting with DNA promoter regions, particularly affecting Ki-67 gene expression which controls cell division. It plays a prominent role in regulating sirtuin 1 (SIRT1) protein levels - a key anti-aging protein activated during calorie restriction. Vesugen enhances mesenchymal stem cell proliferation, reduces senescence markers, improves cell differentiation, and may reverse the Senescence-Associated Secretory Phenotype (SASP) implicated in age-related cardiovascular disease.

**Key Benefits:**
- Protects vascular system from aging effects
- Limits atherosclerosis development
- Decreases endothelial cell dysfunction
- Activates SIRT1 anti-aging pathway
- Enhances stem cell proliferation
- Reduces cellular senescence markers
- Reverses SASP phenotype
- Works synergistically with Cardiogen


---

### Vilon

URL: https://peptide-db.com/peptides/vilon

Vilon is a Khavinson bioregulator dipeptide (KE) consisting of lysine and glutamic acid, originally isolated from thymus gland extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it acts as a molecular signaling compound that restores normal gene expression and protein synthesis in immune and epithelial cells. Research shows Vilon increases mean lifespan by 20-40% in animal studies and suppresses tumor development.

**Mechanism:** Vilon works through epigenetic modulation, restoring chromatin structure and gene expression in immune cells. It stimulates thymocyte proliferation, activates T-helper cells, and increases the proliferative index in thymus tissue (from 26% to 37% in studies). The peptide modulates tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and helps rejuvenate aged immune systems by restoring proper gene expression patterns.

**Key Benefits:**
- Increases mean lifespan 20-40% in animal models
- Suppresses tumor development
- Stimulates thymocyte proliferation
- Activates T-helper cells
- Restores chromatin structure in aged lymphocytes
- Enhances intestinal barrier function
- Improves enzyme activity in aged tissue
- Part of comprehensive longevity protocols


---

### VIP

URL: https://peptide-db.com/peptides/vip

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.

**Mechanism:** VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.

**Key Benefits:**
- Potent vasodilation and blood pressure reduction
- Strong anti-inflammatory effects
- Immunomodulation (Th1-Th2 balance)
- Neuroprotective effects
- Bronchodilation
- Cardioprotective (positive inotropic effects)
- Insulin secretion enhancement (glucose-dependent)
- Gut barrier and permeability regulation


---

### Wolverine Stack

URL: https://peptide-db.com/peptides/wolverine-stack

Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87.5% improvement in knee pain patients per Lee & Padgett 2021 study.

**Mechanism:** BPC-157 increases actin production and modulates nitric oxide for vascular effects; TB-500 sequesters actin for cell migration; synergistic enhancement of fibroblast and immune cell movement to injury sites.

**Key Benefits:**
- Complementary healing mechanisms
- 87.5% improvement in knee pain patients
- Reduced inflammation and enhanced cell migration
- Promotes angiogenesis and reduces scarring


---

## Compound Profiles

### 9-Me-BC

URL: https://peptide-db.com/compounds/9-me-bc

9-Me-BC (9-Methyl-beta-carboline) is a synthetic beta-carboline derivative that has attracted significant attention in the nootropic community for its apparent ability to promote dopaminergic neuron growth, differentiation, and restoration. Unlike conventional dopaminergic drugs that manipulate existing neurotransmitter levels through reuptake inhibition or receptor agonism, 9-Me-BC appears to act at a more fundamental level by upregulating tyrosine hydroxylase expression, stimulating neurotrophic factors, and promoting the outgrowth of dopaminergic neurites. This neurorestorative profile has made it a subject of interest in Parkinson's disease research, where the degeneration of dopaminergic neurons in the substantia nigra is the core pathological feature. In the nootropic and performance-enhancement communities, 9-Me-BC has gained popularity as a tool for 'dopamine repair' -- the attempt to restore normal dopaminergic function after periods of stimulant abuse, chronic stress, or hormonal suppression (such as after SARM cycles). However, the compound carries a critical safety concern: 9-Me-BC is photosensitizing and potentially phototoxic, meaning that UV exposure during use can cause severe skin reactions and, more seriously, DNA damage in skin cells. All available research is limited to animal models and in-vitro cell culture studies, with no human clinical trials conducted to date.

**Mechanism:** 9-Me-BC exerts its effects through multiple convergent mechanisms centered on dopaminergic neuron support and restoration. Its primary documented action is the upregulation of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, which increases the endogenous capacity for dopamine production -- a mechanism it shares conceptually with bromantane, though through a distinct pharmacological pathway rooted in its beta-carboline structure. Beyond TH upregulation, 9-Me-BC has been shown in vitro to promote the differentiation and neurite outgrowth of dopaminergic neurons, suggesting genuine neurotrophic and neurorestorative properties rather than simple neurotransmitter modulation. The compound also demonstrates anti-inflammatory activity in microglial cells, reducing neuroinflammatory signaling that can damage dopaminergic neurons. Additionally, as a beta-carboline, 9-Me-BC possesses inherent monoamine oxidase (MAO) inhibitory activity, though the degree and selectivity of this inhibition at typical doses remains poorly characterized. This MAO activity is relevant both therapeutically (contributing to elevated monoamine levels) and from a safety perspective (creating potential interactions with serotonergic and other monoaminergic drugs). The photosensitizing properties of 9-Me-BC are intrinsic to the beta-carboline chromophore, which absorbs UV radiation and can generate reactive oxygen species that damage DNA and cellular structures in sun-exposed tissues.

**Key Benefits:**
- Upregulates tyrosine hydroxylase expression, enhancing endogenous dopamine synthesis capacity
- Promotes dopaminergic neuron differentiation and neurite outgrowth in preclinical models, suggesting genuine neurorestorative potential
- Anti-inflammatory effects on microglia may protect dopaminergic neurons from neuroinflammatory damage
- Potential application in restoring dopaminergic function after stimulant-induced downregulation or neurotoxic damage
- Low effective dose (milligram range) compared to many other nootropic compounds


---

### Anadrol

URL: https://peptide-db.com/compounds/anadrol

Anadrol (oxymetholone) is one of the most potent oral anabolic steroids ever developed, originally synthesized in the 1960s by Syntex Pharmaceuticals. It was FDA-approved for the treatment of anemias caused by deficient red blood cell production, including aplastic anemia, myelofibrosis, and anemia associated with chronic kidney disease. Anadrol is a DHT-derived compound with a 17-alpha alkylated structure that allows oral bioavailability at the cost of significant hepatic strain. In performance enhancement contexts, it is regarded as the single most powerful oral steroid for rapid mass and strength gains, capable of producing dramatic weight increases of 10-15+ pounds in the first few weeks of use. Despite being a DHT derivative that does not aromatize via the aromatase enzyme, Anadrol produces notable estrogenic side effects including water retention and gynecomastia through a poorly understood mechanism believed to involve direct activation of estrogen receptors. This makes estrogen management uniquely challenging compared to other anabolic steroids.

**Mechanism:** Oxymetholone exerts its effects primarily through binding to the androgen receptor (AR) to promote protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme. However, oxymetholone and its metabolites are believed to directly activate the estrogen receptor, producing estrogenic effects such as water retention and gynecomastia without the involvement of aromatase. This is a critical clinical distinction because aromatase inhibitors (such as anastrozole or letrozole) are ineffective at controlling Anadrol-related estrogenic side effects. The compound also stimulates erythropoietin (EPO) production, significantly increasing red blood cell mass, which is the basis for its FDA-approved indication in anemias. Additionally, oxymetholone inhibits sex hormone-binding globulin (SHBG), increasing the proportion of free testosterone and other anabolic hormones in circulation.

**Key Benefits:**
- Rapid and dramatic increases in muscle mass and bodyweight
- Exceptional strength gains, often noticeable within the first week
- Potent stimulation of erythropoietin and red blood cell production
- Increased appetite and nutrient partitioning in some users
- Improved recovery between training sessions
- Full, round muscle appearance due to intramuscular water and glycogen retention
- FDA-approved treatment for various forms of anemia


---

### Anastrozole

URL: https://peptide-db.com/compounds/anastrozole

Anastrozole is a potent, selective, nonsteroidal aromatase inhibitor that blocks the enzyme aromatase (CYP19A1), preventing the conversion of androgens (testosterone and androstenedione) into estrogens (estradiol and estrone). It is FDA-approved under the brand name Arimidex for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In the bodybuilding and hormone optimization community, anastrozole is widely used as an ancillary compound during testosterone or anabolic steroid cycles to manage estrogen-related side effects such as gynecomastia, water retention, and elevated blood pressure. Unlike SERMs, which block estrogen at the receptor, anastrozole reduces circulating estrogen levels directly by inhibiting its synthesis. This distinction is clinically important: while effective at preventing estrogenic side effects, anastrozole carries the risk of suppressing estrogen too aggressively, which can impair joint health, bone density, cardiovascular markers, and mood. A common starting-point rule of thumb: weekly testosterone dose (mg) divided by 500 equals mg of anastrozole per week. For example, 500 mg of testosterone per week would correspond to roughly 1 mg of anastrozole per week, split across injection days. This is only a rough guideline -- individual aromatization rates vary widely, and dosing should always be refined based on bloodwork.

**Mechanism:** Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain. By blocking this conversion, anastrozole reduces circulating estradiol concentrations by approximately 70-80% at the standard 1mg daily dose. In men using exogenous testosterone, aromatase activity is upregulated due to elevated substrate availability, leading to supraphysiological estradiol. Anastrozole counteracts this by limiting estrogen synthesis at the enzymatic level. The inhibition is reversible, meaning estrogen production resumes once the drug is cleared, unlike exemestane which irreversibly inactivates aromatase. Because estrogen plays essential physiological roles in men -- including bone metabolism, lipid homeostasis, neurocognition, and joint lubrication -- the goal of anastrozole use is modulation rather than elimination.

**Key Benefits:**
- Potent reduction of circulating estradiol levels (70-80% at standard dose)
- Prevents gynecomastia during testosterone or anabolic steroid cycles
- Reduces estrogen-driven water retention and bloating
- Helps control estrogen-related blood pressure elevation
- Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
- Reversible inhibition allows estrogen recovery after discontinuation
- Well-characterized pharmacokinetics with decades of clinical data


---

### Berberine

URL: https://peptide-db.com/compounds/berberine

Berberine is a naturally occurring isoquinoline alkaloid found in several plants including goldenseal (Hydrastis canadensis), barberry (Berberis vulgaris), Oregon grape (Mahonia aquifolium), and Chinese goldthread (Coptis chinensis). It has been used in traditional Chinese and Ayurvedic medicine for centuries, primarily for gastrointestinal infections and inflammatory conditions. In recent years, berberine has gained substantial popularity in the biohacking and metabolic health communities due to a growing body of clinical evidence demonstrating effects on blood glucose regulation, lipid metabolism, and insulin sensitivity that rival some pharmaceutical interventions. Often referred to as "nature's metformin," berberine activates AMP-activated protein kinase (AMPK) through a mechanism similar to metformin, though via a distinct molecular pathway. Its accessibility as an over-the-counter supplement, combined with meaningful clinical data, has made it one of the most widely discussed natural compounds for metabolic optimization. Berberine is particularly popular among individuals using growth hormone secretagogues like MK-677 or exogenous HGH, where blood glucose management becomes an important consideration.

**Mechanism:** Berberine's primary mechanism of action involves activation of AMP-activated protein kinase (AMPK), the cell's master energy-sensing enzyme. Unlike metformin, which activates AMPK primarily through inhibition of mitochondrial Complex I, berberine appears to activate AMPK through multiple pathways, including direct inhibition of mitochondrial Complex I, stimulation of AMPK phosphorylation, and modulation of the AMP-to-ATP ratio. Downstream AMPK activation leads to enhanced glucose uptake in skeletal muscle via GLUT4 transporter translocation, suppression of hepatic gluconeogenesis, increased fatty acid oxidation, and inhibition of cholesterol and triglyceride synthesis. Berberine also upregulates insulin receptor expression, improving cellular insulin sensitivity at the receptor level. In the gut, berberine modulates the intestinal microbiome by promoting the growth of short-chain fatty acid-producing bacteria, which may contribute to its metabolic benefits. Additionally, berberine inhibits PCSK9 expression, which upregulates LDL receptor expression on hepatocytes and enhances LDL cholesterol clearance from the bloodstream. It also exerts anti-inflammatory effects through inhibition of the NF-kB signaling pathway and suppresses hepatic lipogenesis via downregulation of SREBP-1c and fatty acid synthase.

**Key Benefits:**
- Activation of AMPK, improving cellular energy metabolism and glucose utilization
- Clinically demonstrated reductions in fasting blood glucose and HbA1c comparable to metformin in some trials
- Improved lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides
- Enhanced insulin sensitivity through upregulation of insulin receptor expression
- PCSK9 inhibition leading to improved LDL cholesterol clearance
- Gut microbiome modulation favoring beneficial short-chain fatty acid-producing bacteria
- Anti-inflammatory effects via NF-kB pathway suppression
- Available over the counter as a dietary supplement without prescription


---

### Boldenone

URL: https://peptide-db.com/compounds/boldenone

Boldenone is a synthetic anabolic-androgenic steroid derived from testosterone by the introduction of a 1,2-double bond (dehydrogenation at the C1-C2 position). It was originally developed in the 1960s as a long-acting injectable veterinary steroid under the trade name Equipoise for use in horses. Boldenone has never been approved by the FDA for human medical use, and no pharmaceutical-grade human formulation has been marketed. Despite its veterinary origins, boldenone has become one of the more widely used anabolic steroids in bodybuilding and strength sports, valued for producing lean, quality muscle gains with less water retention than testosterone, enhanced vascularity, increased appetite, and a notable boost in red blood cell production and endurance capacity. Its anabolic rating is approximately 100 (equal to testosterone), while its androgenic rating is roughly 50 (half that of testosterone), giving it a favorable anabolic-to-androgenic ratio. Boldenone aromatizes to estradiol at approximately 50% the rate of testosterone, and the compound itself has been reported to possess mild aromatase inhibitor-like properties through its metabolite 1,4-dienedione. The undecylenate ester produces a very long-acting compound with a half-life of approximately 14 days, meaning effects build slowly and the compound has a prolonged detection window of roughly 5 months in anti-doping tests.

**Mechanism:** Boldenone exerts its anabolic effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and increased IGF-1 output in muscle tissue. The 1,2-double bond modification reduces the compound's affinity for 5-alpha reductase, meaning boldenone is not efficiently converted to a more potent dihydro-metabolite in the way testosterone is converted to DHT. Instead, boldenone is reduced by 5-alpha reductase to dihydroboldenone (1-testosterone), a distinct metabolite with its own androgenic profile. This structural difference contributes to boldenone's lower androgenic activity in skin, prostate, and hair follicle tissues compared to testosterone. Boldenone is a potent stimulator of erythropoietin (EPO) production in the kidneys, increasing red blood cell mass and oxygen-carrying capacity to a degree that exceeds most other anabolic steroids at comparable doses. This erythropoietic effect is the primary mechanism behind the increased vascularity and endurance commonly reported by users, but it also represents the compound's most significant health risk, as unchecked hematocrit elevation can increase blood viscosity and cardiovascular event risk. Boldenone aromatizes to estradiol at roughly half the rate of testosterone, and its metabolite 1,4-dienedione acts as a mild aromatase inhibitor, which collectively result in lower estrogenic activity than equidose testosterone. This reduced aromatization contributes to the drier, leaner aesthetic associated with boldenone use. An important practical consideration: approximately 50% of users experience noticeable downward estrogen pressure from boldenone, requiring either reduced AI dosing or an increased testosterone-to-boldenone ratio to avoid low-estrogen symptoms (joint pain, flat mood, low libido). The other 50% do not experience this effect to a significant degree. Because of this individual variability, it is recommended to start with a 2:1 testosterone-to-EQ ratio and adjust based on bloodwork and symptom assessment rather than assuming a fixed AI or testosterone dose will be appropriate.

**Key Benefits:**
- Lean, quality muscle gains with minimal water retention compared to testosterone
- Enhanced vascularity through increased red blood cell production and reduced subcutaneous water
- Significant increase in appetite, supporting caloric surplus during mass-gaining phases
- Potent stimulation of erythropoiesis, increasing oxygen-carrying capacity and endurance
- Lower estrogenic activity than testosterone, reducing the need for aromatase inhibitors
- Lower androgenic side effects (hair loss, acne, prostate stimulation) than testosterone
- Favorable anabolic-to-androgenic ratio (100:50 compared to testosterone at 100:100)
- Improved collagen synthesis reported anecdotally, supporting joint and connective tissue health


---

### Bromantane

URL: https://peptide-db.com/compounds/bromantane

Bromantane (Ladasten) is a synthetic adamantane derivative developed in Russia during the 1980s as part of a military research program aimed at improving soldiers' physical and mental performance under extreme conditions. It was officially registered in Russia in 2002 as an anxiolytic and actoprotector -- a pharmacological class defined by the ability to enhance physical work capacity and mental performance under stressful conditions without the hyperactivation or crash associated with traditional stimulants. Unlike amphetamines, methylphenidate, or modafinil, bromantane does not directly block reuptake or trigger release of monoamines. Instead, it upregulates the gene expression of key enzymes in the dopamine biosynthetic pathway, producing a sustained, physiological increase in dopamine availability. This mechanism gives it a uniquely smooth, non-depleting profile that has made it increasingly popular in the international nootropic community for sustained cognitive energy, motivation, and stress resilience.

**Mechanism:** Bromantane's mechanism of action is fundamentally different from conventional stimulants and most nootropic compounds. Its primary action is the upregulation of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) gene expression in the striatum and other dopaminergic brain regions. Tyrosine hydroxylase is the rate-limiting enzyme in dopamine synthesis, converting L-tyrosine to L-DOPA, while AADC converts L-DOPA to dopamine. By increasing the transcription of these enzymes, bromantane enhances the brain's endogenous capacity to produce dopamine rather than forcing release of existing stores or blocking their reuptake. This results in a gradual, sustained elevation of dopaminergic tone without the rapid depletion, tolerance, or rebound effects characteristic of releasers or reuptake inhibitors. Additionally, bromantane has documented anxiolytic properties, likely mediated through GABAergic facilitation and modulation of hippocampal activity, which contribute to its stress-protective and actoprotective effects. The compound also demonstrates mild serotonergic activity, which may further support its anxiolytic profile. This dual action -- enhanced dopaminergic drive combined with anxiolysis -- is what distinguishes bromantane from virtually all other cognitive enhancers and gives it the 'calm energy' quality users frequently describe.

**Key Benefits:**
- Upregulates endogenous dopamine synthesis via tyrosine hydroxylase gene expression, producing sustained motivational drive without depletion
- Anxiolytic properties reduce stress and anxiety without sedation, creating a state of calm, focused energy
- Actoprotective effects improve both physical and mental performance under stressful or fatiguing conditions
- Very low abuse and dependence potential due to the absence of acute monoamine release or reuptake inhibition
- Minimal tolerance development compared to traditional stimulants, supporting longer-term use patterns
- Smooth onset and offset with no crash or rebound effects


---

### Cabergoline

URL: https://peptide-db.com/compounds/cabergoline

Cabergoline is a potent, long-acting dopamine D2 receptor agonist that powerfully suppresses prolactin secretion from the anterior pituitary. It is FDA-approved under the brand name Dostinex for the treatment of hyperprolactinemic disorders, including prolactin-secreting pituitary adenomas (prolactinomas). In the bodybuilding and performance enhancement community, cabergoline is considered an essential ancillary compound when running 19-nor anabolic steroids such as nandrolone (Deca-Durabolin, NPP) and trenbolone, both of which can elevate prolactin levels through progestogenic activity. Elevated prolactin causes a range of undesirable effects including gynecomastia (particularly the progesterone-mediated variant), sexual dysfunction (erectile dysfunction, decreased libido, anorgasmia), mood disturbances, and lactation. Cabergoline's exceptionally long half-life of 63-69 hours allows for convenient twice-weekly dosing, and its high affinity for D2 receptors makes it significantly more potent and better tolerated than the older dopamine agonist bromocriptine.

**Mechanism:** Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypothalamic dopamine acting on these D2 receptors, and cabergoline mimics this inhibitory signal with high affinity and prolonged duration. By activating D2 receptors, cabergoline suppresses prolactin gene transcription, reduces prolactin synthesis, and inhibits prolactin release into the bloodstream. In patients with prolactinomas, cabergoline also induces tumor shrinkage by inhibiting lactotroph cell proliferation and promoting apoptosis. The drug's selectivity for D2 receptors over D1 receptors contributes to its favorable side effect profile compared to less selective dopamine agonists. In the context of 19-nor steroid use, nandrolone and trenbolone stimulate prolactin release through their progestogenic activity, and cabergoline directly counteracts this elevation by restoring dopaminergic inhibition at the pituitary level.

**Key Benefits:**
- Potent suppression of prolactin levels, often normalizing them within days
- Prevents and reverses prolactin-related gynecomastia from 19-nor compounds
- Restores sexual function impaired by hyperprolactinemia (libido, erectile function, orgasm)
- Long half-life (63-69 hours) allows convenient twice-weekly dosing
- Significantly better tolerated than bromocriptine with fewer gastrointestinal side effects
- Effective at shrinking prolactin-secreting pituitary tumors
- Low doses required for bodybuilding prolactin management (0.25-0.5mg twice weekly)


---

### Cardarine

URL: https://peptide-db.com/compounds/cardarine

Cardarine (GW501516) is a synthetic PPAR-delta (peroxisome proliferator-activated receptor delta) agonist originally developed by GlaxoSmithKline and Ligand Pharmaceuticals in the early 2000s for the treatment of metabolic and cardiovascular diseases, including dyslipidemia, obesity, and diabetes. Despite being almost universally categorized alongside SARMs in the performance enhancement market, Cardarine is not a selective androgen receptor modulator and does not bind to the androgen receptor at all. Its mechanism is entirely distinct: it activates PPAR-delta, a nuclear receptor that regulates fatty acid oxidation, energy expenditure, and lipid metabolism. In preclinical studies, Cardarine demonstrated remarkable effects on endurance capacity, fat oxidation, and lipid profiles. However, development was abandoned by GSK in 2007 after preclinical toxicology studies in rodents revealed an increased incidence of tumors across multiple organ systems when the compound was administered at supratherapeutic doses over extended periods. This cancer signal remains the central controversy and safety concern surrounding Cardarine. The compound has never been approved for human use by any regulatory agency, and no clinical trials have been completed. It is classified as a prohibited substance by the World Anti-Doping Agency (WADA). Despite these concerns, Cardarine continues to be widely available through research chemical suppliers and is used in performance enhancement contexts for its potent endurance-boosting and fat-burning properties.

**Mechanism:** Cardarine acts as a potent and highly selective agonist of PPAR-delta, a nuclear hormone receptor expressed in skeletal muscle, liver, adipose tissue, and the gastrointestinal tract. Upon binding to PPAR-delta, Cardarine triggers a conformational change that promotes heterodimerization with retinoid X receptor (RXR), and the resulting complex binds to PPAR response elements (PPREs) in the promoter regions of target genes. This transcriptional activation upregulates a suite of genes involved in fatty acid oxidation, mitochondrial biogenesis, and energy uncoupling. In skeletal muscle, PPAR-delta activation by Cardarine shifts the metabolic fuel preference from glucose toward fatty acids, dramatically increasing the rate of beta-oxidation. This metabolic reprogramming effectively transforms type II (fast-twitch, glycolytic) muscle fibers toward a more oxidative phenotype, similar to type I (slow-twitch) fibers, which underpins the compound's dramatic effects on endurance capacity. Preclinical studies in mice demonstrated that GW501516 treatment increased running endurance by up to 68% compared to controls. In the liver and adipose tissue, PPAR-delta activation by Cardarine promotes fatty acid catabolism and reduces lipogenesis, resulting in reduced body fat storage and improved lipid profiles (increased HDL, decreased LDL, reduced triglycerides). Critically, Cardarine does not interact with the androgen receptor, does not suppress the hypothalamic-pituitary-gonadal (HPG) axis, and does not affect endogenous testosterone production. This non-hormonal mechanism means it does not cause testosterone suppression and does not require post-cycle therapy.

**Key Benefits:**
- Dramatic increase in endurance capacity through enhanced fatty acid oxidation in skeletal muscle
- Promotes fat loss by shifting metabolic fuel preference toward fatty acid utilization over glucose
- Improves lipid profiles: increases HDL cholesterol, decreases LDL cholesterol, and lowers triglycerides
- Non-hormonal mechanism -- does not suppress testosterone or require post-cycle therapy
- No androgenic side effects (no hair loss, no prostate stimulation, no virilization in women)
- Long half-life (16-24 hours) permits convenient once-daily oral dosing
- May offset lipid disruption caused by SARMs or anabolic steroids when used in combination


---

### Clascoterone

URL: https://peptide-db.com/compounds/clascoterone

Clascoterone (cortexolone 17-alpha-propionate) is a first-in-class topical androgen receptor inhibitor developed by Cassiopea SpA. In August 2020, the FDA approved Winlevi (clascoterone cream 1%) for the treatment of acne vulgaris in patients aged 12 and older, making it the first new mechanism of action for acne treatment in nearly four decades and the first topical anti-androgen approved for acne in the United States. Clascoterone is also under development as Breezula (clascoterone solution 7.5%) for androgenetic alopecia, where it has completed Phase 3 clinical trials. The compound works by competitively inhibiting androgen receptor activation at the site of application -- the sebaceous gland for acne and the hair follicle for androgenetic alopecia -- without producing the systemic anti-androgenic effects associated with oral anti-androgens such as spironolactone or cyproterone acetate. Its steroidal structure allows it to fit precisely into the androgen receptor binding pocket, and its rapid local metabolism to cortexolone (an inactive metabolite) limits systemic exposure. This pharmacological profile makes clascoterone suitable for use in both men and women, unlike systemic anti-androgens which carry risks of feminization in male patients.

**Mechanism:** Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target tissues -- sebaceous glands (for acne) and dermal papilla cells of hair follicles (for alopecia). By occupying the AR binding site, clascoterone prevents dihydrotestosterone (DHT) and testosterone from activating the receptor and initiating the downstream signaling cascade that drives sebum overproduction and hair follicle miniaturization. Structurally, clascoterone is a synthetic derivative of cortexolone (11-deoxycortisol), modified with a 17-alpha-propionate ester. This structural design serves two purposes: the steroidal backbone provides high binding affinity for the androgen receptor, while the ester group is rapidly cleaved by local esterases in the skin, converting clascoterone to cortexolone, which has negligible androgen receptor binding. This built-in metabolic inactivation ensures that any compound reaching systemic circulation is pharmacologically inactive, confining the anti-androgenic effect to the treatment site. In clinical studies, clascoterone showed no meaningful impact on systemic hormone levels including testosterone, DHT, luteinizing hormone, or follicle-stimulating hormone at therapeutic doses, confirming its local mechanism of action.

**Key Benefits:**
- First-in-class topical androgen receptor inhibitor with FDA approval for acne
- Blocks androgen action locally at the sebaceous gland and hair follicle without systemic hormonal effects
- Suitable for both men and women, unlike systemic anti-androgens
- Rapidly metabolized to inactive cortexolone, limiting systemic exposure
- No clinically meaningful effects on systemic testosterone, DHT, or gonadotropin levels
- Addresses the root androgen-driven pathology of both acne and androgenetic alopecia


---

### Clenbuterol

URL: https://peptide-db.com/compounds/clenbuterol

Clenbuterol is a potent, long-acting beta-2 adrenergic receptor agonist originally developed for the treatment of asthma and other respiratory conditions. It is approved as a bronchodilator in many countries throughout Europe, Latin America, and Asia, but has never been approved for human use in the United States, where it is only approved for veterinary use in horses (Ventipulmin). In the context of bodybuilding and physique sports, clenbuterol is widely used as a thermogenic agent during cutting phases to accelerate fat loss while preserving lean muscle mass. Its stimulatory effects on the sympathetic nervous system increase basal metabolic rate, core body temperature, and lipolysis. Unlike anabolic steroids, clenbuterol does not directly promote muscle growth in humans at typical doses, though animal studies have demonstrated significant anabolic effects in livestock, which led to its controversial use in meat production in some countries.

**Mechanism:** Clenbuterol selectively binds to beta-2 adrenergic receptors on cell surfaces, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL) in adipose tissue, directly stimulating lipolysis and the release of free fatty acids for oxidation. In smooth muscle tissue, beta-2 activation causes relaxation of bronchial airways, which accounts for its therapeutic use in asthma. Clenbuterol also stimulates mitochondrial uncoupling and increases thermogenesis, raising basal metabolic rate by an estimated 5-10%. Additionally, clenbuterol has mild anti-catabolic properties in humans, potentially reducing muscle protein breakdown during caloric restriction through beta-2 receptor-mediated inhibition of the ubiquitin-proteasome pathway. A significant limitation is the downregulation of beta-2 receptors with continuous use, typically occurring within 2-3 weeks, which diminishes the thermogenic effect and necessitates cycling protocols or co-administration of ketotifen (an antihistamine that upregulates beta receptors).

**Key Benefits:**
- Increased basal metabolic rate and thermogenesis for accelerated fat loss
- Preferential mobilization of stored body fat through enhanced lipolysis
- Anti-catabolic effects that help preserve lean muscle mass during caloric restriction
- Bronchodilation and improved respiratory capacity during intense exercise
- Appetite suppression in many users, supporting adherence to caloric deficit
- Oral administration with no injections required


---

### Dapoxetine

URL: https://peptide-db.com/compounds/dapoxetine

Dapoxetine is the first and only selective serotonin reuptake inhibitor (SSRI) specifically developed and approved for the on-demand treatment of premature ejaculation (PE) in men aged 18-64. Unlike conventional SSRIs such as paroxetine or sertraline -- which are sometimes used off-label for PE but require daily dosing and weeks to reach therapeutic effect -- dapoxetine was engineered for rapid absorption and short elimination, making it suitable for as-needed use 1-3 hours before sexual activity. Originally developed by Eli Lilly and later licensed to Johnson & Johnson (ALZA Corporation), dapoxetine received its first regulatory approval in Sweden in 2009 under the brand name Priligy, and has since been approved in over 50 countries across Europe, Asia, Latin America, and the Middle East. It has not received FDA approval in the United States despite multiple submissions. Dapoxetine works by increasing serotonin activity at the postsynaptic cleft in the ejaculatory reflex pathway, raising the threshold for ejaculation and improving control over the timing of climax.

**Mechanism:** Dapoxetine selectively inhibits the serotonin transporter (SERT) at presynaptic nerve terminals, blocking reuptake of serotonin (5-HT) from the synaptic cleft. This increases serotonin concentration at postsynaptic receptors in the neural circuits governing the ejaculatory reflex, particularly within the spinal ejaculation generator and supraspinal pathways. The ejaculatory process is modulated by serotonergic neurotransmission: higher serotonin levels at 5-HT1B and 5-HT2C receptors raise the ejaculatory threshold, delaying the emission and expulsion phases of ejaculation. Unlike traditional SSRIs that require 1-2 weeks of daily dosing to achieve steady-state serotonin levels, dapoxetine reaches peak plasma concentration within approximately 1-2 hours after oral administration and is rapidly eliminated (terminal half-life ~1.5 hours, with an initial half-life of ~1.4 hours). This pharmacokinetic profile enables acute, on-demand modulation of serotonergic tone without the sustained receptor desensitization seen with chronic SSRI use.

**Key Benefits:**
- Only SSRI specifically developed for on-demand premature ejaculation treatment
- Rapid onset of action (1-2 hours) allows as-needed dosing before sexual activity
- Ultra-short half-life (~1.5 hours) minimizes sustained serotonergic side effects
- Clinically proven to increase intravaginal ejaculatory latency time (IELT) by 2-3 fold
- Improves perceived control over ejaculation and reduces PE-related distress
- Does not require daily dosing or washout periods
- Well-studied safety profile across multiple international clinical trials
- Approved in over 50 countries for on-demand PE treatment


---

### DHB

URL: https://peptide-db.com/compounds/dhb

Dihydroboldenone (DHB), also known as 1-testosterone, is the 5-alpha reduced metabolite of boldenone. While boldenone itself is converted to DHB in the body via 5-alpha reductase, standalone DHB is used as an injectable anabolic steroid in its own right, most commonly as the cypionate ester. DHB occupies an unusual niche in the anabolic steroid landscape: it possesses a high anabolic rating (approximately 200, double that of testosterone) with a moderate androgenic rating (approximately 100, equal to testosterone), producing lean, dry gains with no estrogenic activity. These properties have led to frequent comparisons with Primobolan (methenolone), as both compounds promote quality lean tissue gains without water retention or estrogen-related side effects. However, DHB is generally considered more potent milligram-for-milligram than Primobolan and is significantly cheaper, making it an attractive alternative for users seeking similar aesthetic results at lower cost. The compound has never been approved by the FDA for any medical indication, and all available DHB products are manufactured by underground laboratories. DHB's most notable drawback is severe post-injection pain (PIP), which is widely reported even at moderate concentrations and can be debilitating enough to limit practical use. This PIP is attributed to the compound's high melting point and crystalline nature, which causes it to precipitate out of solution in muscle tissue after injection, triggering a localized inflammatory response.

**Mechanism:** DHB exerts its anabolic effects through direct binding to the androgen receptor (AR) with high affinity. As a 5-alpha reduced steroid, DHB cannot be further reduced by 5-alpha reductase and is not a substrate for aromatase, meaning it does not convert to estradiol or any estrogenic metabolite. This absence of aromatization is a key pharmacological distinction from both testosterone and its parent compound boldenone. The result is a purely androgenic and anabolic signaling profile without estrogenic contribution to water retention, fat distribution, or gynecomastia risk. DHB promotes nitrogen retention, protein synthesis, and increased IGF-1 expression in skeletal muscle, driving lean tissue accretion. Because DHB does not aromatize, users running it as a secondary compound alongside a testosterone base typically find that their overall estrogen management is simplified, as DHB adds anabolic potency without adding to the estrogenic load. However, this also means that DHB provides none of the beneficial effects of estrogen on lipid profiles, bone density, neuroprotection, or libido, reinforcing the need for a testosterone base to maintain adequate estradiol levels. DHB is reported to have mild hepatotoxic potential, which is somewhat unusual for a non-17-alpha-alkylated injectable steroid and may relate to its metabolic pathway or the high concentrations of carrier solvents (such as guaiacol or ethyl oleate) used in UGL formulations to keep the compound in solution.

**Key Benefits:**
- High anabolic potency (approximately 200:100 anabolic-to-androgenic ratio) promoting lean, quality muscle gains
- No aromatization to estrogen, eliminating water retention, bloating, and gynecomastia risk from the compound itself
- Produces dry, lean aesthetic gains comparable to Primobolan at a fraction of the cost
- Does not convert to DHT or other more androgenic metabolites via 5-alpha reductase, as it is already 5-alpha reduced
- Can be stacked with testosterone without significantly complicating estrogen management
- Moderate androgenic activity supports strength gains without excessive androgenic side effects in most users


---

### Dianabol

URL: https://peptide-db.com/compounds/dianabol

Dianabol (methandrostenolone) is the original oral anabolic steroid, developed in the late 1950s by Dr. John Ziegler in collaboration with Ciba Pharmaceuticals for the US Olympic team. It was briefly FDA-approved for medical use but was discontinued from the US market in the 1980s due to abuse potential and side effect concerns. Despite its removal from pharmaceutical production, Dianabol remains one of the most widely used performance-enhancing compounds in the world due to its rapid and dramatic effects on muscle mass and strength. It is a 17-alpha-alkylated derivative of testosterone with an added C1-C2 double bond, which shifts its profile toward more anabolic and less androgenic activity compared to testosterone. Dianabol aromatizes heavily to methylestradiol, causing significant water retention and estrogenic side effects. Its short half-life of 4-6 hours necessitates split dosing throughout the day for stable blood levels. It is most commonly used as a 4-6 week kickstart to injectable cycles, providing rapid size and strength gains while longer-acting compounds like testosterone enanthate or cypionate reach steady-state levels.

**Mechanism:** Dianabol exerts its effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle tissue. Its 17-alpha-alkylated structure allows it to survive first-pass hepatic metabolism, enabling oral bioavailability but placing significant stress on the liver. Dianabol has a notably high anabolic-to-androgenic ratio compared to testosterone, meaning it preferentially drives muscle-building pathways over androgenic effects such as body hair growth and prostate stimulation. It also strongly promotes intramuscular water and glycogen storage, which contributes to the rapid weight gains and fullness characteristic of its use. Dianabol aromatizes readily via the aromatase enzyme, converting to methylestradiol (a potent estrogen), which drives much of the water retention, blood pressure elevation, and gynecomastia risk associated with the compound. This heavy aromatization typically necessitates concurrent use of an aromatase inhibitor at moderate to high doses.

**Key Benefits:**
- Rapid and dramatic increases in muscle mass and bodyweight
- Significant strength gains within the first 1-2 weeks
- Enhanced nitrogen retention and protein synthesis
- Improved glycogenolysis and muscular endurance
- Pronounced muscle fullness and pumps from increased intracellular water and glycogen
- Effective oral kickstart while waiting for injectable compounds to saturate
- One of the fastest-acting anabolic compounds available


---

### Doxepin

URL: https://peptide-db.com/compounds/doxepin

Doxepin is a tricyclic compound with a remarkably dose-dependent pharmacological profile. At higher doses (75-300 mg), it functions as a traditional tricyclic antidepressant (TCA) with activity across multiple neurotransmitter systems. However, at ultra-low doses (3-6 mg), doxepin acts almost exclusively as a highly selective histamine H1 receptor antagonist, making it one of the most targeted sleep maintenance agents available. This ultra-low dose formulation was approved by the FDA in 2010 under the brand name Silenor specifically for the treatment of insomnia characterized by difficulty with sleep maintenance. The distinction between high-dose and ultra-low dose doxepin is critical: at 3-6 mg, the drug avoids the anticholinergic, noradrenergic, and serotonergic side effects that characterize tricyclic antidepressants, resulting in a remarkably clean side effect profile. For biohackers and those seeking a non-habit-forming sleep aid, ultra-low dose doxepin offers a compelling option -- it does not produce dependence, does not cause rebound insomnia upon discontinuation, and maintains efficacy with long-term use. Unlike benzodiazepines and Z-drugs, it carries no abuse potential and is not a scheduled substance.

**Mechanism:** At ultra-low doses (3-6 mg), doxepin's mechanism of action is dominated by potent and selective antagonism of the histamine H1 receptor. Doxepin has one of the highest affinities for the H1 receptor of any known compound (Ki approximately 0.17 nM), which means that even at very low plasma concentrations, it effectively blocks histaminergic wakefulness signaling. The histamine system is a key component of the ascending arousal pathway -- histaminergic neurons in the tuberomammillary nucleus of the hypothalamus fire during wakefulness and become quiescent during sleep. By blocking H1 receptors, ultra-low dose doxepin reduces this wake-promoting signal, particularly during the latter half of the night when endogenous histamine levels naturally begin to rise, which is why it is especially effective for sleep maintenance insomnia. At these low doses, doxepin has negligible affinity for muscarinic, adrenergic, and serotonergic receptors, which explains the absence of anticholinergic side effects (dry mouth, constipation, urinary retention) and cardiovascular effects that plague higher-dose TCA use. At antidepressant doses (75-300 mg), doxepin additionally inhibits reuptake of serotonin and norepinephrine and blocks muscarinic, alpha-1 adrenergic, and 5-HT2 receptors, producing a much broader and less selective pharmacological profile.

**Key Benefits:**
- FDA-approved specifically for sleep maintenance insomnia at ultra-low doses (3-6 mg as Silenor)
- Highly selective H1 antihistamine at low doses, avoiding the side effects of traditional tricyclic antidepressants
- Non-habit-forming with no dependence, tolerance, or abuse potential
- No rebound insomnia upon discontinuation, unlike benzodiazepines and Z-drugs
- Particularly effective for maintaining sleep in the latter half of the night, when many other sleep aids have worn off
- Extremely well-tolerated side effect profile at ultra-low doses


---

### Dutasteride

URL: https://peptide-db.com/compounds/dutasteride

Dutasteride is a potent dual 5-alpha reductase inhibitor that blocks both Type I and Type II isoforms of the enzyme responsible for converting testosterone to dihydrotestosterone (DHT). FDA-approved at 0.5mg daily for benign prostatic hyperplasia (BPH) under the brand name Avodart, it is widely used off-label for the treatment of androgenetic alopecia (male pattern hair loss). By inhibiting both isoforms, dutasteride achieves approximately 90% suppression of serum DHT, compared to roughly 70% with finasteride, which blocks only the Type II isoform. This greater DHT suppression translates to potentially superior hair regrowth outcomes in head-to-head comparisons, though it also carries a somewhat higher risk of DHT-related side effects. Dutasteride has an exceptionally long half-life of approximately 5 weeks, meaning it takes several months to reach steady-state levels and equally long for effects to fully wash out after discontinuation.

**Mechanism:** Dutasteride competitively inhibits both the Type I and Type II isoforms of the enzyme 5-alpha reductase. Type II is the predominant isoform in the prostate and hair follicles, while Type I is found primarily in the skin, sebaceous glands, and liver. By blocking both isoforms, dutasteride suppresses serum DHT levels by approximately 90% at the standard 0.5mg dose, compared to the roughly 70% suppression achieved by finasteride (which blocks only Type II). This near-complete DHT suppression more effectively reduces the androgenic stimulus driving follicular miniaturization in genetically susceptible individuals. The exceptionally long elimination half-life of approximately 5 weeks is due to extensive tissue binding and slow clearance. Serum testosterone may increase modestly (10-20%) as a compensatory response to the pronounced reduction in DHT, though this increase remains within the normal physiological range for most men.

**Key Benefits:**
- Inhibits both Type I and Type II 5-alpha reductase for more complete DHT suppression
- Reduces serum DHT by approximately 90%, compared to 70% with finasteride
- Head-to-head trials show superior hair count improvements over finasteride at 12 and 24 weeks
- FDA-approved for BPH with well-established long-term safety data
- Extremely long half-life allows for flexible dosing schedules (daily or 3x per week)
- Convenient once-daily oral dosing with no injections required
- Can be combined with minoxidil for enhanced hair loss treatment


---

### Ecdysterone

URL: https://peptide-db.com/compounds/ecdysterone

Ecdysterone (20-Hydroxyecdysone) is a naturally occurring phytoecdysteroid -- a class of steroid hormones that regulate molting and metamorphosis in insects and crustaceans. Despite its name and steroidal structure, ecdysterone does not interact with the androgen receptor and operates through an entirely different mechanism than anabolic-androgenic steroids. It is found in meaningful concentrations in common foods such as spinach (Spinacia oleracea), quinoa (Chenopodium quinoa), and various other plants. Ecdysterone gained significant attention in the strength and performance community following a 2019 study from Freie Universitat Berlin, which demonstrated that trained individuals supplementing with ecdysterone experienced significantly greater muscle mass gains compared to placebo over a 10-week resistance training program. The effect sizes were large enough that the study authors themselves recommended the World Anti-Doping Agency (WADA) consider adding ecdysterone to the prohibited substances list. Unlike traditional anabolic agents, ecdysterone does not cause hormonal suppression, does not require post-cycle therapy, and carries an exceptionally mild side effect profile. Its mechanism appears to involve signaling through estrogen receptor beta (ERbeta), which activates anabolic pathways in skeletal muscle without the androgenic, estrogenic, or hepatotoxic effects associated with traditional performance-enhancing compounds. An injectable form has gained popularity among advanced users seeking higher bioavailability, as oral ecdysterone suffers from significant first-pass metabolism.

**Mechanism:** Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling. ERbeta is expressed in skeletal muscle tissue, and its activation triggers downstream anabolic signaling cascades including the PI3K/Akt pathway, which promotes muscle protein synthesis and inhibits protein degradation. This pathway converges on mTOR (mechanistic target of rapamycin), a master regulator of muscle hypertrophy, leading to increased translation of muscle-specific proteins. Importantly, ecdysterone does not activate estrogen receptor alpha (ERalpha), which is responsible for the feminizing effects of estrogens, nor does it bind to the androgen receptor, glucocorticoid receptor, or mineralocorticoid receptor. This selectivity explains why ecdysterone does not produce the hormonal side effects associated with anabolic steroids -- there is no testosterone suppression, no testicular atrophy, no gynecomastia, no liver toxicity, and no virilization in women. Additional proposed mechanisms include enhanced nitrogen retention in muscle tissue, improved calcium handling in muscle fibers leading to better contractile efficiency, and mild anti-inflammatory effects that may support recovery from exercise-induced muscle damage. Some in vitro studies also suggest ecdysterone may increase satellite cell proliferation, which could contribute to long-term muscle growth capacity.

**Key Benefits:**
- Activation of muscle protein synthesis through ERbeta/PI3K/Akt/mTOR signaling without androgen receptor binding
- Statistically significant increases in lean muscle mass demonstrated in a controlled human trial in trained subjects
- No hormonal suppression -- does not affect testosterone, LH, or FSH levels, eliminating the need for post-cycle therapy
- No androgenic side effects (no hair loss, acne, prostate issues, or virilization in women)
- No hepatotoxicity, unlike oral anabolic steroids that undergo 17-alpha alkylation
- Naturally occurring in common foods (spinach, quinoa), with a long history of safe dietary exposure
- Compatible with other performance compounds due to its non-hormonal mechanism
- Available as a dietary supplement without prescription in most jurisdictions


---

### Enclomiphene

URL: https://peptide-db.com/compounds/enclomiphene

Enclomiphene is the trans-isomer of clomifene citrate, a selective estrogen receptor modulator (SERM) that acts primarily as an estrogen antagonist at the hypothalamus and pituitary. Unlike the racemic mixture clomifene (Clomid), which contains both enclomiphene and the cis-isomer zuclomifene, enclomiphene lacks significant estrogenic agonist activity. This makes it better suited for raising endogenous testosterone through increased LH and FSH secretion without the estrogenic side effects commonly associated with clomifene. It was developed under the trade name Androxal for the treatment of secondary hypogonadism in men but has not yet received FDA approval as a standalone product.

**Mechanism:** Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Elevated LH drives Leydig cell testosterone synthesis in the testes, while FSH supports Sertoli cell function and spermatogenesis. Because enclomiphene lacks the estrogenic agonist properties of zuclomifene, it provides cleaner HPTA stimulation without paradoxical estrogenic effects on mood, vision, or other tissues.

**Key Benefits:**
- Raises endogenous testosterone by stimulating the HPTA axis
- Preserves fertility and spermatogenesis (unlike exogenous testosterone)
- No estrogenic agonist activity (unlike racemic clomifene/Clomid)
- Oral dosing with no injections required
- Does not suppress the HPTA or cause testicular atrophy
- Effective for post-cycle therapy and secondary hypogonadism
- Well-tolerated with a favorable side effect profile


---

### Exemestane

URL: https://peptide-db.com/compounds/exemestane

Exemestane is a steroidal, irreversible aromatase inhibitor (often called a suicide inhibitor) that permanently inactivates the aromatase enzyme (CYP19A1), preventing conversion of androgens into estrogens. It is FDA-approved under the brand name Aromasin for the treatment of hormone receptor-positive breast cancer in postmenopausal women, particularly after prior tamoxifen therapy. In bodybuilding and hormone optimization, exemestane is valued for two properties that distinguish it from nonsteroidal AIs like anastrozole: its irreversible binding mechanism means there is no estrogen rebound when the drug is discontinued, and its steroidal structure confers mild androgenic activity that may partially offset some of the joint and mood side effects associated with estrogen suppression. Because exemestane permanently destroys aromatase molecules rather than temporarily blocking them, estrogen levels recover only as the body synthesizes new enzyme -- a process that takes several days. A common rule of thumb from community dosing guidelines: weekly testosterone dose (mg) divided by 20 equals mg of exemestane per week. For example, 500 mg of testosterone per week corresponds to approximately 25 mg of exemestane per week. This is a rough starting point only -- individual aromatization rates vary widely, and dosing should always be guided by bloodwork.

**Mechanism:** Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site. Once bound, aromatase processes exemestane, generating an intermediate that covalently and irreversibly binds to the enzyme, permanently inactivating it. This is fundamentally different from competitive, reversible inhibitors like anastrozole and letrozole, which dissociate from the enzyme over time. The irreversible nature of exemestane's inhibition means that aromatase activity can only recover through de novo synthesis of new enzyme protein, which typically takes 2-3 days. At the standard 25mg daily dose, exemestane reduces circulating estradiol by approximately 85-95% in postmenopausal women. In men using exogenous testosterone, the degree of suppression varies with dose and individual aromatization rates. A clinically relevant advantage of this irreversible mechanism is the absence of estrogen rebound: when exemestane is discontinued, estrogen levels rise gradually as new aromatase is synthesized, rather than surging back as accumulated substrate is rapidly converted (a phenomenon that can occur when reversible AIs like anastrozole are abruptly stopped). Additionally, exemestane and its primary metabolite 17-hydroexemestane possess mild androgenic activity, binding weakly to the androgen receptor. This androgenic property may help preserve bone mineral density and joint comfort relative to nonsteroidal AIs, though the clinical significance in men on exogenous androgens is modest.

**Key Benefits:**
- Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
- Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
- Potent estrogen suppression (85-95% reduction in estradiol at full dose)
- Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
- Prevents gynecomastia during testosterone or aromatizable steroid cycles
- Reduces estrogen-driven water retention, bloating, and blood pressure elevation
- Oral dosing with once-daily or less frequent administration for cycle support


---

### Ezetimibe

URL: https://peptide-db.com/compounds/ezetimibe

Ezetimibe is a selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the brush border of the small intestine, preventing dietary and biliary cholesterol from entering the bloodstream. Approved by the FDA in 2002, it occupies a unique niche among lipid-lowering agents by targeting intestinal cholesterol uptake rather than hepatic cholesterol synthesis. In the context of anabolic steroid use, ezetimibe has become a go-to ancillary compound for managing the dyslipidemia that accompanies many AAS cycles, particularly oral steroids like oxandrolone (Anavar) and stanozolol (Winstrol) that are notorious for crashing HDL cholesterol and elevating LDL. While statins remain the first-line treatment for hypercholesterolemia in the general population, ezetimibe is frequently used alone or stacked with a statin by steroid users seeking to mitigate cycle-induced lipid damage without adding yet another hepatotoxic compound to the mix.

**Mechanism:** Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle. By blocking this transporter, ezetimibe reduces cholesterol delivery to the liver, which in turn upregulates hepatic LDL receptor expression to compensate for the reduced cholesterol supply. This upregulation increases LDL clearance from the bloodstream. The mechanism is entirely complementary to statins, which inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis. When the liver is deprived of cholesterol from both sources simultaneously, the LDL-lowering effect is significantly amplified. Ezetimibe undergoes glucuronidation in the intestinal wall and liver to form its active metabolite, ezetimibe-glucuronide, which is also pharmacologically active and participates in enterohepatic recirculation, contributing to the drug's prolonged duration of action.

**Key Benefits:**
- Reduces LDL cholesterol by 15-20% as monotherapy
- Complementary mechanism to statins allows additive LDL reduction of 25% when combined
- Minimal hepatotoxicity, making it suitable alongside hepatotoxic oral AAS
- Simple once-daily dosing with no titration required
- No significant impact on CoQ10 levels (unlike statins)
- Well tolerated with a side effect profile comparable to placebo in clinical trials
- Proven cardiovascular outcome benefit when added to statin therapy (IMPROVE-IT trial)
- Helps manage the severe lipid disruption caused by oral steroids like Anavar and Winstrol


---

### Finasteride

URL: https://peptide-db.com/compounds/finasteride

Finasteride is an FDA-approved 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgen responsible for androgenetic alopecia (male pattern hair loss) and benign prostatic hyperplasia (BPH). At 1mg daily, it reduces scalp DHT levels by approximately 66%, slowing or halting hair loss in roughly 90% of men and producing visible regrowth in about 48% over one to two years. Originally developed for prostate enlargement at 5mg (Proscar), the lower 1mg dose (Propecia) was approved specifically for hair loss in 1997. It remains one of only two FDA-approved oral treatments for androgenetic alopecia and has decades of long-term safety data.

**Mechanism:** Finasteride competitively and selectively inhibits the Type II isoform of the enzyme 5-alpha reductase, which is predominantly found in hair follicles, the prostate, and the liver. This enzyme converts testosterone into dihydrotestosterone (DHT). By blocking this conversion, finasteride reduces serum DHT levels by approximately 70% and scalp DHT by roughly 66% at the 1mg dose. Since DHT is the primary androgen driving miniaturization of hair follicles in genetically susceptible individuals, lowering DHT levels allows affected follicles to recover, extend the anagen (growth) phase, and produce thicker terminal hairs. Notably, finasteride does not block androgen receptors and has minimal effect on testosterone levels, which may increase slightly (by about 10-15%) as a compensatory response to reduced DHT.

**Key Benefits:**
- Reduces scalp DHT by approximately 66% at 1mg daily
- Slows or stops hair loss progression in roughly 90% of men
- Produces visible hair regrowth in approximately 48% of men within 1-2 years
- FDA-approved with over 25 years of clinical use and long-term safety data
- Convenient once-daily oral dosing with no injections required
- Well-characterized side effect profile with low incidence of adverse events
- Can be combined with minoxidil for enhanced efficacy


---

### Halotestin

URL: https://peptide-db.com/compounds/halotestin

Halotestin (fluoxymesterone) is a synthetic oral anabolic-androgenic steroid derived from testosterone, first introduced in the late 1950s by Upjohn under the brand name Halotestin. It is characterized by an extraordinarily high androgenic rating of approximately 1900 relative to testosterone, paired with an anabolic rating of roughly 1900 as well, though its real-world muscle-building effects are far less pronounced than these numbers suggest. The compound was originally FDA-approved for the treatment of male hypogonadism and advanced breast cancer in women, though it is rarely prescribed today due to the availability of safer alternatives. Fluoxymesterone does not aromatize to estrogen, meaning it produces no estrogenic side effects such as water retention or gynecomastia. In performance contexts, halotestin is used almost exclusively by advanced athletes and competitive bodybuilders in the final weeks before competition or powerlifting meets, where its ability to dramatically increase aggression, neural drive, and strength output without adding water weight makes it uniquely valuable. It is considered one of the harshest oral steroids with respect to hepatotoxicity and is unsuitable for general physique enhancement or beginner use.

**Mechanism:** Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue. The compound's performance-enhancing effects are largely mediated through the central nervous system, increasing aggression, motivation, and perceived energy through androgen receptor activation in the brain. Fluoxymesterone also stimulates erythropoietin production, increasing red blood cell mass and oxygen-carrying capacity, which was the basis for its historical use in treating certain anemias. It enhances hemoglobin synthesis and may improve muscular endurance through improved oxygen delivery. The 17-alpha-methylation allows oral bioavailability but imposes significant hepatic stress, as the liver must process the intact steroid through first-pass metabolism. Fluoxymesterone suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis, and its extreme androgenic load can rapidly affect mood, lipid profiles, and prostate tissue.

**Key Benefits:**
- Dramatic increase in strength and power output without water retention
- Pronounced increase in aggression and competitive drive
- Does not aromatize to estrogen, producing a hard and dry appearance
- Enhances red blood cell production and oxygen-carrying capacity
- Rapid onset of effects, typically noticeable within days
- Uniquely suited for pre-competition or pre-meet peaking protocols
- Short cycle duration limits cumulative exposure


---

### Ketoconazole

URL: https://peptide-db.com/compounds/ketoconazole

Ketoconazole is an FDA-approved azole antifungal that has gained widespread use as a topical adjunct in hair loss treatment. Available as a 1-2% medicated shampoo, ketoconazole disrupts DHT binding at the hair follicle and reduces scalp inflammation driven by the fungus Malassezia, both of which contribute to follicular miniaturization. It is a core component of the widely referenced "big 3" hair loss stack alongside finasteride and minoxidil. While ketoconazole was originally developed as a systemic antifungal for conditions like fungal infections and seborrheic dermatitis, its topical anti-androgenic properties at the scalp level have made it a practical and low-risk addition to hair loss regimens. When used as a shampoo, systemic absorption is negligible, keeping the side effect profile limited to occasional local irritation.

**Mechanism:** Ketoconazole works through multiple pathways relevant to hair loss. As an azole antifungal, it inhibits the enzyme lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis and killing Malassezia fungi that colonize the scalp and contribute to inflammation and seborrheic dermatitis. This anti-inflammatory effect reduces the chronic follicular inflammation associated with androgenetic alopecia. Independently, ketoconazole has demonstrated topical anti-androgenic activity by disrupting the binding of dihydrotestosterone (DHT) and other androgens to receptors at the hair follicle. Some evidence also suggests it may interfere with local androgen synthesis pathways. Unlike systemic anti-androgens such as finasteride, ketoconazole shampoo exerts these effects locally at the scalp without meaningful systemic hormonal changes, making it a well-tolerated complement to oral DHT-blocking therapies.

**Key Benefits:**
- Disrupts DHT binding at the follicle level with topical application
- Reduces Malassezia colonization and scalp inflammation associated with hair loss
- Negligible systemic absorption when used as a shampoo
- FDA-approved and widely available over the counter (1%) or by prescription (2%)
- Part of the established "big 3" hair loss protocol with finasteride and minoxidil
- Treats concurrent seborrheic dermatitis and dandruff while addressing hair loss
- Simple to incorporate into existing shower routines


---

### Letrozole

URL: https://peptide-db.com/compounds/letrozole

Letrozole is the most potent of the three commonly used aromatase inhibitors (letrozole > anastrozole > exemestane), capable of suppressing circulating estradiol by approximately 98% at the standard medical dose of 2.5mg daily. It is FDA-approved under the brand name Femara for the treatment of hormone receptor-positive breast cancer in postmenopausal women and is also used off-label for ovulation induction in fertility medicine. In the bodybuilding and hormone optimization context, letrozole is often considered the "nuclear option" among AIs -- reserved for severe gynecomastia flare-ups, very high aromatizing cycles, or situations where anastrozole has proven insufficient. Its extreme potency is a double-edged sword: while it is highly effective at controlling estrogen, it is also very easy to crash estrogen to undetectable levels, which produces debilitating side effects including severe joint pain, profound fatigue, mood disturbance, and impaired sexual function. Most experienced users treat letrozole as a rescue compound rather than a first-line estrogen management tool, reaching for it only when other options have failed or when rapid, aggressive estrogen suppression is genuinely necessary.

**Mechanism:** Letrozole competitively and reversibly binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), inhibiting its catalytic activity with greater potency than any other commercially available aromatase inhibitor. Aromatase catalyzes the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain. At the standard 2.5mg daily dose, letrozole achieves greater than 99% aromatase inhibition in vivo, reducing circulating estradiol by approximately 98%. Even at lower doses used in bodybuilding protocols (0.25-0.5mg every other day), letrozole produces substantial estrogen suppression that exceeds what anastrozole achieves at standard doses. The inhibition is reversible, meaning estrogen production resumes after the drug is cleared, though the approximately 2-day half-life means recovery takes several days after discontinuation. Because estrogen plays critical physiological roles in men -- including bone metabolism, lipid homeostasis, neurocognition, joint lubrication, and cardiovascular protection -- the overwhelming potency of letrozole demands careful, conservative dosing and regular bloodwork monitoring.

**Key Benefits:**
- Most potent aromatase inhibitor available, achieving ~98% estradiol suppression at medical doses
- Effective rescue compound for acute gynecomastia flare-ups unresponsive to other AIs
- Capable of managing estrogen on very high aromatizing cycles where anastrozole is insufficient
- Oral dosing with a 2-day half-life supports every-other-day scheduling
- Well-characterized pharmacokinetics with extensive clinical data from breast cancer treatment
- Reversible inhibition allows estrogen recovery after discontinuation
- FDA-approved with decades of safety and efficacy data


---

### LGD-4033

URL: https://peptide-db.com/compounds/lgd-4033

LGD-4033 (Ligandrol) is a nonsteroidal investigational selective androgen receptor modulator (SARM) originally developed by Ligand Pharmaceuticals and later licensed to Viking Therapeutics (under the designation VK5211). It is one of the most widely studied SARMs in clinical trials, having completed Phase 1 safety studies in healthy volunteers and a Phase 2 trial evaluating its efficacy in patients recovering from hip fracture surgery. LGD-4033 was designed to provide anabolic benefits, specifically increased lean muscle mass and improved physical function, with reduced androgenic side effects compared to testosterone. In clinical studies, it demonstrated dose-dependent increases in lean body mass, leg press strength, and stair-climbing speed in hip fracture patients. LGD-4033 is broadly considered the most potent SARM for lean mass accrual, exceeding Ostarine (MK-2866) in anabolic potency at comparable doses. Despite promising clinical data, LGD-4033 is not approved by any regulatory agency for any medical indication. Its widespread use in performance enhancement contexts is based on a combination of clinical trial data, preclinical studies, and anecdotal reports.

**Mechanism:** LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin. In preclinical studies, LGD-4033 produced dose-dependent increases in muscle mass (levator ani weight) with significantly less stimulation of prostate weight compared to testosterone. At the molecular level, AR activation by LGD-4033 drives gene transcription pathways involved in protein synthesis, nitrogen retention, and myogenic differentiation in skeletal muscle. The compound also promotes osteoblast activity and bone mineral density through AR signaling in bone tissue. LGD-4033 does not undergo aromatization to estrogen and is not a substrate for 5-alpha reductase, so it does not produce estrogenic side effects (gynecomastia, water retention from estrogen) or DHT-mediated side effects (prostate enlargement, androgenic alopecia). However, as a potent exogenous AR agonist, LGD-4033 suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis in a dose-dependent manner. This suppression is generally considered more pronounced than that caused by Ostarine at equivalent effective doses, consistent with its greater AR binding affinity and anabolic potency.

**Key Benefits:**
- Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
- Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
- Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
- No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
- No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
- Convenient once-daily oral dosing due to 24-36 hour half-life
- Phase 2 clinical data available, providing a stronger evidence base than most other SARMs


---

### Liothyronine (T3)

URL: https://peptide-db.com/compounds/liothyronine

Liothyronine (T3) is the biologically active form of thyroid hormone, responsible for regulating basal metabolic rate, thermogenesis, protein synthesis, and cellular energy metabolism throughout the body. Unlike levothyroxine (T4), which serves primarily as a prohormone requiring peripheral conversion by deiodinase enzymes, T3 acts directly on nuclear thyroid hormone receptors to exert its metabolic effects. It has been FDA-approved since the 1950s for the treatment of hypothyroidism, myxedema coma, and as a diagnostic agent in thyroid suppression tests. Pharmaceutical T3 is available as Cytomel (brand) and generic liothyronine sodium tablets. In performance and biohacking contexts, T3 is widely used during cutting phases to accelerate fat loss by directly upregulating metabolic rate, and by individuals seeking metabolic optimization when peripheral T4-to-T3 conversion is impaired due to caloric restriction, stress, or other factors.

**Mechanism:** Liothyronine enters target cells via monocarboxylate transporter 8 (MCT8) and other thyroid hormone transporters, then binds to nuclear thyroid hormone receptors (primarily TR-beta in metabolic tissues and TR-alpha in cardiac tissue). The T3-receptor complex forms heterodimers with retinoid X receptors (RXR) and binds to thyroid hormone response elements (TREs) on DNA, directly modulating gene transcription. This increases expression of Na+/K+ ATPase (driving cellular energy expenditure), uncoupling proteins (UCP1 in brown adipose tissue, promoting thermogenesis), and enzymes involved in fatty acid oxidation, gluconeogenesis, and protein turnover. T3 also upregulates beta-adrenergic receptor density, which amplifies catecholamine sensitivity and contributes to increased heart rate, lipolysis, and thermogenesis. At physiological doses, T3 supports healthy metabolism; at supraphysiological doses, it shifts the body into a catabolic state where both fat and lean tissue can be catabolized for energy.

**Key Benefits:**
- Direct and rapid increase in basal metabolic rate
- Enhanced fat oxidation and lipolysis
- Improved energy levels and reduction of hypothyroid fatigue
- Faster-acting than T4 with effects noticeable within hours to days
- Useful when peripheral T4-to-T3 conversion is impaired (illness, caloric deficit, stress)
- Supports body temperature regulation and thermogenesis
- Can improve cognitive clarity and reduce brain fog associated with low thyroid function


---

### Masteron

URL: https://peptide-db.com/compounds/masteron

Masteron (drostanolone) is a synthetic dihydrotestosterone (DHT)-derived anabolic-androgenic steroid originally developed and marketed as Masteril and Drostanolone Propionate for the treatment of inoperable breast cancer in postmenopausal women. It received FDA approval for this indication in the 1970s but has since been discontinued from pharmaceutical markets. Structurally, drostanolone is DHT with a 2-alpha-methyl group, which increases its anabolic potency and protects it from metabolic breakdown by 3-alpha-hydroxysteroid dehydrogenase in muscle tissue. As a DHT derivative, Masteron does not aromatize to estrogen and exhibits mild anti-estrogenic properties, likely through competitive inhibition at the aromatase enzyme or direct antagonism at the estrogen receptor. This makes it uniquely suited for cutting and contest preparation cycles where a dry, hard, and grainy physique is desired. Masteron is not a mass-building compound; its primary value lies in aesthetic enhancement, estrogen management, and synergy with other anabolic agents. It is available in two ester forms: the short-acting propionate (original pharmaceutical form) and the longer-acting enanthate (underground lab formulation). Effective results are most visible at lower body fat percentages, typically below 12-15%, where its hardening and drying effects become pronounced.

**Mechanism:** Drostanolone binds to the androgen receptor with high affinity, promoting protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, eliminating estrogen-related side effects such as water retention and gynecomastia from the compound itself. Masteron exhibits anti-estrogenic activity through a dual mechanism: it competitively inhibits aromatase enzyme activity (reducing conversion of other aromatizable steroids like testosterone to estradiol) and may act as a weak antagonist at estrogen receptors in breast tissue, which was the basis for its historical use in breast cancer treatment. This anti-estrogenic property is the reason Masteron can reduce or eliminate the need for dedicated aromatase inhibitors when stacked with testosterone. Unlike testosterone, drostanolone is not a substrate for 5-alpha reductase, as it is already a DHT derivative and cannot be further reduced. This means its full androgenic potency is expressed in all tissues, including hair follicles and the prostate, which accounts for its significant hair loss potential in genetically predisposed individuals. The 2-alpha-methyl modification prevents inactivation by 3-alpha-hydroxysteroid dehydrogenase in muscle, allowing drostanolone to exert its full anabolic effect at the tissue level rather than being rapidly metabolized to inactive forms as unmodified DHT would be.

**Key Benefits:**
- Produces a hard, dry, and grainy appearance by eliminating subcutaneous water retention
- Mild anti-estrogenic properties that can reduce or replace the need for aromatase inhibitors on cycle
- Does not aromatize, eliminating estrogen-mediated side effects from the compound itself
- Enhances the visual effects of other steroids in a stack by reducing water retention and bloat
- Modest increases in strength without significant weight gain, useful for weight-class athletes
- Improves muscle density and vascularity at low body fat percentages
- Well-tolerated with a relatively mild side effect profile compared to other anabolic steroids
- Short detection window with propionate ester compared to many other injectable steroids


---

### Meldonium

URL: https://peptide-db.com/compounds/meldonium

Meldonium (marketed as Mildronate) is a cardioprotective and anti-ischemic drug developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. It is approved and widely prescribed in Latvia, Lithuania, Russia, and several other post-Soviet states for the treatment of coronary artery disease, heart failure, and cerebrovascular conditions. Meldonium has never been approved by the FDA or EMA, and it remains unavailable through conventional pharmaceutical channels in the United States and most of Western Europe. The drug gained worldwide notoriety in March 2016 when tennis star Maria Sharapova announced she had tested positive for meldonium after the World Anti-Doping Agency (WADA) added it to the Prohibited List effective January 1, 2016. Her positive test was far from isolated -- WADA reported that meldonium was the most common substance detected in doping control samples in early 2016, with hundreds of athletes across multiple sports testing positive, predominantly from Eastern European and Central Asian countries. This widespread use reflected meldonium's longstanding popularity among athletes in those regions, where it was both legally available by prescription and culturally accepted as a general-purpose cardioprotective and performance-enhancing agent. In the performance enhancement community, meldonium has attracted particular interest among anabolic steroid users seeking cardiac protection during cycles, given the well-documented cardiotoxic effects of supraphysiological androgen use including left ventricular hypertrophy, impaired diastolic function, and accelerated atherosclerosis.

**Mechanism:** Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time. Since carnitine is essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, reduced carnitine levels impair fatty acid beta-oxidation. This forces cells -- particularly cardiomyocytes and skeletal muscle cells -- to shift their metabolic fuel preference from fatty acid oxidation toward glucose oxidation. This metabolic shift is the cornerstone of meldonium's cardioprotective mechanism. Under ischemic conditions (reduced blood flow), fatty acid oxidation becomes metabolically inefficient and even harmful: incomplete fatty acid oxidation generates toxic intermediates (long-chain acylcarnitines and acyl-CoA species) that damage cell membranes and impair mitochondrial function. Glucose oxidation, by contrast, requires less oxygen per molecule of ATP produced and does not generate these toxic intermediates. By forcing the heart to rely more on glucose, meldonium effectively optimizes energy production under oxygen-limited conditions and reduces the accumulation of cardiotoxic lipid metabolites. Additionally, the accumulation of GBB that results from BBOX inhibition has been shown to stimulate nitric oxide (NO) production via an ester-mediated mechanism, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance. Meldonium also upregulates the expression of glucose transporter proteins (GLUT-1 and GLUT-4) and activates components of the Akt-dependent cardioprotective signaling pathway, further enhancing myocardial resistance to ischemic injury.

**Key Benefits:**
- Cardioprotective effects through metabolic optimization under ischemic conditions
- Shifts cardiac energy metabolism from fatty acid oxidation to more oxygen-efficient glucose oxidation
- Reduces accumulation of toxic fatty acid intermediates (long-chain acylcarnitines) in heart tissue
- Promotes nitric oxide synthesis and endothelial function via GBB accumulation
- May improve exercise capacity and reduce recovery time through enhanced glucose utilization
- Used as adjunctive cardiac protection during anabolic steroid cycles to mitigate androgen-induced cardiotoxicity
- Well-established safety profile in Eastern European clinical use spanning over 30 years


---

### MENT

URL: https://peptide-db.com/compounds/ment

MENT (7-alpha-methyl-19-nortestosterone), also known as trestolone, is an experimental synthetic anabolic-androgenic steroid that belongs to the 19-nor (nandrolone) family. It was originally developed by the Population Council as a potential male hormonal contraceptive and androgen replacement therapy. MENT is estimated to be roughly 10 times more potent than testosterone on a milligram-per-milligram basis, which allows for effective use at very low doses. Unlike nandrolone, MENT does not cause the characteristic sexual dysfunction ('deca dick') associated with other 19-nor compounds, because it maintains sufficient androgenic activity in the central nervous system and sexual tissues. This property has generated significant interest in MENT as a potential standalone replacement for testosterone -- a compound that could serve as both the anabolic and androgenic base in hormone replacement protocols. MENT aromatizes, but its aromatization product is 7-alpha-methyl-estradiol rather than standard estradiol. This methylated estrogen behaves differently from estradiol in some respects, and aromatase inhibitors like anastrozole have reduced efficacy against it. Estrogen management on MENT is therefore considered more challenging than with testosterone. The acetate ester is the most widely available formulation and has an extremely short half-life of approximately 40 minutes, necessitating daily or twice-daily injections for stable blood levels. Research into longer-acting esters and delivery systems (including subdermal implants) is ongoing. MENT remains an investigational compound with no current FDA approval, though Phase 2 clinical trials for male contraception have been conducted.

**Mechanism:** MENT binds to the androgen receptor with high affinity, estimated at roughly 10 times the potency of testosterone, driving robust activation of AR-dependent gene transcription pathways responsible for protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Its 7-alpha methyl group renders it resistant to 5-alpha reductase, meaning it is not converted to a reduced metabolite in androgen-sensitive tissues the way testosterone is converted to DHT or nandrolone is converted to DHN. MENT itself acts directly on androgen receptors throughout the body, including the brain, prostate, and sexual tissues, which is why it maintains libido and sexual function unlike nandrolone. MENT aromatizes via the aromatase enzyme, but the product is 7-alpha-methyl-estradiol rather than estradiol. This methylated estrogen retains estrogenic activity and binds to estrogen receptors, but conventional aromatase inhibitors (anastrozole, letrozole) have diminished ability to block its formation. The mechanism behind this reduced AI efficacy appears related to the 7-alpha methyl group altering the substrate's interaction with the aromatase active site. MENT powerfully suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH to near-undetectable levels at relatively low doses. This profound gonadotropin suppression is the basis for its investigation as a male contraceptive, as it can reduce sperm production to azoospermia or severe oligospermia in most men. Despite its 19-nor classification, MENT does not appear to have the significant progestogenic activity that nandrolone exhibits, though some degree of progesterone receptor interaction has been reported in preclinical studies.

**Key Benefits:**
- Approximately 10x more potent than testosterone, allowing effective results at very low doses (5-25 mg/day)
- Does not cause the sexual dysfunction associated with other 19-nor compounds like nandrolone
- Can potentially serve as a standalone base, replacing testosterone in hormone replacement protocols
- Rapid clearance of the acetate ester allows quick dose adjustments and fast resolution of side effects upon discontinuation
- Powerful lean mass accretion and strength gains relative to dose
- Under investigation as a reversible male hormonal contraceptive
- Resistance to 5-alpha reductase means it does not convert to DHT, potentially sparing hair follicles from direct DHT-mediated damage
- Robust suppression of gonadotropins (LH/FSH), which is therapeutically useful in contraceptive applications


---

### Metformin

URL: https://peptide-db.com/compounds/metformin

Metformin is a biguanide compound and the most widely prescribed oral medication for type 2 diabetes mellitus worldwide, with over 150 million prescriptions annually. Originally derived from the French lilac (Galega officinalis), metformin was introduced in clinical practice in the 1950s in Europe and received FDA approval in the United States in 1995. Beyond its well-established role in glucose regulation, metformin has attracted significant attention in longevity and aging research. The Targeting Aging with Metformin (TAME) trial, a landmark multi-center study, is investigating whether metformin can delay the onset of age-related diseases in non-diabetic older adults. Observational data have suggested that diabetic patients taking metformin may have lower all-cause mortality than age-matched non-diabetic controls, prompting serious scientific interest in its potential geroprotective properties.

**Mechanism:** Metformin exerts its primary effects through activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK activation triggers a cascade of downstream metabolic improvements: enhanced glucose uptake in skeletal muscle, suppression of hepatic gluconeogenesis, improved mitochondrial function, and increased fatty acid oxidation. Metformin also inhibits Complex I of the mitochondrial electron transport chain, which contributes to its AMPK-activating effects by increasing the AMP-to-ATP ratio. Beyond glucose metabolism, metformin modulates several pathways implicated in aging, including inhibition of mTOR signaling (a key regulator of cellular growth and senescence), reduction of oxidative stress and reactive oxygen species, attenuation of chronic low-grade inflammation via NF-kB pathway suppression, and activation of autophagy. These pleiotropic mechanisms underpin both its antidiabetic efficacy and its potential as an anti-aging compound.

**Key Benefits:**
- Improved insulin sensitivity and glucose regulation
- Activation of AMPK, the master metabolic energy sensor
- Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
- Reduced hepatic glucose output (gluconeogenesis suppression)
- Modest weight loss or weight neutrality compared to other diabetes medications
- Anti-inflammatory effects through NF-kB pathway suppression
- Potential anti-cancer properties via mTOR inhibition and AMPK activation
- Improved lipid profile with modest reductions in LDL cholesterol and triglycerides


---

### Methylene Blue

URL: https://peptide-db.com/compounds/methylene-blue

Methylene blue (methylthioninium chloride) is one of the oldest synthetic drugs in medicine, first synthesized in 1876 and originally used as a textile dye before its medicinal properties were discovered. It is FDA-approved for the treatment of methemoglobinemia, a condition in which hemoglobin is unable to carry oxygen effectively. Beyond its approved indication, methylene blue has attracted significant interest as a mitochondrial-enhancing nootropic and neuroprotective agent. At low doses (0.5-2 mg/kg), it acts as an alternative electron carrier in the mitochondrial electron transport chain, bypassing Complex I and Complex III to donate electrons directly to Complex IV (cytochrome c oxidase). This enhances mitochondrial respiration, increases ATP production, and reduces the generation of reactive oxygen species. Methylene blue also inhibits monoamine oxidase (MAO-A), nitric oxide synthase, and has demonstrated anti-inflammatory, antimalarial, and antimicrobial properties. Its neuroprotective potential has been explored in Alzheimer's disease, Parkinson's disease, and traumatic brain injury models.

**Mechanism:** Methylene blue functions as a redox cycling agent in mitochondria. In its oxidized form, it accepts electrons from NADH through Complex I and is reduced to leucomethylene blue. The reduced form then donates these electrons directly to cytochrome c, which passes them to Complex IV (cytochrome c oxidase), the terminal enzyme in the electron transport chain. This creates an alternative electron transfer pathway that can bypass dysfunctional Complex I and Complex III, maintaining the proton gradient across the inner mitochondrial membrane and sustaining ATP synthesis even under conditions of mitochondrial stress or inhibition. Additionally, by diverting electron flow away from sites of superoxide generation at Complex I and Complex III, methylene blue reduces mitochondrial production of reactive oxygen species. Methylene blue also inhibits monoamine oxidase A (MAO-A), which slows the degradation of serotonin, norepinephrine, and dopamine, contributing to its mood and cognitive effects. It inhibits nitric oxide synthase (NOS) and guanylate cyclase, which can affect vascular tone and neuroinflammation. At higher concentrations, methylene blue exhibits pro-oxidant behavior rather than antioxidant, which is why therapeutic benefit follows a hormetic dose-response curve where low doses enhance function and high doses become counterproductive.

**Key Benefits:**
- Enhances mitochondrial respiration and ATP production by acting as an alternative electron carrier
- Reduces mitochondrial reactive oxygen species generation
- Supports memory consolidation and cognitive performance at low doses
- Neuroprotective effects demonstrated in models of Alzheimer's, Parkinson's, and traumatic brain injury
- Improves mitochondrial function in aging cells and tissues
- FDA-approved treatment for acquired methemoglobinemia
- Anti-inflammatory and antimicrobial properties


---

### Minoxidil

URL: https://peptide-db.com/compounds/minoxidil

Minoxidil is an FDA-approved vasodilator originally developed in the 1970s as an oral antihypertensive medication. Its hair growth properties were discovered as a side effect, and topical formulations (2% and 5%) were subsequently approved for the treatment of androgenetic alopecia. It remains one of only two FDA-approved treatments for pattern hair loss and is available over the counter in most countries. In recent years, off-label oral minoxidil at low doses (0.625-5mg) has gained significant traction among dermatologists and the biohacker community as a more convenient and potentially more effective alternative to topical application, particularly for individuals who find the topical formulation inconvenient or who experience scalp irritation.

**Mechanism:** Minoxidil is a potassium channel opener that acts on ATP-sensitive potassium channels in vascular smooth muscle cells, causing vasodilation. When applied topically or taken orally, it is converted to its active metabolite minoxidil sulfate by the enzyme sulfotransferase (SULT1A1) in hair follicle outer root sheath cells. The sulfated form opens potassium channels in dermal papilla cells and vascular smooth muscle surrounding hair follicles, increasing local blood flow and nutrient delivery. Beyond vasodilation, minoxidil upregulates vascular endothelial growth factor (VEGF) expression, extends the anagen (growth) phase of the hair cycle, increases follicle size, and stimulates the transition of resting follicles from telogen into anagen. It also has anti-fibrotic properties that may benefit the perifollicular environment. Notably, minoxidil's hair growth effects are androgen-independent, making it effective regardless of DHT levels and complementary to 5-alpha reductase inhibitors like finasteride.

**Key Benefits:**
- FDA-approved for androgenetic alopecia with decades of clinical evidence
- Stimulates new hair growth and increases hair follicle size independent of androgen pathways
- Available over the counter as a topical treatment without a prescription
- Effective in both men and women for pattern hair loss
- Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
- Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
- Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle


---

### MK-2866

URL: https://peptide-db.com/compounds/mk-2866

MK-2866 (Ostarine, Enobosarm) is a non-steroidal selective androgen receptor modulator (SARM) originally developed by GTx, Inc. (now Oncternal Therapeutics) for the prevention and treatment of muscle wasting and sarcopenia. It is the most extensively studied SARM in clinical trials, having progressed through Phase I, II, and III trials for cancer-related cachexia, stress urinary incontinence, and age-related muscle loss. MK-2866 selectively binds to androgen receptors in muscle and bone tissue with high affinity while exhibiting minimal activity in prostate and sebaceous glands, which differentiates it from traditional anabolic-androgenic steroids. Despite promising clinical data demonstrating significant lean body mass gains in cancer patients and elderly subjects, the FDA has not granted approval, and GTx's New Drug Application for stress urinary incontinence was not approved in 2018. MK-2866 remains classified as an investigational compound and is prohibited by WADA in competitive sports.

**Mechanism:** MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation. The tissue selectivity of MK-2866 arises from its non-steroidal structure, which produces a distinct AR conformational change compared to testosterone or DHT. This results in differential coactivator and corepressor recruitment across tissues. In skeletal muscle, MK-2866 robustly activates anabolic signaling pathways including PI3K/Akt/mTOR, increasing muscle protein synthesis and reducing protein degradation via suppression of ubiquitin-proteasome and myostatin pathways. In bone, it stimulates osteoblast differentiation and mineralization. Critically, MK-2866 demonstrates reduced androgenic activity in prostate tissue and does not undergo 5-alpha reduction to a more potent metabolite (unlike testosterone), nor does it aromatize to estrogen, which accounts for its lower incidence of androgenic and estrogenic side effects.

**Key Benefits:**
- Increases lean body mass in a dose-dependent manner with clinical trial support
- Preserves muscle mass during caloric deficit or catabolic conditions
- Selective tissue activity reduces androgenic side effects compared to anabolic steroids
- Oral bioavailability eliminates the need for injections
- Does not aromatize to estrogen, avoiding gynecomastia and water retention
- Improves physical function and stair-climbing power in clinical populations
- Long 24-hour half-life allows convenient once-daily dosing
- Mild side effect profile at commonly studied doses


---

### Modafinil

URL: https://peptide-db.com/compounds/modafinil

Modafinil is a wakefulness-promoting agent (eugeroic) originally developed in France in the late 1970s and approved by the FDA in 1998. It is prescribed for the treatment of excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea. Unlike traditional psychostimulants such as amphetamines, modafinil produces wakefulness and alertness with a markedly lower abuse potential and a more favorable side effect profile. It has become one of the most widely used compounds in the nootropic and biohacker community due to its ability to sustain focus, reduce fatigue, and enhance executive function during extended periods of cognitive demand. Armodafinil, the R-enantiomer, is marketed separately under the brand name Nuvigil and offers a longer duration of action at a lower dose.

**Mechanism:** The exact mechanism of action of modafinil is not fully understood, which distinguishes it from most prescription stimulants. The primary mechanism appears to involve inhibition of the dopamine transporter (DAT), leading to increased extracellular dopamine concentrations in the nucleus accumbens and cortical regions. However, modafinil's pharmacological profile is distinct from classical dopaminergic stimulants. It also modulates several other neurotransmitter systems: it increases histamine release from the tuberomammillary nucleus (promoting wakefulness), elevates norepinephrine in the prefrontal cortex and hypothalamus, increases serotonin in the amygdala and frontal cortex, and enhances orexin/hypocretin neuron activation in the lateral hypothalamus. Additionally, modafinil reduces GABA release in the cortex and sleep-promoting regions, tipping the balance toward sustained arousal. This multi-target profile is thought to explain why modafinil promotes wakefulness without the jitteriness, peripheral sympathetic activation, or crash associated with amphetamine-class stimulants.

**Key Benefits:**
- Sustained wakefulness and alertness for 10-15 hours without the jitteriness of traditional stimulants
- Enhanced executive function, working memory, and decision-making under fatigue
- Improved focus and concentration during prolonged cognitive tasks
- Reduced impulsivity and improved task completion in sleep-deprived individuals
- Low abuse potential relative to amphetamine-class stimulants (Schedule IV)
- Minimal impact on normal sleep architecture when taken in the morning


---

### Naltrexone

URL: https://peptide-db.com/compounds/naltrexone

Naltrexone is an opioid receptor antagonist originally developed and FDA-approved at full dose (50 mg) for the treatment of opioid and alcohol use disorders. At this dose, it competitively blocks mu-opioid receptors, preventing the euphoric and reinforcing effects of opioids and reducing alcohol cravings. However, naltrexone has gained enormous popularity in the biohacking and functional medicine communities at dramatically lower doses (1-4.5 mg), commonly referred to as Low-Dose Naltrexone (LDN). At these sub-therapeutic doses, naltrexone produces a brief, transient blockade of opioid receptors lasting only a few hours, which triggers a compensatory upregulation of endogenous endorphins and enkephalins. This rebound effect, combined with direct modulation of the Opioid Growth Factor (OGF) - OGF receptor axis, produces broad anti-inflammatory and immunomodulatory effects that have shown promise across a wide range of autoimmune, inflammatory, and chronic pain conditions.

**Mechanism:** At low doses (1-4.5 mg), naltrexone produces a brief nocturnal blockade of opioid receptors that lasts approximately 4-6 hours. This transient blockade triggers a compensatory upregulation of endogenous opioid production, including beta-endorphin and met-enkephalin (also known as Opioid Growth Factor, OGF). Elevated OGF interacts with the OGF receptor (OGFr) to modulate cell proliferation and immune function. LDN also directly antagonizes Toll-like receptor 4 (TLR4) on microglia and macrophages, reducing neuroinflammation and systemic inflammatory cytokine production including TNF-alpha, IL-6, and IL-12. The net effect is a shift from a pro-inflammatory Th1/Th17-dominant immune profile toward a more balanced regulatory state. Additionally, LDN has been shown to increase circulating endorphin levels by 200-300%, which contributes to improved mood, reduced pain perception, and enhanced immune surveillance. The bedtime dosing strategy is deliberate: the brief receptor blockade occurs during the natural nocturnal endorphin surge, maximizing the compensatory rebound effect.

**Key Benefits:**
- Broad anti-inflammatory and immunomodulatory effects via OGF-OGFr axis upregulation
- Reduction in pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) through TLR4 antagonism
- Compensatory upregulation of endogenous endorphins and enkephalins (200-300% increase)
- Improved immune regulation and rebalancing of Th1/Th2/Th17 responses
- Reduction in chronic pain through central and peripheral opioid system modulation
- Potential improvement in mood, anhedonia, and overall well-being via endorphin enhancement
- Extremely well-tolerated with minimal side effects at low doses
- Low cost, especially as compounded LDN formulation


---

### Nandrolone

URL: https://peptide-db.com/compounds/nandrolone

Nandrolone is a synthetic 19-nortestosterone anabolic-androgenic steroid that has been in clinical use since the 1960s. Structurally, it differs from testosterone by the absence of a methyl group at the C19 position, which significantly reduces its androgenic activity relative to its anabolic potency. Nandrolone decanoate (Deca-Durabolin) was FDA-approved for the treatment of anemia associated with chronic renal failure and has also been used clinically for osteoporosis, wasting diseases, and severe burn recovery. Among anabolic steroids, nandrolone is particularly valued for its positive effects on collagen synthesis, joint health, and bone mineral density. It has one of the most favorable anabolic-to-androgenic ratios of any synthetic steroid (approximately 125:37 compared to testosterone at 100:100), making it a frequent choice for individuals seeking muscle growth with reduced androgenic side effects. Nandrolone is available in two primary ester formulations: the long-acting decanoate ester and the shorter-acting phenylpropionate ester (NPP).

**Mechanism:** Nandrolone binds to the androgen receptor (AR) with affinity comparable to testosterone, promoting nitrogen retention, protein synthesis, and satellite cell activation in skeletal muscle tissue. Its anabolic effects are mediated through AR-dependent gene transcription that upregulates muscle-specific proteins including myosin heavy chain and IGF-1. A key distinguishing feature of nandrolone is its interaction with 5-alpha reductase: unlike testosterone, which is converted to the more potent androgen dihydrotestosterone (DHT), nandrolone is reduced to dihydronandrolone (DHN), a weaker androgen. This results in lower androgenic activity in tissues rich in 5-alpha reductase (skin, prostate, hair follicles). Nandrolone also stimulates collagen synthesis and bone mineral content through direct effects on osteoblasts and fibroblasts, contributing to its well-documented benefits for joint and connective tissue health. It exhibits moderate progestogenic activity, binding to the progesterone receptor at approximately 20% the affinity of progesterone, which can influence prolactin levels and contribute to progesterone-related side effects. Nandrolone aromatizes to estradiol at roughly 20% the rate of testosterone, resulting in lower but not absent estrogenic activity.

**Key Benefits:**
- Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
- Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
- Increased bone mineral density through direct osteoblast stimulation
- Improved nitrogen retention and protein synthesis for accelerated recovery
- Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
- Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
- Clinically demonstrated efficacy in treating anemia of chronic renal failure
- Potential neuroprotective properties observed in preclinical research


---

### NMN

URL: https://peptide-db.com/compounds/nmn

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular energy metabolism, DNA repair, sirtuin activation, and hundreds of enzymatic reactions. NAD+ levels decline significantly with age, and this decline is implicated in mitochondrial dysfunction, genomic instability, and many hallmarks of aging. NMN supplementation aims to restore NAD+ levels by providing the immediate substrate for the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT), which catalyzes the final step of NAD+ biosynthesis in the salvage pathway. Popularized by Harvard geneticist David Sinclair, NMN has become one of the most widely studied and used longevity supplements. While animal data is extensive and compelling, human clinical trial data is still accumulating, with several trials showing increases in blood NAD+ levels and improvements in various biomarkers of aging.

**Mechanism:** NMN is converted to NAD+ via the NAD+ salvage pathway. After oral ingestion, NMN is absorbed in the gut, where it may be partially converted to nicotinamide riboside (NR) by the enzyme CD73 for cellular uptake, then re-phosphorylated intracellularly back to NMN. The enzyme NMNAT then converts NMN to NAD+. The resulting increase in NAD+ levels activates multiple longevity-associated pathways: sirtuins (SIRT1-7), a family of NAD+-dependent deacetylases that regulate mitochondrial biogenesis, DNA repair, inflammation, and stress resistance; PARP enzymes involved in DNA damage repair; and CD38/CD157 involved in immune cell signaling. By restoring NAD+ pools, NMN supplementation supports mitochondrial electron transport chain function and ATP production, enhances oxidative metabolism in skeletal muscle, and may counteract age-related metabolic decline. In the Slc12a8 transporter discovery, a dedicated NMN transporter was identified in the small intestine, supporting direct NMN absorption without prior conversion to NR.

**Key Benefits:**
- Increases blood and tissue NAD+ levels, counteracting age-related decline
- Supports mitochondrial function and cellular energy production
- Activates sirtuin pathways involved in DNA repair and longevity
- May improve insulin sensitivity and glucose metabolism
- Supports cardiovascular function and vascular health
- May enhance exercise capacity and muscle endurance
- Promotes healthy aging at the cellular level
- Supports cognitive function and neuroprotection


---

### Noopept

URL: https://peptide-db.com/compounds/noopept

Noopept (GVS-111, omberacetam) is a synthetic nootropic dipeptide developed at the Russian Academy of Medical Sciences in the 1990s. It is approved and marketed in Russia and several CIS countries for cognitive impairment of various origins, including post-traumatic and cerebrovascular conditions. Structurally related to the racetam family, Noopept is not technically a racetam itself but is often grouped with them due to a shared mechanism of action involving modulation of glutamatergic neurotransmission. Its standout characteristic is extraordinary potency -- roughly 1000 times more potent than piracetam by weight -- which allows effective dosing in the 10-30 mg range rather than the multi-gram doses required by piracetam. Noopept is rapidly absorbed and converted to its primary active metabolite, cycloprolylglycine, an endogenous neuropeptide that mediates much of the compound's sustained cognitive and neuroprotective activity.

**Mechanism:** Noopept exerts its nootropic and neuroprotective effects through several interconnected mechanisms. It modulates glutamatergic neurotransmission by acting as a positive modulator at AMPA and NMDA receptors, enhancing long-term potentiation (LTP) in the hippocampus -- the core cellular process underlying memory formation. A defining feature of Noopept is its ability to increase the expression of both brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cerebral cortex. BDNF supports synaptic plasticity, neuronal survival, and the growth of new dendritic connections, while NGF is critical for the maintenance and survival of cholinergic neurons in the basal forebrain, a population that degenerates in Alzheimer's disease. Noopept also exhibits antioxidant and anti-inflammatory properties, reducing oxidative stress and inhibiting neurotoxicity induced by excess calcium and glutamate. Additionally, it enhances the activity of inhibitory mechanisms that prevent excitotoxic neuronal damage. After oral administration, Noopept is rapidly metabolized to cycloprolylglycine, which crosses the blood-brain barrier and is thought to mediate much of the compound's longer-lasting neurotrophic activity.

**Key Benefits:**
- Enhanced memory formation and consolidation through upregulation of BDNF and NGF
- Neuroprotective effects against oxidative stress, excitotoxicity, and amyloid-beta toxicity
- Improved learning capacity and information retrieval via AMPA/NMDA receptor modulation
- Ultra-low effective dose (10-30 mg) compared to classical racetams, reducing pill burden and cost
- Anxiolytic properties observed at standard nootropic doses without sedation
- Fast onset of subjective effects despite the short parent compound half-life, due to active metabolite persistence


---

### Ondansetron

URL: https://peptide-db.com/compounds/ondansetron

Ondansetron is a selective serotonin 5-HT3 receptor antagonist originally developed and FDA-approved for the prevention of nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It works by blocking serotonin signaling in both the gut and the brain's chemoreceptor trigger zone, making it one of the most effective and widely prescribed anti-emetics available. In the performance-enhancement and peptide community, ondansetron has become an essential support compound for managing nausea caused by a range of commonly used agents. GLP-1 receptor agonists like semaglutide and tirzepatide are notorious for dose-dependent nausea, particularly during titration phases, and ondansetron is the go-to solution for keeping users compliant with their protocols. It is similarly relied upon for nausea triggered by HCG, nandrolone (Deca/NPP), pramipexole, and various oral compounds that cause gastric distress. The orally disintegrating tablet (ODT) formulation is especially popular because it dissolves on the tongue in seconds and does not require swallowing a pill while actively nauseated.

**Mechanism:** Ondansetron exerts its anti-emetic effects through selective antagonism of serotonin 5-HT3 receptors. These receptors are concentrated in two key areas relevant to nausea: the vagal afferent nerve terminals in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the area postrema of the brainstem. When emetogenic stimuli (chemotherapy, medications, gut irritation) cause enterochromaffin cells in the gut to release large amounts of serotonin, this serotonin activates 5-HT3 receptors on vagal afferents, which transmit nausea signals to the brainstem vomiting center. Ondansetron blocks this signaling pathway at both the peripheral (gut) and central (CTZ) level. Unlike dopamine antagonists such as metoclopramide, ondansetron does not block D2 receptors and therefore does not cause extrapyramidal side effects or prolactin elevation, making it a much cleaner anti-emetic for long-term or repeated use. The drug is metabolized hepatically via CYP3A4 and CYP1A2 and is eliminated with a half-life of approximately 4 hours.

**Key Benefits:**
- Highly effective at controlling nausea and vomiting from a wide range of causes, including GLP-1 agonists, HCG, and nandrolone
- Orally disintegrating tablet (ODT) dissolves on the tongue in seconds, ideal for use during active nausea when swallowing pills is difficult
- Does not cause sedation, extrapyramidal symptoms, or prolactin elevation, unlike dopamine-blocking anti-emetics
- Fast onset of action (15-30 minutes oral, near-immediate for ODT) with reliable 4-8 hour duration
- Well-tolerated with a mild side effect profile at standard doses
- Widely available as an inexpensive generic in multiple formulations


---

### Oxandrolone

URL: https://peptide-db.com/compounds/oxandrolone

Oxandrolone is a synthetic oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT), first synthesized in 1962 by Raphael Pappo at Searle Laboratories and introduced to the market in 1964 under the brand name Anavar. It was designed to be a mild anabolic agent with minimal androgenic activity, achieved through a structural modification where an oxygen atom replaces the carbon-2 atom in the A-ring of the DHT backbone. This modification significantly reduces androgenic potency while preserving anabolic effects on skeletal muscle. Oxandrolone is FDA-approved for the promotion of weight regain following involuntary weight loss due to surgery, chronic infection, severe trauma, and prolonged corticosteroid use, and for the relief of bone pain associated with osteoporosis. It has been extensively studied in burn recovery, HIV/AIDS-related wasting, and pediatric growth disorders. Among oral anabolic steroids, oxandrolone is considered one of the mildest with respect to hepatotoxicity and virilizing side effects, which has made it one of the few anabolic steroids used in women and children in clinical settings.

**Mechanism:** Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tissue. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, which means it does not cause estrogen-mediated water retention or gynecomastia. The 2-oxo modification in the A-ring reduces its affinity for 5-alpha reductase, limiting conversion to more potent androgens in peripheral tissues and contributing to its relatively low androgenic profile. Oxandrolone increases protein synthesis through direct AR-mediated gene transcription, enhances the expression of genes involved in muscle hypertrophy and repair, and promotes collagen synthesis. It has also been shown to reduce cortisol-binding globulin levels and attenuate the catabolic effects of glucocorticoids, which is particularly relevant in burn patients and those recovering from severe trauma. Additionally, oxandrolone stimulates hepatic production of sex hormone-binding globulin (SHBG) to a lesser degree than other oral steroids, though it does suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis.

**Key Benefits:**
- Promotes lean muscle mass gains with minimal water retention
- Supports recovery of lost body weight following surgery, trauma, or chronic illness
- Reduces bone pain associated with osteoporosis and improves bone mineral density
- Does not aromatize to estrogen, avoiding estrogen-related side effects
- Well-studied safety profile in women, children, and burn patients
- Enhances nitrogen retention and protein synthesis during caloric deficit
- Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
- Lower androgenic potency compared to most oral anabolic steroids


---

### Oxiracetam

URL: https://peptide-db.com/compounds/oxiracetam

Oxiracetam (ISF-2522) is a synthetic nootropic compound belonging to the racetam family, first developed in the 1970s by ICF, an Italian pharmaceutical company. It is a hydroxylated derivative of piracetam and is approved as a prescription medication in Italy and several other European and Asian countries for the treatment of cognitive decline associated with dementia and organic brain syndromes. Among the racetams, oxiracetam is widely regarded as the most effective for logical reasoning, mathematical thinking, and technical work -- a reputation that distinguishes it from piracetam, which users more commonly associate with verbal fluency and creative thinking. Oxiracetam is well absorbed orally with high bioavailability, is not significantly metabolized by the liver, and is excreted largely unchanged by the kidneys, giving it a clean pharmacokinetic profile with minimal drug-drug interaction potential.

**Mechanism:** Oxiracetam enhances cognitive function primarily through positive allosteric modulation of AMPA-type glutamate receptors, increasing the excitatory postsynaptic response to glutamate and facilitating long-term potentiation (LTP) in hippocampal and cortical circuits. This AMPA modulation is thought to underlie its effects on memory encoding and retrieval. Additionally, oxiracetam stimulates cholinergic neurotransmission by increasing the release of acetylcholine in the hippocampus and cortex, which contributes to improvements in attention, working memory, and the speed of information processing. Unlike some stimulant nootropics, oxiracetam does not act on dopaminergic or serotonergic systems, which accounts for its low abuse potential and absence of mood-altering side effects. Oxiracetam also increases phospholipid metabolism in the brain, specifically the turnover of phosphatidylcholine and phosphatidylethanolamine, which may support membrane integrity and synaptic function. The compound increases D-aspartate release in the hippocampus, providing an additional pathway for NMDA receptor activation and synaptic plasticity. Its selectivity for logical and analytical cognition, as reported by users, may relate to preferential enhancement of cortical circuits involved in sequential reasoning and working memory manipulation, though this distinction has not been rigorously dissected in controlled studies.

**Key Benefits:**
- Enhanced logical reasoning, analytical thinking, and mathematical ability -- the cognitive domains where oxiracetam most clearly outperforms other racetams
- Improved processing speed and working memory capacity, facilitating technical work and complex problem-solving
- Mild psychostimulant effect that increases mental alertness without the jitteriness or crash associated with caffeine or amphetamines
- Strong safety profile with decades of clinical use in Europe and Asia, minimal hepatic metabolism, and low interaction potential
- Enhanced memory formation and consolidation through AMPA receptor modulation and increased hippocampal acetylcholine release
- Neuroprotective properties demonstrated in animal models of ischemia and excitotoxic injury


---

### Phenibut

URL: https://peptide-db.com/compounds/phenibut

Phenibut (beta-phenyl-gamma-aminobutyric acid) is a synthetic GABA analog developed in the Soviet Union in the 1960s. It was designed to cross the blood-brain barrier, which GABA itself cannot do efficiently, by adding a phenyl ring to the GABA molecule. Phenibut has been prescribed in Russia and several former Soviet states since the 1960s for the treatment of anxiety, insomnia, post-traumatic stress disorder, vestibular disorders, and stuttering. It was famously included in the medical kit of Soviet cosmonauts for its calming effects without impairing cognitive performance. Phenibut is NOT approved by the FDA, EMA, or any Western regulatory agency as a pharmaceutical drug. In the United States, Australia, and parts of Europe, it has been sold as a dietary supplement or nootropic, though several countries have moved to restrict or ban its sale due to growing reports of dependence, withdrawal, and adverse events. The addiction and dependence potential of phenibut is HIGH, and tolerance develops rapidly with repeated use. This compound should be treated with the same caution as benzodiazepines or other GABAergic drugs.

**Mechanism:** Phenibut acts primarily as an agonist at GABA-B receptors, the same receptor target as baclofen (to which it is structurally related). GABA-B receptor activation inhibits neuronal excitability by opening potassium channels and reducing calcium influx at presynaptic terminals, leading to decreased neurotransmitter release and a net inhibitory effect on the central nervous system. This produces anxiolytic, sedative, and muscle-relaxant effects. In addition to GABA-B agonism, phenibut blocks voltage-dependent calcium channels (VDCCs), particularly alpha-2-delta subunit-containing channels, a mechanism shared with gabapentin and pregabalin. This contributes to its anxiolytic and analgesic properties. At higher doses, phenibut may also weakly stimulate GABA-A receptors, contributing to its sedative effects, though this is not its primary mechanism at typical doses. The R-enantiomer of phenibut is responsible for the majority of its GABA-B receptor activity, while the S-enantiomer is more selective for the alpha-2-delta VDCC subunit.

**Key Benefits:**
- Reduction of anxiety and social inhibition
- Improved sleep onset and sleep quality
- Mild mood elevation and sense of well-being
- Reduced cognitive effects of stress without heavy sedation at low doses
- Potential benefit for vestibular disorders (clinical use in Russia)


---

### Phenylpiracetam

URL: https://peptide-db.com/compounds/phenylpiracetam

Phenylpiracetam (also known as Phenotropil, Carphedon, or Fonturacetam) is a phenylated derivative of piracetam developed in Russia in 1983, originally for Soviet cosmonauts to enhance cognitive function, physical stamina, and cold tolerance during space missions. The addition of a phenyl group to piracetam's pyrrolidone nucleus fundamentally changes the compound's pharmacological profile -- it crosses the blood-brain barrier more readily, has significantly greater affinity for multiple neurotransmitter systems, and exhibits pronounced psychostimulant and physical performance-enhancing properties absent in piracetam. Phenylpiracetam was approved and marketed in Russia as Phenotropil for cognitive impairment, asthenia, and convulsive disorders until its manufacturer ceased production. It gained notoriety in the sporting world after the World Anti-Doping Agency (WADA) added it to the prohibited substances list following its detection in several Olympic athletes, confirming its reputation as a legitimate performance enhancer. One of its most distinctive properties is the enhancement of cold tolerance, a trait that directly reflects its origins as a cosmonaut support compound and has been demonstrated in animal models of hypothermia.

**Mechanism:** Phenylpiracetam modulates multiple neurotransmitter systems, which accounts for its broad spectrum of cognitive and physical effects. Like other racetams, it acts as a positive allosteric modulator of AMPA receptors, enhancing glutamatergic transmission and facilitating long-term potentiation in hippocampal circuits critical for memory formation. However, unlike piracetam, phenylpiracetam also significantly affects dopaminergic and noradrenergic signaling -- it increases the density of dopamine D1, D2, and D3 receptors and noradrenaline receptors in the striatum and other brain regions, which underpins its stimulant, mood-elevating, and motivation-enhancing properties. It also modulates nicotinic acetylcholine receptors and NMDA-type glutamate receptors, contributing to its procognitive effects. The phenyl group increases lipophilicity, allowing faster and more complete penetration of the blood-brain barrier compared to piracetam. Phenylpiracetam also demonstrates anticonvulsant activity and has been shown to reduce the threshold for cold-induced stress responses, likely through modulation of hypothalamic thermoregulatory circuits and peripheral adrenergic mechanisms. The compound's physical performance-enhancing effects are attributed to increased noradrenergic and dopaminergic tone, enhanced muscular endurance, and reduced perception of effort and fatigue.

**Key Benefits:**
- Potent cognitive enhancement including improved memory, focus, and information processing speed
- Psychostimulant properties that increase motivation, mental energy, and alertness without the jitteriness of classical stimulants
- Physical performance enhancement through improved stamina, reduced perception of effort, and increased exercise tolerance
- Enhanced cold tolerance -- a unique property among nootropics, originally developed for extreme-environment performance
- Anxiolytic effects at standard doses, reducing stress reactivity without sedation
- Anticonvulsant activity demonstrated in preclinical models


---

### Pitavastatin

URL: https://peptide-db.com/compounds/pitavastatin

Pitavastatin is a newer-generation synthetic statin approved by the FDA in 2009 under the brand name Livalo. It distinguishes itself from other statins through its minimal cytochrome P450 metabolism, which translates to significantly fewer drug-drug interactions than atorvastatin, simvastatin, or lovastatin. This characteristic makes pitavastatin particularly attractive for individuals taking multiple medications or compounds simultaneously, a situation common among anabolic steroid users who may be running ancillaries, aromatase inhibitors, and other support compounds alongside their cycles. Unlike most statins that are heavily metabolized by CYP3A4 or CYP2C9, pitavastatin is primarily metabolized via glucuronidation by UGT1A3 and UGT2B7, with negligible involvement of CYP enzymes. This means compounds and medications that inhibit or induce CYP3A4 do not meaningfully alter pitavastatin blood levels. Clinically, pitavastatin delivers LDL reductions of 38-45% at its standard 2-4 mg dose range, placing it in the moderate-to-high intensity category. Perhaps most notably, pitavastatin carries the lowest risk of new-onset diabetes among all statins, a finding consistently demonstrated across multiple clinical trials and meta-analyses including the LIVES study and J-PREDICT trial. This makes it an especially prudent choice for individuals with pre-existing insulin resistance or those using compounds known to impact glucose metabolism.

**Mechanism:** Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface. The increased LDL receptor density enhances the clearance of circulating LDL cholesterol, VLDL remnants, and IDL particles from the bloodstream. Pitavastatin has high binding affinity for HMG-CoA reductase and demonstrates potent LDL-lowering efficacy relative to its low milligram dosing. Beyond direct lipid lowering, pitavastatin exerts pleiotropic cardiovascular effects: it improves endothelial function by enhancing nitric oxide production, reduces vascular inflammation and oxidative stress, and stabilizes atherosclerotic plaques. Uniquely among statins, pitavastatin has been shown to raise HDL cholesterol more robustly than other agents in the class, with increases of 5-15% commonly observed. This HDL-raising effect is thought to involve upregulation of apolipoprotein A-I synthesis and enhanced reverse cholesterol transport. In the context of AAS use, pitavastatin addresses the classic androgen-induced dyslipidemia pattern of elevated LDL and suppressed HDL, with its relatively stronger HDL-raising capacity being an advantage over other statins when HDL suppression is a primary concern.

**Key Benefits:**
- Minimal CYP450 metabolism — does not interact with CYP3A4, making it ideal for users taking multiple compounds
- Lowest risk of new-onset diabetes among all statins, supported by the LIVES study and J-PREDICT trial data
- LDL reductions of 38-45% at standard doses (2-4 mg/day)
- More robust HDL-raising effect (5-15%) compared to other statins in the class
- 12-hour half-life supports convenient once-daily dosing
- Favorable safety profile with low incidence of muscle-related side effects
- Compatible with CYP3A4 inhibitors and inducers that would alter levels of other statins
- Effective at counteracting AAS-induced lipid disturbances without adding to drug interaction burden


---

### PP405

URL: https://peptide-db.com/compounds/pp405

PP405 is an investigational topical drug developed by Pelage Pharmaceuticals for the treatment of androgenetic alopecia. Based on research conducted at UCLA, PP405 works through a fundamentally different mechanism than existing hair loss treatments: rather than blocking androgens like finasteride or promoting blood flow like minoxidil, it targets the metabolic dormancy of hair follicle stem cells directly. By inhibiting the mitochondrial pyruvate carrier (MPC1/MPC2), PP405 causes pyruvate accumulation in hair follicle stem cells, stimulating lactate dehydrogenase activity and triggering a metabolic shift that reactivates dormant follicles. Phase 2a clinical trial results showed increased hair count and thickness with a 0.05% gel formulation applied once daily. As of 2025, the drug has completed Phase 2a trials, with Phase 3 trials planned for 2026.

**Mechanism:** PP405 is a dual inhibitor of the mitochondrial pyruvate carrier complex, targeting both the MPC1 and MPC2 subunits. Under normal conditions, the MPC transports pyruvate from the cytoplasm into the mitochondrial matrix, where it enters the tricarboxylic acid (TCA) cycle for oxidative metabolism. In hair follicle stem cells (HFSCs), this standard metabolic pathway is associated with quiescence and dormancy. By blocking MPC1/MPC2, PP405 prevents pyruvate from entering the mitochondria, causing it to accumulate in the cytoplasm. This pyruvate buildup stimulates lactate dehydrogenase (LDH) activity, which converts pyruvate to lactate, shifting the cell's metabolic profile toward aerobic glycolysis. This metabolic reprogramming mimics the signaling environment that naturally triggers HFSCs to exit quiescence and re-enter the cell cycle. The activated stem cells then initiate a new anagen (growth) phase in dormant hair follicles. Critically, this mechanism is entirely independent of the androgen/DHT pathway targeted by finasteride and dutasteride, and distinct from the vasodilatory effects of minoxidil, meaning PP405 could be effective regardless of a patient's androgen status.

**Key Benefits:**
- Novel non-hormonal mechanism of action targeting hair follicle stem cell metabolism
- Directly addresses the root cause of follicle dormancy rather than downstream hormonal effects
- Potentially effective regardless of androgen status, broadening the treatable population
- Topical application (0.05% gel) limits systemic exposure
- Phase 2a results demonstrated increased hair count and thickness
- Compatible with existing hair loss treatments (finasteride, minoxidil) for combination therapy
- No known sexual or hormonal side effects based on available trial data


---

### Pramipexole

URL: https://peptide-db.com/compounds/pramipexole

Pramipexole is a non-ergoline dopamine agonist with preferential affinity for the D3 dopamine receptor subtype. It is FDA-approved under the brand names Mirapex and Mirapexin for the treatment of Parkinson's disease and restless legs syndrome (RLS). In the bodybuilding and performance enhancement context, pramipexole serves as an alternative to cabergoline for managing prolactin elevation caused by 19-nor anabolic steroids such as nandrolone (Deca-Durabolin, NPP) and trenbolone. While less potent than cabergoline at suppressing prolactin, pramipexole is typically cheaper and more readily available, making it a practical option when cabergoline is difficult to source. Its shorter half-life of approximately 8 hours necessitates daily dosing (usually at bedtime), and it must be titrated slowly from a low starting dose to minimize side effects -- particularly nausea, which is common during initiation. Pramipexole is generally considered a second-choice prolactin management agent behind cabergoline due to its lower potency, shorter duration, and less favorable side effect profile at the doses sometimes needed for adequate prolactin suppression.

**Mechanism:** Pramipexole exerts its prolactin-suppressing effects by acting as a full agonist at dopamine D2 and D3 receptors, with a marked preference for the D3 subtype. In the anterior pituitary, prolactin secretion by lactotroph cells is tonically inhibited by hypothalamic dopamine acting on D2 receptors. Pramipexole stimulates these D2 receptors to suppress prolactin gene transcription, synthesis, and release. Its preferential D3 activity also contributes to its clinical effects in Parkinson's disease and may account for some of its neuropsychiatric side effects, particularly impulse control disorders, which are mediated through mesolimbic D3 signaling pathways. In the context of 19-nor steroid use, nandrolone and trenbolone elevate prolactin through progestogenic activity at the pituitary, and pramipexole counteracts this by restoring dopaminergic inhibition. However, because pramipexole has lower D2 affinity and a much shorter half-life than cabergoline, higher relative doses and more frequent administration are needed to achieve comparable prolactin suppression.

**Key Benefits:**
- Suppresses prolactin elevation caused by 19-nor anabolic steroids
- Non-ergoline structure eliminates the risk of cardiac valve fibrosis associated with ergot-derived agents like cabergoline
- Generally cheaper and more widely available than cabergoline
- FDA-approved with a well-characterized safety and pharmacokinetic profile
- Can restore sexual function impaired by prolactin elevation on nandrolone or trenbolone cycles
- Viable alternative when cabergoline cannot be sourced


---

### Primobolan

URL: https://peptide-db.com/compounds/primobolan

Primobolan (metenolone) is a dihydrotestosterone (DHT)-derived anabolic steroid that has been in clinical and performance use since the 1960s. It was originally marketed by Schering as Primobolan (oral acetate) and Primobolan Depot (injectable enanthate) for the treatment of muscle wasting diseases, malnutrition, and osteoporosis. Although it was once FDA-approved in the United States, it has since been discontinued from the US market and is primarily available through international pharmacies and underground production. Primobolan is widely considered one of the mildest and safest anabolic steroids in terms of side effect profile. It does not aromatize to estrogen, carries low androgenic activity relative to its anabolic effects (anabolic-to-androgenic ratio of approximately 88:44 compared to testosterone at 100:100), and the injectable form is not hepatotoxic. It gained legendary status in golden-era bodybuilding, with Arnold Schwarzenegger reportedly favoring it as part of his competition preparation. Primobolan is particularly valued for lean tissue preservation during caloric deficits, quality muscle gains without water retention, and its compatibility with longer cycle durations due to its mild nature. Its primary drawback is cost -- it is one of the most expensive anabolic steroids per milligram, and effective doses require relatively high volumes of oil for injection.

**Mechanism:** Metenolone binds to the androgen receptor (AR) to promote nitrogen retention, protein synthesis, and anti-catabolic effects in skeletal muscle tissue. As a DHT derivative, it cannot be aromatized by the aromatase enzyme, meaning it produces no estrogenic metabolites and does not contribute to water retention, gynecomastia, or estrogen-mediated fat gain. Unlike testosterone, which is converted to the more potent DHT by 5-alpha reductase, metenolone is already a DHT derivative and undergoes no further activation in androgen-sensitive tissues, resulting in a relatively mild androgenic profile. Metenolone has a strong affinity for androgen receptors in muscle tissue and exerts significant anti-catabolic effects by reducing glucocorticoid receptor expression and inhibiting cortisol-mediated protein breakdown. This makes it particularly effective during caloric restriction, where it helps preserve lean tissue. It also enhances immune function at moderate doses, which was one of its original clinical applications in immunocompromised patients. The injectable enanthate form bypasses hepatic first-pass metabolism entirely, making it non-hepatotoxic. The oral acetate form, while possessing a 1-methyl modification that provides some degree of oral bioavailability, is not 17-alpha-alkylated in the traditional sense but still exerts measurable hepatic stress at sustained doses.

**Key Benefits:**
- Lean muscle mass preservation during caloric deficits with minimal water retention
- Does not aromatize to estrogen, eliminating estrogen-related side effects
- One of the mildest androgenic profiles among anabolic steroids, with reduced risk of acne, aggression, and prostate issues
- Injectable form is non-hepatotoxic, allowing extended cycle durations
- Strong anti-catabolic properties through glucocorticoid receptor modulation
- Immune-enhancing effects at moderate therapeutic doses
- Quality, keepable muscle gains without the bloated appearance common with aromatizing steroids
- Compatible with long cycle lengths (16-20 weeks) due to mild overall impact on health markers


---

### Propranolol

URL: https://peptide-db.com/compounds/propranolol

Propranolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) and one of the oldest and most widely prescribed drugs in its class. FDA-approved since 1967 and marketed as Inderal, it blocks both beta-1 receptors in the heart (reducing heart rate, contractility, and cardiac output) and beta-2 receptors in the bronchial and vascular smooth muscle. In the performance-enhancing drug community, propranolol serves two primary roles: managing elevated resting heart rate caused by compounds such as trenbolone and clenbuterol, and controlling performance anxiety or situational anxiety symptoms. Trenbolone is notorious for raising resting heart rate and causing nocturnal tachycardia, while clenbuterol directly stimulates beta-2 receptors to increase heart rate as part of its sympathomimetic action. Propranolol's non-selective beta blockade makes it effective against both mechanisms. Its rapid onset (within 30-60 minutes of oral dosing) and relatively short duration of action make it well-suited for as-needed use, though it can also be dosed regularly for sustained heart rate control throughout an AAS cycle.

**Mechanism:** Propranolol competitively blocks both beta-1 and beta-2 adrenergic receptors. Beta-1 blockade in the sinoatrial node and myocardium reduces heart rate (negative chronotropy), decreases the force of cardiac contraction (negative inotropy), and slows atrioventricular conduction (negative dromotropy). This directly counteracts the tachycardia induced by sympathomimetic compounds like clenbuterol and the unexplained heart rate elevation commonly reported with trenbolone use. Beta-2 blockade in peripheral vasculature contributes to a modest increase in peripheral vascular resistance initially, though chronic use leads to a net reduction in blood pressure through decreased cardiac output and suppression of renin release from the juxtaglomerular cells. Propranolol is highly lipophilic, readily crossing the blood-brain barrier, which accounts for its efficacy in managing anxiety symptoms, essential tremor, and the physical manifestations of sympathetic nervous system activation (tremor, palpitations, sweating). This central penetration also explains why propranolol is more effective for anxiety-related indications than hydrophilic beta blockers like atenolol. The drug undergoes extensive first-pass hepatic metabolism via CYP2D6 and CYP1A2, resulting in variable bioavailability (approximately 25-35%).

**Key Benefits:**
- Rapid reduction of elevated heart rate within 30-60 minutes of oral dosing
- Effective against tachycardia from both trenbolone and clenbuterol through non-selective beta blockade
- Well-established anxiolytic effect for performance anxiety without cognitive impairment or sedation
- Short half-life allows flexible as-needed dosing without prolonged hemodynamic effects
- Extensive clinical safety data spanning over 50 years of use
- Inexpensive and widely available as a generic medication
- Does not cause dependence or withdrawal symptoms typical of benzodiazepines
- Effective for controlling physical anxiety symptoms (tremor, palpitations, sweating)


---

### Proviron

URL: https://peptide-db.com/compounds/proviron

Proviron (mesterolone) is an orally active dihydrotestosterone (DHT) derivative that has been used in clinical medicine since the 1960s, primarily in Europe and other international markets. Unlike most oral anabolic steroids, Proviron is not 17-alpha alkylated, which gives it a remarkably low hepatotoxicity profile. It was originally developed for the treatment of androgen deficiency, male infertility (at low doses it can improve sperm quality without fully suppressing the HPT axis), and mood disturbances related to low androgen status. Proviron is approved in numerous countries outside the United States including Germany, the UK, and several countries across Asia, South America, and the Middle East. Its most distinctive pharmacological property is its exceptionally strong binding affinity for sex hormone-binding globulin (SHBG), which effectively displaces testosterone from SHBG and increases the proportion of circulating free testosterone. This mechanism makes Proviron a popular adjunct to testosterone replacement therapy and performance enhancement protocols, where it amplifies the biological activity of co-administered testosterone without meaningfully increasing total androgen load. Proviron is also valued for its anti-estrogenic properties — as a DHT derivative, it cannot aromatize to estrogen, and it competes with testosterone for the aromatase enzyme, reducing overall estrogen conversion. Users consistently report improvements in mood, libido, confidence, and a general sense of well-being, along with a harder, drier, and more defined physical appearance.

**Mechanism:** Proviron exerts its effects primarily through direct binding to the androgen receptor (AR) as a potent DHT analogue. However, its most therapeutically relevant mechanism is its exceptionally high binding affinity for sex hormone-binding globulin (SHBG). By occupying SHBG binding sites, Proviron displaces testosterone that would otherwise be bound and biologically inactive, effectively increasing free testosterone levels without requiring additional exogenous testosterone. This SHBG-displacement mechanism is the primary reason Proviron is considered synergistic with testosterone — it amplifies the effective androgenic signal from a given dose of testosterone. Proviron also acts as a mild aromatase inhibitor. Because it is a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, and it competes with aromatizable androgens (like testosterone) for access to aromatase, reducing the overall rate of estrogen conversion. This dual mechanism — increasing free testosterone while reducing estrogen — produces the characteristic effects of improved mood, enhanced libido, and the harder, drier physique that Proviron is known for. In muscle tissue, Proviron's anabolic effects are limited because it is rapidly inactivated by 3-alpha hydroxysteroid dehydrogenase, similar to DHT itself. This enzyme is highly expressed in skeletal muscle, which is why Proviron is not considered a significant muscle-building agent on its own but rather an enhancer of other androgens.

**Key Benefits:**
- Strong SHBG binding frees more circulating testosterone, enhancing TRT efficacy
- Improved mood, motivation, confidence, and overall sense of well-being
- Significant enhancement of libido and sexual function
- Anti-estrogenic effect reduces the need for dedicated aromatase inhibitors
- Harder, drier, more defined physical appearance without water retention
- Minimal hepatotoxicity due to absence of 17-alpha alkylation
- May improve sperm quality at low doses in subfertile men
- Rapid onset of subjective well-being effects (often within days)


---

### RAD-140

URL: https://peptide-db.com/compounds/rad-140

RAD-140 (Testolone) is a nonsteroidal investigational selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. for the potential treatment of muscle wasting conditions and hormone receptor-positive breast cancer. It was designed to provide the anabolic benefits of testosterone, specifically increased lean muscle mass and bone density, while minimizing androgenic side effects in tissues such as the prostate and skin. RAD-140 has demonstrated a high degree of tissue selectivity in preclinical models, with an anabolic-to-androgenic ratio substantially greater than that of testosterone. It entered Phase 1 clinical trials for metastatic breast cancer (ER+/HER2-) and has shown preliminary safety and tolerability in that context. However, RAD-140 is not approved for any medical use by any regulatory agency. It remains a research compound, and its widespread use in performance and physique enhancement contexts is based almost entirely on preclinical data and anecdotal reports rather than completed clinical trials for those indications.

**Mechanism:** RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands. In preclinical studies, RAD-140 demonstrated potent anabolic effects on levator ani muscle mass comparable to testosterone, while showing significantly less stimulation of prostate weight. RAD-140 also crosses the blood-brain barrier and has demonstrated neuroprotective properties in in vitro models, reducing cell death caused by apoptotic insults in hippocampal neurons. At the molecular level, it activates AR-dependent gene transcription pathways involved in protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Importantly, RAD-140 does not undergo aromatization to estrogen and is not a substrate for 5-alpha reductase, meaning it does not produce estrogenic or DHT-mediated side effects. However, like all exogenous AR agonists, it suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis.

**Key Benefits:**
- Potent anabolic activity in muscle tissue with high oral bioavailability
- Tissue-selective action sparing the prostate and other androgen-sensitive organs
- No aromatization to estrogen (no estrogen-related side effects such as water retention or gynecomastia)
- No conversion to DHT (reduced risk of hair loss and prostate stimulation compared to testosterone)
- Long half-life (~60 hours) permitting convenient once-daily oral dosing
- Neuroprotective properties observed in preclinical models
- Increased lean body mass and reduced fat mass in preclinical studies


---

### Raloxifene

URL: https://peptide-db.com/compounds/raloxifene

Raloxifene is a second-generation selective estrogen receptor modulator (SERM) FDA-approved for the prevention and treatment of postmenopausal osteoporosis and for breast cancer risk reduction. Unlike tamoxifen, raloxifene has a benzothiophene core rather than a triphenylethylene backbone, giving it a distinct tissue-selectivity profile. In performance enhancement contexts, raloxifene is widely regarded as the preferred SERM for gynecomastia reversal because of its stronger antagonist activity at breast tissue estrogen receptors with fewer off-target effects. However, raloxifene is not an effective standalone post-cycle therapy drug because it does not stimulate the hypothalamic-pituitary-testicular axis as robustly as tamoxifen or enclomiphene. Its weaker antagonism at hypothalamic estrogen receptors means it produces comparatively modest elevations in LH and FSH, making it poorly suited for driving testosterone recovery after anabolic steroid cycles. Raloxifene carries a lower risk of endometrial stimulation than tamoxifen, as it acts as an estrogen antagonist rather than a partial agonist in uterine tissue.

**Mechanism:** Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity. This strong breast-tissue antagonism underlies its effectiveness for gynecomastia treatment and breast cancer risk reduction. In bone, raloxifene acts as an estrogen agonist, maintaining bone mineral density by inhibiting osteoclast-mediated resorption. Critically, raloxifene is a weaker antagonist at hypothalamic estrogen receptors compared to tamoxifen, which means it produces less disruption of estrogen-driven negative feedback on GnRH secretion. The result is a more modest increase in LH and FSH compared to tamoxifen, limiting its utility as a standalone PCT agent. In the uterus, raloxifene does not exhibit the partial agonist activity seen with tamoxifen, which translates to a substantially lower risk of endometrial hyperplasia and endometrial cancer with long-term use. Raloxifene is metabolized primarily through glucuronidation rather than CYP450-dependent oxidation, which reduces the potential for drug-drug interactions compared to tamoxifen.

**Key Benefits:**
- Superior breast tissue estrogen receptor antagonism makes it the preferred SERM for gynecomastia reversal
- No estrogen agonist activity in the uterus, avoiding the endometrial risks associated with tamoxifen
- Estrogen agonist activity in bone preserves bone mineral density and reduces fracture risk
- Lower overall thromboembolic risk compared to tamoxifen
- Metabolized via glucuronidation rather than CYP2D6, avoiding the drug interaction concerns that affect tamoxifen
- Simple once-daily oral dosing with a manageable 28-hour half-life
- FDA-approved with decades of clinical safety data in postmenopausal women


---

### Rapamycin

URL: https://peptide-db.com/compounds/rapamycin

Rapamycin (sirolimus) is a macrolide compound originally discovered in 1972 from a soil bacterium (Streptomyces hygroscopicus) found on Easter Island (Rapa Nui). It was FDA-approved in 1999 as an immunosuppressant for the prevention of organ transplant rejection and has since become the most studied pharmacological intervention for lifespan extension. Rapamycin is the only drug that has consistently extended lifespan in every organism tested, including yeast, worms, flies, and mice, making it the benchmark compound in longevity research. At immunosuppressive doses (daily administration), it prevents transplant rejection and treats certain cancers. At lower pulsed doses (weekly administration), it is increasingly used off-label in the longevity community to target aging-related pathways while minimizing immunosuppressive side effects. The distinction between daily immunosuppressive dosing and weekly pulsed longevity dosing is critical, as the side effect profiles differ substantially between these two regimens.

**Mechanism:** Rapamycin exerts its effects by binding to the intracellular protein FKBP12, forming a complex that directly and specifically inhibits mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 is a master nutrient-sensing kinase that integrates signals from growth factors, amino acids, energy status, and stress to regulate cell growth, proliferation, and metabolism. When mTORC1 is active, it promotes anabolic processes including protein synthesis (via S6K1 and 4E-BP1 phosphorylation), lipid synthesis, and nucleotide synthesis while suppressing autophagy. By inhibiting mTORC1, rapamycin shifts the cellular balance from growth toward maintenance and repair: it upregulates autophagy (cellular self-cleaning), enhances mitochondrial function, reduces senescent cell accumulation, improves proteostasis, and reduces chronic low-grade inflammation (inflammaging). With chronic daily dosing, rapamycin can also inhibit mTORC2, which mediates Akt signaling and is responsible for some of the metabolic side effects (insulin resistance, lipid changes). Pulsed weekly dosing preferentially inhibits mTORC1 while allowing mTORC2 to recover between doses, which is believed to account for the improved side effect profile of longevity protocols.

**Key Benefits:**
- Lifespan extension demonstrated in every model organism tested (yeast, worms, flies, mice)
- Upregulation of autophagy and cellular quality control mechanisms
- Reduction of senescent cell burden and associated inflammatory secretome
- Improved immune function at low pulsed doses (paradoxical immune enhancement)
- Reduced age-related inflammation (inflammaging) via mTORC1 inhibition
- Enhanced mitochondrial function and biogenesis
- Potential reduction in age-related cancer risk through growth pathway suppression
- Improved vaccine response in elderly populations at low intermittent doses


---

### Rosuvastatin

URL: https://peptide-db.com/compounds/rosuvastatin

Rosuvastatin is the most potent statin currently available, offering the greatest LDL cholesterol reduction per milligram among all HMG-CoA reductase inhibitors. FDA-approved in 2003 under the brand name Crestor, it rapidly became one of the most prescribed medications worldwide for hyperlipidemia and cardiovascular risk reduction. Rosuvastatin is particularly popular in the anabolic steroid community, where it is widely used to manage lipid disturbances caused by androgenic-anabolic steroids (AAS), especially oral compounds like oxandrolone, stanozolol, and methandrostenolone that are notorious for dramatically worsening lipid profiles. Its long 19-hour half-life allows convenient once-daily dosing, and its hydrophilic nature gives it hepatic selectivity with a potentially lower incidence of muscle-related side effects compared to lipophilic statins like atorvastatin and simvastatin. The JUPITER trial demonstrated that rosuvastatin significantly reduces cardiovascular events even in individuals with normal LDL but elevated high-sensitivity C-reactive protein (hsCRP), highlighting its anti-inflammatory properties beyond pure lipid lowering.

**Mechanism:** Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface. The increased density of LDL receptors enhances clearance of LDL cholesterol and its precursors (VLDL and IDL) from the bloodstream. Rosuvastatin has the highest binding affinity for HMG-CoA reductase among all available statins, which accounts for its superior potency. Beyond lipid lowering, rosuvastatin exerts pleiotropic effects that contribute to cardiovascular protection: improvement of endothelial function via increased nitric oxide bioavailability, reduction of vascular inflammation (lowering hsCRP by 30-50%), stabilization of atherosclerotic plaques, decreased oxidative stress, and modest antithrombotic effects. In the context of AAS use, rosuvastatin counteracts the characteristic lipid derangement pattern caused by androgens -- namely suppressed HDL cholesterol and elevated LDL cholesterol -- by directly reducing LDL production and, to a lesser extent, raising HDL through unclear mechanisms thought to involve apolipoprotein A-I upregulation.

**Key Benefits:**
- Most potent statin available, with LDL reductions of 45-63% depending on dose
- Long half-life (19 hours) allows flexible once-daily dosing at any time of day
- Effective at counteracting AAS-induced lipid disturbances, particularly elevated LDL
- Significant reduction in high-sensitivity CRP (30-50%), indicating anti-inflammatory benefit
- Hydrophilic structure provides hepatic selectivity with potentially fewer muscle side effects
- Raises HDL cholesterol by 8-14%, partially offsetting AAS-mediated HDL suppression
- Proven cardiovascular event and mortality reduction in large-scale clinical trials
- Reduces triglycerides by 10-35%, beneficial during bulking phases or when using compounds that elevate TG


---

### RU-58841

URL: https://peptide-db.com/compounds/ru-58841

RU-58841 is a non-steroidal anti-androgen originally developed by Roussel Uclaf (later Hoechst Marion Roussel) in the 1970s-80s for topical treatment of androgen-dependent conditions including acne and androgenetic alopecia. It works by competitively binding to androgen receptors at the hair follicle, blocking the effects of dihydrotestosterone (DHT) locally without significantly reducing systemic androgen levels. Development was abandoned after Phase II clinical trials, and the compound was never submitted for regulatory approval. Despite this, RU-58841 has developed a substantial following in the hair loss community, where users source it as a raw research chemical and prepare their own topical solutions. Its extremely short systemic half-life means that even if absorbed through the skin, it is rapidly metabolized, limiting systemic anti-androgenic effects. However, the lack of completed clinical trials means its long-term safety profile remains unknown.

**Mechanism:** RU-58841 functions as a competitive antagonist of the androgen receptor (AR). When applied topically to the scalp, it penetrates the skin and binds directly to androgen receptors in dermal papilla cells of hair follicles, preventing dihydrotestosterone (DHT) and testosterone from activating those receptors. This is fundamentally different from 5-alpha reductase inhibitors like finasteride, which reduce DHT production systemically. RU-58841 does not lower DHT or testosterone levels at all; it simply blocks their action at the receptor level in the tissue where it is applied. The compound has a very high binding affinity for the androgen receptor but an extremely short systemic half-life of roughly one hour due to rapid hydrolysis of its amide bond in the bloodstream. This pharmacokinetic profile is intentional: it confines the anti-androgenic activity to the scalp while minimizing the risk of systemic side effects such as sexual dysfunction or hormonal disruption. Animal studies in hamster flank organ and stumptail macaque models demonstrated significant local anti-androgenic effects, including hair regrowth and inhibition of androgen-dependent sebaceous gland activity, without measurable systemic anti-androgenic effects at therapeutic topical doses.

**Key Benefits:**
- Blocks DHT directly at the androgen receptor in hair follicles without reducing systemic DHT levels
- Extremely short systemic half-life limits risk of systemic anti-androgenic side effects
- Different mechanism of action from finasteride/dutasteride, allowing combination therapy
- Animal studies demonstrated significant hair regrowth in androgen-dependent alopecia models
- Topical application targets the site of action directly
- Does not interfere with systemic testosterone or DHT levels


---

### Sildenafil

URL: https://peptide-db.com/compounds/sildenafil

Sildenafil is the first PDE5 inhibitor to reach the market and remains one of the most widely recognized pharmaceuticals in the world. Originally developed by Pfizer scientists investigating treatments for angina and hypertension, sildenafil's pronounced effect on erectile function was discovered during Phase I clinical trials in 1992. It received FDA approval for erectile dysfunction in 1998 under the brand name Viagra, and subsequently gained a second FDA approval in 2005 as Revatio for the treatment of pulmonary arterial hypertension (PAH). Sildenafil is a shorter-acting PDE5 inhibitor with a half-life of 3-5 hours and a therapeutic window of approximately 4-6 hours. Unlike tadalafil, sildenafil absorption is significantly reduced by high-fat meals, and its lower selectivity for PDE5 over PDE6 (the retinal phosphodiesterase) can produce transient visual disturbances such as a blue-tinged color shift at higher doses. Despite the availability of longer-acting alternatives, sildenafil remains a first-line treatment for ED due to its well-established efficacy, extensive safety data spanning over 25 years, and wide generic availability.

**Mechanism:** Sildenafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for the hydrolysis and degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. During sexual arousal, nitric oxide (NO) is released from nerve terminals and endothelial cells in the corpus cavernosum, activating soluble guanylate cyclase and increasing intracellular cGMP concentrations. Elevated cGMP activates protein kinase G (PKG), which phosphorylates multiple targets leading to smooth muscle relaxation, vasodilation of penile arteries, and engorgement of the corpora cavernosa with blood. By inhibiting PDE5, sildenafil prevents cGMP breakdown, prolonging and amplifying this vasodilatory cascade. Sildenafil requires sexual stimulation to be effective, as NO release is the initiating signal. In pulmonary arterial hypertension, the same PDE5 inhibition relaxes pulmonary vascular smooth muscle, reducing pulmonary artery pressure and pulmonary vascular resistance, thereby decreasing right ventricular afterload and improving exercise capacity. Sildenafil also has moderate inhibitory activity against PDE6, the phosphodiesterase isoform in retinal photoreceptors, which underlies the transient visual color changes reported by some users.

**Key Benefits:**
- First and most extensively studied PDE5 inhibitor with over 25 years of clinical data
- Rapid onset of action (30-60 minutes) allows event-based dosing
- FDA-approved for both erectile dysfunction (Viagra) and pulmonary arterial hypertension (Revatio)
- Flexible dosing range (25-100mg) permits individualized titration
- Shorter duration of action may be preferred by patients who want time-limited pharmacological effect
- Extensive generic availability makes it one of the most affordable PDE5 inhibitors
- Well-established safety profile across diverse patient populations
- Proven efficacy in difficult-to-treat ED including diabetic and post-prostatectomy patients


---

### SR-9009

URL: https://peptide-db.com/compounds/sr-9009

SR-9009 (Stenabolic) is a synthetic Rev-Erb agonist developed by Professor Thomas Burris at the Scripps Research Institute. Despite being almost universally marketed and sold alongside SARMs, SR-9009 is not a selective androgen receptor modulator and does not bind to or activate the androgen receptor in any capacity. Its mechanism is entirely distinct: it acts as an agonist of the Rev-Erb-alpha and Rev-Erb-beta nuclear receptors, which are key components of the molecular circadian clock and play critical roles in regulating lipid and glucose metabolism, inflammatory responses, and mitochondrial biogenesis. In preclinical studies conducted in mice, SR-9009 demonstrated notable effects on exercise capacity, metabolic rate, fat oxidation, and circadian rhythm regulation. Treated mice showed increased oxygen consumption, decreased fat mass, and enhanced endurance without changes in food intake. However, the most significant limitation of SR-9009 is its extremely poor oral bioavailability, estimated at approximately 2% in rodent models. This means that the vast majority of an orally administered dose is destroyed by first-pass hepatic metabolism before reaching systemic circulation. The impressive preclinical results were obtained via injection, raising serious questions about whether oral dosing in humans can achieve pharmacologically meaningful plasma concentrations. SR-9009 has never been tested in human clinical trials, is not approved for any medical use, and is classified as a prohibited substance by the World Anti-Doping Agency (WADA). It remains available through research chemical suppliers, where it is used in performance enhancement contexts primarily for its purported effects on fat loss, endurance, and energy levels.

**Mechanism:** SR-9009 functions as a synthetic agonist of the Rev-Erb-alpha (NR1D1) and Rev-Erb-beta (NR1D2) nuclear receptors. Rev-Erb proteins are constitutive transcriptional repressors that form a critical negative feedback loop within the mammalian circadian clock. They repress the transcription of BMAL1 and CLOCK, core clock genes that drive circadian oscillation of gene expression throughout the body. By activating Rev-Erb receptors, SR-9009 modulates circadian gene expression and thereby influences a broad array of downstream metabolic processes. In skeletal muscle, Rev-Erb activation by SR-9009 increases mitochondrial content and oxidative capacity. The compound upregulates genes involved in mitochondrial biogenesis, fatty acid oxidation, and glucose utilization. Studies in mice demonstrated that SR-9009 treatment increased the number of mitochondria in skeletal muscle, enhanced oxygen consumption, and improved exercise endurance. In the liver, Rev-Erb activation suppresses genes involved in lipogenesis (de novo fat synthesis) and gluconeogenesis, resulting in reduced hepatic fat accumulation and improved glucose homeostasis. In adipose tissue, SR-9009 reduces fat storage by downregulating genes involved in triglyceride synthesis. The net metabolic effect is an increase in energy expenditure and a shift toward a leaner metabolic phenotype. Critically, because SR-9009 acts through the Rev-Erb pathway and not the androgen receptor, it does not cause testosterone suppression, does not affect the hypothalamic-pituitary-gonadal axis, and does not require post-cycle therapy. The compound is entirely non-hormonal in its mechanism.

**Key Benefits:**
- Enhances mitochondrial function and biogenesis in skeletal muscle, increasing oxidative capacity
- Increases exercise endurance and energy expenditure through metabolic reprogramming
- Promotes fat loss by suppressing lipogenesis and increasing fatty acid oxidation
- Non-hormonal mechanism -- does not suppress testosterone or require post-cycle therapy
- No androgenic side effects (no hair loss, no prostate stimulation, no virilization)
- May improve wakefulness, alertness, and circadian rhythm regulation through Rev-Erb modulation
- Does not cause hormonal suppression, making it stackable with SARMs without compounding HPG axis disruption


---

### Superdrol

URL: https://peptide-db.com/compounds/superdrol

Superdrol (methyldrostanolone, also known as methasterone) is a synthetic oral anabolic-androgenic steroid derived from drostanolone (Masteron) with the addition of a 17-alpha-methyl group for oral bioavailability. It is widely regarded as one of the most potent oral anabolic steroids ever produced, delivering dramatic strength and lean mass gains in very short timeframes. Superdrol was originally marketed in the United States as a "prohormone" dietary supplement beginning in 2005 by Designer Supplements, exploiting a regulatory loophole since it was not explicitly listed as a controlled substance at the time. It was pulled from the market and subsequently classified as a Schedule III controlled substance under the Designer Anabolic Steroid Control Act of 2014. Despite its remarkable anabolic potency, Superdrol carries an extreme hepatotoxicity profile that distinguishes it from virtually all other commonly used oral steroids. Cases of severe cholestatic jaundice, liver failure, and hospitalizations have been reported even at moderate doses and short cycle lengths. It does not aromatize to estrogen, which means it does not cause water retention or gynecomastia, but this also means it provides no estrogenic support for joints, mood, or libido when used without a testosterone base. Superdrol is strictly an advanced-only compound and is not suitable for beginners under any circumstances.

**Mechanism:** Superdrol exerts its effects through high-affinity binding to the intracellular androgen receptor (AR), stimulating androgen-responsive gene transcription that promotes nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle. As a DHT derivative, it cannot be aromatized by the CYP19 aromatase enzyme, so it produces no estrogenic metabolites. This accounts for the characteristic dry, hard appearance it produces without subcutaneous water retention. The 2-alpha-methyl group enhances its anabolic potency relative to its parent compound drostanolone, giving it an anabolic-to-androgenic ratio that significantly favors muscle-building effects over androgenic side effects in target tissues. The 17-alpha-methyl group allows it to survive first-pass hepatic metabolism, but this same modification is responsible for its severe hepatotoxicity. Superdrol is metabolized primarily by the liver, placing enormous stress on hepatic conjugation and bile transport pathways. It has been shown to cause dose-dependent cholestasis by disrupting bile salt export pump (BSEP) function, leading to intrahepatic bile acid accumulation. This mechanism underlies the cholestatic jaundice and hepatocellular injury that are disproportionately common with this compound compared to other 17-alpha-alkylated steroids.

**Key Benefits:**
- Rapid and dramatic increases in lean muscle mass within 2-3 weeks
- Significant strength gains, often among the most pronounced of any oral steroid
- No aromatization to estrogen, producing a dry and hard muscular appearance
- No water retention or estrogen-mediated side effects such as gynecomastia
- Pronounced improvements in muscle fullness, vascularity, and density
- Effective at very low doses relative to other oral anabolic steroids


---

### Tadalafil

URL: https://peptide-db.com/compounds/tadalafil

Tadalafil is a long-acting PDE5 inhibitor FDA-approved for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). Its extended half-life of approximately 17.5 hours provides a therapeutic window of up to 36 hours, earning it the nickname 'the weekend pill.' Unlike shorter-acting PDE5 inhibitors, tadalafil is uniquely suited for daily low-dose use (2.5-5mg), which maintains steady-state plasma levels and allows for spontaneous sexual activity without timing constraints. Originally developed by ICOS Corporation and marketed by Eli Lilly as Cialis, tadalafil received FDA approval in 2003 for ED and has since become one of the most widely prescribed medications in its class. Beyond sexual health, tadalafil has gained attention for its cardiovascular and hemodynamic benefits, including improved endothelial function, reduced blood pressure, and enhanced exercise capacity.

**Mechanism:** Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in smooth muscle tissue. During sexual stimulation, nitric oxide (NO) is released in the corpus cavernosum, activating guanylate cyclase and increasing cGMP levels. Elevated cGMP causes smooth muscle relaxation in penile arteries and the corpus cavernosum, facilitating increased blood flow and erection. By blocking PDE5, tadalafil prolongs and amplifies this cGMP-mediated vasodilatory signaling cascade. PDE5 is also expressed in pulmonary vasculature, prostatic smooth muscle, and the bladder neck, which accounts for tadalafil's therapeutic effects in PAH and BPH/LUTS. Tadalafil has high selectivity for PDE5 over PDE6 (the retinal isoform), which contributes to its lower incidence of visual disturbances compared to sildenafil.

**Key Benefits:**
- Long-acting duration with a 36-hour therapeutic window
- Daily low-dose option (2.5-5mg) eliminates timing constraints
- FDA-approved for both ED and BPH/LUTS
- Minimal food interaction compared to other PDE5 inhibitors
- Improved endothelial function and blood flow
- Lower incidence of visual side effects vs. sildenafil
- Potential benefits for exercise performance via enhanced blood flow
- Well-established long-term safety profile


---

### Tamoxifen

URL: https://peptide-db.com/compounds/tamoxifen

Tamoxifen is a first-generation selective estrogen receptor modulator (SERM) that has been in clinical use since the 1970s. It is FDA-approved for the treatment and prevention of estrogen receptor-positive breast cancer and remains one of the most widely prescribed cancer therapies worldwide. In the context of performance enhancement, tamoxifen is used extensively for post-cycle therapy (PCT) to restore the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids, and for on-cycle gynecomastia prevention by blocking estrogen receptors in breast tissue. Tamoxifen acts as an estrogen antagonist in breast and hypothalamic tissue while functioning as a partial estrogen agonist in bone, the uterus, and the cardiovascular system. Its active metabolite endoxifen, produced via CYP2D6 metabolism, is responsible for much of its pharmacological activity.

**Mechanism:** Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling. At the hypothalamus and anterior pituitary, this antagonism removes estrogen-driven negative feedback on GnRH secretion, leading to increased pulsatile GnRH release and subsequent elevation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The rise in LH stimulates Leydig cell testosterone production, which is the basis for its use in post-cycle therapy. In bone tissue, tamoxifen acts as a partial estrogen agonist, providing a protective effect on bone mineral density. Tamoxifen is a prodrug that requires hepatic metabolism via CYP3A4 and CYP2D6 to generate its active metabolites, particularly endoxifen, which has approximately 100-fold greater affinity for the estrogen receptor than the parent compound.

**Key Benefits:**
- Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
- Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
- Restores endogenous testosterone production during post-cycle therapy
- Partial estrogen agonist activity in bone preserves bone mineral density
- Extremely long half-life allows for flexible dosing schedules
- Decades of clinical use with a well-characterized safety and efficacy profile
- Oral administration with no injections or reconstitution required


---

### Telmisartan

URL: https://peptide-db.com/compounds/telmisartan

Telmisartan is an angiotensin II receptor blocker (ARB) originally developed for the treatment of hypertension and cardiovascular risk reduction. FDA-approved since 1998 and marketed as Micardis, it has become the preferred ARB among performance-enhancing drug users and anabolic steroid communities due to its long half-life, strong evidence for organ protection, and unique partial PPAR-gamma agonist activity. Unlike other ARBs, telmisartan activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) at clinically relevant doses, conferring metabolic benefits that extend beyond blood pressure reduction. Anabolic androgenic steroids (AAS) are well-documented to elevate blood pressure, promote left ventricular hypertrophy, accelerate atherosclerosis, and impair renal function -- making proactive cardiovascular protection an essential component of harm reduction. Telmisartan addresses these concerns with once-daily dosing, 24-hour blood pressure coverage, and a favorable side effect profile that does not impair exercise performance or recovery.

**Mechanism:** Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling. This is particularly relevant for AAS users, where supraphysiological androgen levels stimulate the renin-angiotensin-aldosterone system (RAAS) and promote myocardial fibrosis and left ventricular hypertrophy. Telmisartan also has the longest half-life of any ARB (approximately 24 hours), providing consistent receptor blockade throughout the dosing interval. Its unique partial agonism of PPAR-gamma -- a nuclear receptor involved in glucose and lipid metabolism -- distinguishes it from other ARBs. PPAR-gamma activation enhances insulin sensitivity, improves adiponectin secretion, reduces visceral fat accumulation, and exerts anti-inflammatory effects. Additionally, telmisartan demonstrates nephroprotective properties by reducing intraglomerular pressure and proteinuria, and has been shown in the ONTARGET trial to provide cardiovascular protection comparable to the ACE inhibitor ramipril in high-risk patients.

**Key Benefits:**
- Potent 24-hour blood pressure reduction with once-daily dosing
- Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
- Nephroprotection through reduced intraglomerular pressure and proteinuria
- Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
- No negative impact on exercise performance, VO2 max, or recovery
- Reduction of pathological vascular remodeling and arterial stiffness
- Longest half-life of all ARBs ensuring consistent 24-hour coverage
- Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)


---

### Testosterone

URL: https://peptide-db.com/compounds/testosterone

Testosterone is the primary endogenous androgenic-anabolic steroid hormone produced mainly by the Leydig cells of the testes in males and in smaller quantities by the ovaries and adrenal glands in females. It is essential for the development and maintenance of male reproductive tissues, secondary sexual characteristics, muscle mass, bone density, red blood cell production, and overall well-being. Exogenous testosterone has been FDA-approved for the treatment of male hypogonadism since the 1950s and remains the gold standard for testosterone replacement therapy (TRT). It is available in multiple pharmaceutical formulations including intramuscular injectables, transdermal gels, transdermal patches, subcutaneous pellets, and oral capsules. In supraphysiological doses, testosterone is also widely used for performance enhancement, though such use falls outside approved medical indications.

**Mechanism:** Testosterone exerts its effects primarily through binding to the intracellular androgen receptor (AR), forming a hormone-receptor complex that translocates to the nucleus and modulates gene transcription. This drives protein synthesis in skeletal muscle (anabolic effect), stimulates erythropoietin production in the kidneys to increase red blood cell mass, promotes osteoblast activity and bone mineral density, and regulates libido and cognitive function. Testosterone is also converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase in peripheral tissues (skin, prostate, hair follicles), where DHT mediates androgenic effects with greater potency. Additionally, testosterone is aromatized to estradiol by the enzyme aromatase in adipose tissue, which is important for bone health, lipid metabolism, and cardiovascular function but can cause estrogenic side effects at supraphysiological doses.

**Key Benefits:**
- Restoration of normal testosterone levels in hypogonadal men
- Increased lean muscle mass and strength
- Improved bone mineral density and reduced fracture risk
- Enhanced libido, sexual function, and erectile quality
- Improved mood, energy, motivation, and cognitive clarity
- Reduction in body fat percentage, particularly visceral fat
- Increased red blood cell production and oxygen-carrying capacity
- Improved insulin sensitivity and metabolic health markers


---

### Trazodone

URL: https://peptide-db.com/compounds/trazodone

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that was originally approved by the FDA in 1981 for the treatment of major depressive disorder. However, its clinical use has shifted dramatically over the decades. Today, trazodone is prescribed almost exclusively at low doses as a sleep aid rather than as an antidepressant, making it one of the most commonly prescribed medications for insomnia in the United States. Its popularity stems from the fact that it is non-habit-forming, does not carry the dependence risk associated with benzodiazepines or Z-drugs, and can be used long-term without tolerance development. Trazodone has become particularly well-known in the bodybuilding and performance-enhancement community as a go-to solution for managing insomnia caused by trenbolone and other 19-nortestosterone derivatives, which are notorious for disrupting sleep architecture. Unlike many sleep medications, trazodone actually improves slow-wave sleep (deep sleep) rather than simply inducing sedation, which makes it especially valuable for recovery-focused athletes.

**Mechanism:** Trazodone's sleep-promoting effects arise from a combination of pharmacological actions across multiple receptor systems. At low doses (25-100 mg), the dominant mechanism is potent antagonism of 5-HT2A serotonin receptors, which promotes slow-wave sleep and reduces sleep latency. Trazodone also blocks histamine H1 receptors, contributing to its sedative properties, and antagonizes alpha-1 adrenergic receptors, which produces additional drowsiness and accounts for the orthostatic hypotension sometimes observed. At higher doses used for depression (150-400 mg), serotonin reuptake inhibition (SRI) becomes more relevant, increasing serotonergic tone in a manner similar to SSRIs but with a distinct receptor profile. The compound is metabolized primarily by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP), which has serotonin agonist properties. The dose-dependent shift in pharmacological profile explains why trazodone is sedating at low doses but can be activating or cause more typical serotonergic side effects at antidepressant doses.

**Key Benefits:**
- Effective sleep aid that improves sleep onset and sleep maintenance without the dependence risk of benzodiazepines
- Enhances slow-wave (deep) sleep, which is critical for physical recovery and growth hormone release
- Non-habit-forming with no significant tolerance development, even with long-term use
- Widely used and well-tolerated solution for trenbolone-induced and steroid-related insomnia
- Does not suppress REM sleep the way many other sleep medications do
- Inexpensive, widely available as a generic, and has decades of safety data


---

### Trenbolone

URL: https://peptide-db.com/compounds/trenbolone

Trenbolone is a synthetic 19-nortestosterone derivative and one of the most potent anabolic-androgenic steroids in common use. Originally developed for veterinary applications -- specifically as the implant pellet product Finaplix for increasing feed efficiency and lean mass in cattle -- trenbolone has never been approved for human medical use. The sole exception was a brief period in the 1980s and 1990s when trenbolone hexahydrobenzylcarbonate was marketed as Parabolan in France for human clinical use, primarily for muscle wasting and cachexia, before being voluntarily discontinued. Trenbolone's pharmacological profile is remarkable: it exhibits approximately five times the anabolic and androgenic potency of testosterone, reflected in its anabolic:androgenic ratio of 500:500 compared to testosterone's 100:100. This extraordinary potency stems from three conjugated double bonds in its steroid nucleus that dramatically enhance androgen receptor binding affinity. Unlike its parent compound nandrolone, trenbolone does not aromatize to estrogen, which contributes to its pronounced ability to produce lean, dry gains without significant water retention. However, trenbolone does exhibit significant progestogenic activity, which can elevate prolactin levels and produce a distinct set of side effects unrelated to estrogen. Trenbolone is widely regarded as the most powerful commonly available anabolic steroid for body recomposition -- simultaneously building muscle while reducing body fat. This reputation comes at a considerable cost: trenbolone carries one of the harshest side effect profiles of any steroid, including insomnia, night sweats, cardiovascular strain, respiratory distress upon injection (tren cough), anxiety, and aggression. It is strictly an advanced-only compound that should never be used by beginners or individuals without extensive experience managing anabolic steroid cycles and their ancillary requirements.

**Mechanism:** Trenbolone binds to the androgen receptor with approximately three to five times the affinity of testosterone, making it one of the strongest known AR agonists among anabolic steroids. This exceptional binding affinity drives potent activation of AR-dependent gene transcription, resulting in dramatically enhanced nitrogen retention, protein synthesis, and satellite cell proliferation in skeletal muscle. Trenbolone also powerfully inhibits glucocorticoid receptors, reducing cortisol-mediated catabolism and shifting the body's metabolic environment decisively toward anabolism even during caloric restriction -- a property central to its reputation as a recomposition agent. The compound significantly increases IGF-1 expression in muscle tissue, further amplifying its anabolic signaling cascade. A distinguishing feature of trenbolone is its complete resistance to aromatization. The conjugated double bond system in the A-ring prevents interaction with the aromatase enzyme, meaning trenbolone produces no estrogenic metabolites. This eliminates estrogen-mediated water retention and fat deposition but does not protect against gynecomastia, because trenbolone activates progesterone receptors at meaningful affinity. Progesterone receptor activation can sensitize breast tissue to circulating estrogen (from a concurrent testosterone base) and independently elevate prolactin levels, potentially causing lactation, sexual dysfunction, and mood disturbance. Trenbolone also strongly increases nutrient partitioning efficiency, directing calories preferentially toward muscle protein synthesis rather than adipose storage. This effect, originally exploited in cattle feed lots to produce leaner beef, translates to the dramatic body recomposition effects observed in human users. Unlike nandrolone, trenbolone is not meaningfully metabolized by 5-alpha reductase. In fact, 5-alpha reductase inhibitors like finasteride do not reduce trenbolone's androgenic activity and can paradoxically worsen androgenic side effects, because trenbolone's own metabolites (produced through different enzymatic pathways) are more androgenic than the parent compound in certain tissues. Trenbolone's impact on the cardiovascular system is notably severe: it reduces HDL cholesterol, increases LDL cholesterol, promotes left ventricular hypertrophy, and may directly damage cardiac tissue through mechanisms independent of its effects on lipids.

**Key Benefits:**
- Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
- Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
- Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
- Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
- Significant increases in strength across all compound movements, often rapid in onset
- Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
- Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
- Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways


---

### Tretinoin

URL: https://peptide-db.com/compounds/tretinoin

Tretinoin is the gold standard topical retinoid for skin aging and acne, FDA-approved since 1971 for acne vulgaris and later for the treatment of photoaging (fine wrinkles, mottled hyperpigmentation, roughness). As the acid form of vitamin A, it is the most extensively studied topical anti-aging compound in dermatology, backed by decades of clinical evidence. Tretinoin accelerates epidermal cell turnover, stimulates collagen synthesis in the dermis, and improves the overall architecture of photodamaged skin. It has become a cornerstone of the biohacking and skincare optimization community due to its proven ability to reduce fine lines, even out skin tone, and improve skin texture with consistent long-term use.

**Mechanism:** Tretinoin binds to retinoic acid receptors (RARs) in the cell nucleus, specifically RAR-alpha, RAR-beta, and RAR-gamma, which form heterodimers with retinoid X receptors (RXRs). These activated receptor complexes bind to retinoic acid response elements (RAREs) in DNA, modulating the transcription of genes involved in cellular differentiation, proliferation, and apoptosis. In the epidermis, tretinoin accelerates keratinocyte turnover from the typical 28-day cycle to approximately 14-16 days, promoting the shedding of damaged surface cells and their replacement with newer, healthier cells. In the dermis, tretinoin stimulates fibroblast activity, increasing the production of procollagen I and III, fibronectin, and elastin. It also inhibits matrix metalloproteinases (MMPs) that degrade collagen, and promotes angiogenesis, improving dermal blood supply. The net result is thicker, more organized epidermis, increased dermal collagen density, and reduced fine wrinkling.

**Key Benefits:**
- Reduces fine lines and wrinkles with consistent long-term use (strongest evidence of any topical)
- Stimulates new collagen synthesis (procollagen I and III) in photoaged skin
- Accelerates epidermal cell turnover, improving skin texture and smoothness
- Reduces mottled hyperpigmentation and evens skin tone
- FDA-approved treatment for acne vulgaris with over 50 years of clinical use
- Treats and prevents comedonal and inflammatory acne by normalizing follicular keratinization
- Enhances penetration and efficacy of other active skincare ingredients


---

### Turinabol

URL: https://peptide-db.com/compounds/turinabol

Turinabol (4-chlorodehydromethyltestosterone) is a synthetic oral anabolic-androgenic steroid developed in the 1960s by Jenapharm, an East German pharmaceutical company. It was created by modifying the structure of methandrostenolone (Dianabol) with a 4-chloro substitution derived from clostebol, producing a compound with a significantly altered pharmacological profile. Turinabol became notorious as the cornerstone of East Germany's state-sponsored doping program (Staatsplan 14.25), which systematically administered the drug to thousands of Olympic athletes from the late 1960s through the 1980s, often without their knowledge. The 4-chloro modification prevents aromatization to estrogen, meaning turinabol does not cause water retention, gynecomastia, or other estrogen-related side effects. This made it particularly attractive for athletes in weight-class sports and those requiring speed, strength, and endurance without visible changes in body mass. Unlike many oral anabolic steroids, turinabol produces slow, steady, lean gains rather than rapid increases in size and strength. It has never been approved for medical use by the FDA or any current Western regulatory body, and it was withdrawn from the market following German reunification and the exposure of the East German doping program. Today it remains one of the most commonly detected substances in anti-doping testing due to the discovery of long-term metabolites detectable for many months after last use.

**Mechanism:** Turinabol exerts its anabolic effects through binding to the intracellular androgen receptor (AR), promoting nitrogen retention, protein synthesis, and positive nitrogen balance in skeletal muscle. The 4-chloro substitution on the A-ring is the defining structural feature, serving two key pharmacological purposes: it completely prevents aromatization by the aromatase enzyme (blocking conversion to estrogenic metabolites), and it reduces the compound's androgenic potency relative to its anabolic activity. This results in a favorable anabolic-to-androgenic ratio, estimated at approximately 54:6 compared to methyltestosterone. Like other 17-alpha-alkylated steroids, turinabol resists first-pass hepatic metabolism, allowing oral bioavailability at the cost of increased hepatic stress. Turinabol enhances protein synthesis through AR-mediated gene transcription and increases red blood cell production, contributing to improved oxygen delivery and muscular endurance. It also promotes creatine phosphate synthesis within muscle cells, supporting ATP regeneration during high-intensity activity. The compound does not significantly interact with 5-alpha reductase, and its androgenic metabolites have low potency, contributing to its relatively mild androgenic side effect profile. It suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback, reducing endogenous testosterone production in a dose-dependent manner.

**Key Benefits:**
- Promotes lean, dry muscle gains without water retention or bloating
- Does not aromatize to estrogen, eliminating risk of gynecomastia and estrogen-related side effects
- Favorable anabolic-to-androgenic ratio, reducing androgenic side effects relative to muscle-building potential
- Enhances muscular endurance and recovery through increased red blood cell production
- Increases strength without significant body weight gain, beneficial for weight-class athletes
- Improves creatine phosphate resynthesis, supporting repeated high-intensity efforts
- Relatively mild androgenic profile compared to most oral anabolic steroids
- Produces slow, steady, maintainable gains rather than rapid temporary increases


---

### Winstrol

URL: https://peptide-db.com/compounds/winstrol

Winstrol is the brand name for stanozolol, a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). It was developed in 1962 by Winthrop Laboratories and approved by the FDA for the treatment of hereditary angioedema, a condition characterized by episodic swelling of the face, extremities, genitals, bowel wall, and upper airway. Stanozolol is structurally unique among DHT derivatives due to the addition of a pyrazole group fused to the A-ring, which significantly alters its pharmacological profile. It possesses a high anabolic-to-androgenic ratio (320:30 relative to methyltestosterone), making it one of the more anabolic oral steroids available. Winstrol does not aromatize to estrogen, producing no estrogenic side effects such as water retention or gynecomastia, which has made it a staple compound in cutting and pre-contest bodybuilding protocols. It is available in both oral tablet and injectable aqueous suspension forms, with both preparations being 17-alpha-alkylated and therefore hepatotoxic. Winstrol gained widespread notoriety after sprinter Ben Johnson tested positive for it following his gold medal performance at the 1988 Seoul Olympics, which remains one of the most publicized doping cases in sports history.

**Mechanism:** Stanozolol exerts its effects through binding to the intracellular androgen receptor (AR), promoting nitrogen retention, protein synthesis, and red blood cell production. As a DHT derivative, it cannot be aromatized by the aromatase enzyme, eliminating estrogen-mediated side effects. The pyrazole modification to the A-ring distinguishes stanozolol from other DHT derivatives by enhancing its oral bioavailability and altering its receptor binding characteristics. Stanozolol has a notable effect on sex hormone-binding globulin (SHBG), suppressing it more potently than most other anabolic steroids, which increases the fraction of free (bioactive) testosterone and other steroids in circulation. This SHBG-lowering property makes it particularly effective when stacked with other compounds. Stanozolol also stimulates collagen synthesis, though paradoxically it is associated with joint discomfort, likely due to its potent anti-estrogenic environment reducing synovial fluid production. It increases erythropoiesis through enhanced erythropoietin production, contributing to improved oxygen delivery. In hereditary angioedema, stanozolol increases serum levels of C1-esterase inhibitor and C4 complement, reducing the frequency and severity of angioedema attacks through a mechanism distinct from its anabolic properties.

**Key Benefits:**
- Produces a dry, hard, and vascular appearance without water retention
- Significant strength increases without proportional weight gain, favored in weight-class sports
- Does not aromatize to estrogen, eliminating gynecomastia and bloating concerns
- Potent suppression of SHBG, increasing free testosterone and enhancing the effectiveness of stacked compounds
- Available in both oral and injectable formulations
- High anabolic-to-androgenic ratio (320:30) relative to methyltestosterone
- FDA-approved for hereditary angioedema prophylaxis
- Enhances vascularity and muscle definition during caloric deficit


---

### YK-11

URL: https://peptide-db.com/compounds/yk-11

YK-11 is a steroidal compound that occupies a unique position among selective androgen receptor modulators (SARMs) due to its dual mechanism of action: it functions as both a partial agonist of the androgen receptor and an inhibitor of myostatin through upregulation of follistatin. First described by Kanno et al. in 2011, YK-11 was identified in cell-based assays as a compound that selectively activates androgen-responsive gene transcription while simultaneously inducing follistatin expression, a glycoprotein that binds and neutralizes myostatin, a negative regulator of muscle growth. Unlike all other commercially known SARMs, YK-11 possesses a steroidal backbone structurally related to dihydrotestosterone (DHT), making its classification as a traditional SARM debatable. It is more accurately described as a steroidal SARM hybrid with myostatin-inhibiting properties. The research base for YK-11 is extremely limited. All published data comes from in vitro (cell culture) studies only. There are no animal studies, no pharmacokinetic studies, and no human clinical trials. As a result, virtually everything reported about YK-11's effects in living organisms, its half-life, optimal dosing, and side effect profile, is derived from structural analogy to related compounds, theoretical pharmacology, and anecdotal user reports. YK-11 is not approved for any medical use and is classified as an investigational research chemical.

**Mechanism:** YK-11 exerts its effects through two distinct but complementary pathways. First, it acts as a partial agonist of the androgen receptor (AR). In C2C12 myoblast cell culture studies, YK-11 induced androgen receptor-dependent gene transcription at levels comparable to DHT for certain target genes, but with partial rather than full agonist activity. This partial agonism may theoretically confer some degree of tissue selectivity, though this has never been demonstrated in vivo. Second, and more uniquely, YK-11 stimulates the expression of follistatin in muscle cells. Follistatin is an endogenous glycoprotein that binds and inhibits myostatin (GDF-8), a member of the TGF-beta superfamily that acts as a potent negative regulator of skeletal muscle mass. By increasing follistatin levels, YK-11 may effectively reduce myostatin signaling, thereby removing a biological brake on muscle hypertrophy. In the original Kanno et al. study, YK-11-treated C2C12 cells showed significantly greater follistatin expression than cells treated with DHT alone, and this effect was blocked by an androgen receptor antagonist, indicating the follistatin induction is AR-dependent. The 17-alpha alkylation of YK-11's steroidal structure provides oral bioavailability but also subjects it to hepatic first-pass metabolism, with the associated risk of liver stress characteristic of 17-alpha alkylated compounds. Due to the complete absence of in vivo pharmacokinetic data, the compound's actual bioavailability, distribution, metabolism, and elimination profile in living systems remain unknown.

**Key Benefits:**
- Dual mechanism combining partial AR agonism with myostatin inhibition via follistatin upregulation
- May theoretically promote muscle growth beyond what AR activation alone can achieve by removing myostatin-mediated growth limits
- Steroidal structure providing oral bioavailability without requiring injection
- Partial AR agonist activity may confer tissue selectivity with reduced androgenic side effects compared to full agonists (theoretical, not demonstrated in vivo)
- Short half-life allows for relatively rapid clearance if side effects necessitate discontinuation


---

# About Peptide Database

Peptide Database provides research-based information on over 90 peptides, including molecular data, dosing protocols, interaction profiles, and safety information. It features interactive tools including a reconstitution calculator with visual syringe guides, an accumulation plotter for pharmacokinetic modelling, and a blend calculator for multi-peptide preparations.

**Key features:**
- Comprehensive peptide profiles with molecular weights, sequences, half-lives, and bioavailability data
- Cross-referenced interaction profiles between peptides
- Evidence-graded indications distinguishing human clinical data from animal studies and anecdotal reports
- Interactive reconstitution calculator, accumulation plotter, and blend calculator
- In-depth guides with research citations

Peptide Database is an educational resource. It does not sell peptides or provide medical advice.